
<html lang="en"     class="pb-page"  data-request-id="0e80fd7e-3400-4aeb-9ba2-a0d466b5c06b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2012.55.issue-3;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm201640m"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease" /></meta><meta name="dc.Creator" content="Brian C.  Shook" /></meta><meta name="dc.Creator" content="Stefanie  Rassnick" /></meta><meta name="dc.Creator" content="Nathaniel  Wallace" /></meta><meta name="dc.Creator" content="Jeffrey  Crooke" /></meta><meta name="dc.Creator" content="Mark  Ault" /></meta><meta name="dc.Creator" content="Devraj  Chakravarty" /></meta><meta name="dc.Creator" content="J. Kent  Barbay" /></meta><meta name="dc.Creator" content="Aihua  Wang" /></meta><meta name="dc.Creator" content="Mark T.  Powell" /></meta><meta name="dc.Creator" content="Kristi  Leonard" /></meta><meta name="dc.Creator" content="Vernon  Alford" /></meta><meta name="dc.Creator" content="Robert H.  Scannevin" /></meta><meta name="dc.Creator" content="Karen  Carroll" /></meta><meta name="dc.Creator" content="Lisa  Lampron" /></meta><meta name="dc.Creator" content="Lori  Westover" /></meta><meta name="dc.Creator" content="Heng-Keang  Lim" /></meta><meta name="dc.Creator" content="Ronald  Russell" /></meta><meta name="dc.Creator" content="Shawn  Branum" /></meta><meta name="dc.Creator" content="Kenneth M.  Wells" /></meta><meta name="dc.Creator" content="Sandra  Damon" /></meta><meta name="dc.Creator" content="Scott  Youells" /></meta><meta name="dc.Creator" content="Xun  Li" /></meta><meta name="dc.Creator" content="Derek A.  Beauchamp" /></meta><meta name="dc.Creator" content="Kenneth  Rhodes" /></meta><meta name="dc.Creator" content="Paul F.  Jackson" /></meta><meta name="dc.Description" content="The design and characterization of two, dual adenosine A2A/A1 receptor antagonists in several animal models of Parkinson's disease is described. Compound 1 was previously reported as a potential tr..." /></meta><meta name="Description" content="The design and characterization of two, dual adenosine A2A/A1 receptor antagonists in several animal models of Parkinson's disease is described. Compound 1 was previously reported as a potential tr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 26, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm201640m" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm201640m" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm201640m" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm201640m" /></link>
        
    
    

<title>Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm201640m" /></meta><meta property="og:title" content="Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0014.jpeg" /></meta><meta property="og:description" content="The design and characterization of two, dual adenosine A2A/A1 receptor antagonists in several animal models of Parkinson's disease is described. Compound 1 was previously reported as a potential treatment for Parkinson's disease. Further characterization of 1 revealed that it was metabolized to reactive intermediates that caused the genotoxicity of 1 in the Ames and mouse lymphoma L51784 assays. The identification of the metabolites enabled the preparation of two optimized compounds 13 and 14 that were devoid of the metabolic liabilities associated with 1. Compounds 13 and 14 are potent dual A2A/A1 receptor antagonists that have excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse and rat models of reserpine-induced akinesia, and the rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm201640m"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm201640m">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-31/acsodf.2021.6.issue-31/20210810/acsodf.2021.6.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-31/ancham.2021.93.issue-31/20210810/ancham.2021.93.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-31/bichaw.2021.60.issue-31/20210810/bichaw.2021.60.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-15/cmatex.2021.33.issue-15/20210810/cmatex.2021.33.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-8/estlcu.2021.8.issue-8/20210810/estlcu.2021.8.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-8/jceda8.2021.98.issue-8/20210810/jceda8.2021.98.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/jctcce/largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-31/langd5.2021.37.issue-31/20210810/langd5.2021.37.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-15/mamobx.2021.54.issue-15/20210810/mamobx.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm201640m&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm201640m&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm201640m&amp;href=/doi/10.1021/jm201640m" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1402-1417</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201615t" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm201197z" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Characterization of Optimized Adenosine A<sub>2A</sub>/A<sub>1</sub> Receptor Antagonists for the Treatment of Parkinson's Disease</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+C.++Shook">Brian C. Shook</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefanie++Rassnick">Stefanie Rassnick</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathaniel++Wallace">Nathaniel Wallace</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Crooke">Jeffrey Crooke</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Ault">Mark Ault</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Devraj++Chakravarty">Devraj Chakravarty</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=J.+Kent++Barbay">J. Kent Barbay</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aihua++Wang">Aihua Wang</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+T.++Powell">Mark T. Powell</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kristi++Leonard">Kristi Leonard</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vernon++Alford">Vernon Alford</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+H.++Scannevin">Robert H. Scannevin</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Carroll">Karen Carroll</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Lampron">Lisa Lampron</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lori++Westover">Lori Westover</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heng-Keang++Lim">Heng-Keang Lim</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ronald++Russell">Ronald Russell</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shawn++Branum">Shawn Branum</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+M.++Wells">Kenneth M. Wells</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Damon">Sandra Damon</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Youells">Scott Youells</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xun++Li">Xun Li</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Derek+A.++Beauchamp">Derek A. Beauchamp</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth++Rhodes">Kenneth Rhodes</a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+F.++Jackson">Paul F. Jackson</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Janssen Research and Development, L.L.C., Welsh and McKean Roads, P.O. Box 776, Spring House, Pennsylvania 19477, United States</span></div><div class="corresp-info"><strong>*</strong>Tel: 215-628-7047. Fax: 215-540-4612. E-mail: <a href="/cdn-cgi/l/email-protection#096b7a6166666249607d7a27636763276a6664"><span class="__cf_email__" data-cfemail="9ffdecf7f0f0f4dff6ebecb1f5f1f5b1fcf0f2">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm201640m&amp;href=/doi/10.1021%2Fjm201640m" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1402â1417</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 12, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 December 2011</li><li><span class="item_label"><b>Published</b> online</span>26 January 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 February 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm201640m" title="DOI URL">https://doi.org/10.1021/jm201640m</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1402%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBrian%2BC.%2BShook%252C%2BStefanie%2BRassnick%252C%2BNathaniel%2BWallace%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D3%26contentID%3Djm201640m%26title%3DDesign%2Band%2BCharacterization%2Bof%2BOptimized%2BAdenosine%2BA2A%252FA1%2BReceptor%2BAntagonists%2Bfor%2Bthe%2BTreatment%2Bof%2BParkinson%2527s%2BDisease%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1417%26publicationDate%3DFebruary%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm201640m"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2288</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm201640m" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Characterization of Optimized Adenosine A2A/A1 Receptor Antagonists for the Treatment of Parkinson's Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;C. Shook&quot;},{&quot;first_name&quot;:&quot;Stefanie&quot;,&quot;last_name&quot;:&quot;Rassnick&quot;},{&quot;first_name&quot;:&quot;Nathaniel&quot;,&quot;last_name&quot;:&quot;Wallace&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Crooke&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Ault&quot;},{&quot;first_name&quot;:&quot;Devraj&quot;,&quot;last_name&quot;:&quot;Chakravarty&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Kent Barbay&quot;},{&quot;first_name&quot;:&quot;Aihua&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;T. Powell&quot;},{&quot;first_name&quot;:&quot;Kristi&quot;,&quot;last_name&quot;:&quot;Leonard&quot;},{&quot;first_name&quot;:&quot;Vernon&quot;,&quot;last_name&quot;:&quot;Alford&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;H. Scannevin&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Carroll&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Lampron&quot;},{&quot;first_name&quot;:&quot;Lori&quot;,&quot;last_name&quot;:&quot;Westover&quot;},{&quot;first_name&quot;:&quot;Heng-Keang&quot;,&quot;last_name&quot;:&quot;Lim&quot;},{&quot;first_name&quot;:&quot;Ronald&quot;,&quot;last_name&quot;:&quot;Russell&quot;},{&quot;first_name&quot;:&quot;Shawn&quot;,&quot;last_name&quot;:&quot;Branum&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;M. Wells&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Damon&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Youells&quot;},{&quot;first_name&quot;:&quot;Xun&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Derek&quot;,&quot;last_name&quot;:&quot;A. Beauchamp&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;Rhodes&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;F. Jackson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;1402-1417&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm201640m&quot;},&quot;abstract&quot;:&quot;The design and characterization of two, dual adenosine A2A/A1 receptor antagonists in several animal models of Parkinson's disease is described. Compound 1 was previously reported as a potential treatment for Parkinson's disease. Further characterization of 1 revealed that it was metabolized to reactive intermediates that caused the genotoxicity of 1 in the Ames and mouse lymphoma L51784 assays. The identification of the metabolites enabled the preparation of two optimized compounds 13 and 14 that were devoid of the metabolic liabilities associated with 1. Compounds 13 and 14 are potent dual A2A/A1 receptor antagonists that have excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse and rat models of reserpine-induced akinesia, and the rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201640m&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201640m" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201640m&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201640m" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201640m&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201640m" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm201640m&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201640m&amp;href=/doi/10.1021/jm201640m" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm201640m" /></input><a href="/doi/pdf/10.1021/jm201640m" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm201640m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm201640m%26sid%3Dliteratum%253Aachs%26pmid%3D22239465%26genre%3Darticle%26aulast%3DShook%26date%3D2012%26atitle%3DDesign%2Band%2BCharacterization%2Bof%2BOptimized%2BAdenosine%2BA2A%252FA1%2BReceptor%2BAntagonists%2Bfor%2Bthe%2BTreatment%2Bof%2BParkinson%2527s%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D3%26spage%3D1402%26epage%3D1417%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291308" title="Nucleic acids">Nucleic acids</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jmcmar.2012.55.issue-3/production/jmcmar.2012.55.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The design and characterization of two, dual adenosine A<sub>2A</sub>/A<sub>1</sub> receptor antagonists in several animal models of Parkinson's disease is described. Compound <b>1</b> was previously reported as a potential treatment for Parkinson's disease. Further characterization of <b>1</b> revealed that it was metabolized to reactive intermediates that caused the genotoxicity of <b>1</b> in the Ames and mouse lymphoma L51784 assays. The identification of the metabolites enabled the preparation of two optimized compounds <b>13</b> and <b>14</b> that were devoid of the metabolic liabilities associated with <b>1</b>. Compounds <b>13</b> and <b>14</b> are potent dual A<sub>2A</sub>/A<sub>1</sub> receptor antagonists that have excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse and rat models of reserpine-induced akinesia, and the rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson's disease (PD) is a chronic, progressive neurodegenerative disease that is characterized by progressive impairment in motor function that is often accompanied by anxiety, depression, and cognitive impairment.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The majority of motor impairments of PD are caused by a gradual loss of dopamine-producing neurons in the ventral midbrain and concomitant loss of dopamine (DA) input to forebrain (striatal) motor structures.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> The cellular mechanisms underlying the relatively selective loss of midbrain DA neurons remains poorly understood. The loss of DA input to the neostriatum leads to dysregulation of striatal function and the classic motor symptoms of PD, such as resting tremor, muscular rigidity, akinesia, and bradykinesia. Although the loss of striatal DA precipitates many of the classical motor symptoms of PD, chronic neurodegeneration and inflammatory processes also affect other brain regions. Degenerative processes in these regions are likely to underlie the depression, cognitive impairment, and postural/gait instability in PD patients.</div><div class="NLM_p">Understanding the loss of dopaminergic cells led to the majority of treatments that restore DA signaling and thereby reduce the severity of the motor symptoms. DA replacement therapy using levodopamine (L-DOPA), the precursor to DA, remains the gold-standard treatment for PD. Other approaches include inhibition of DA turnover using monoamine oxidase type B (MAO-B) inhibitors,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> catechol <i>O</i>-methyl-transferase (COMT) inhibitors,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and inhibition of DA reuptake<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> or direct agonists<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> of postsynaptic DA receptors. Although the DA-targeted therapies work well to address the PD-related motor disturbances, they all produce undesirable side effects (dyskinesia, hallucinations, and onâoff effects) that become more severe and problematic with continued treatment. The aforementioned therapies typically show reduced efficacy as motor functions deteriorate and the disease progresses. Moreover, these treatments do not alter disease progression and do not address the comorbidities associated with PD including mood, postural instability, or cognitive disturbances. These comorbidities stem from progressive neurodeneration in non-DA brain systems and therefore are not amenable to treatment with agents targeting DA signaling.</div><div class="NLM_p">The limitations of DA replacement agents initiated non-DA-based approaches for the treatment of PD. One attractive nondopaminergic strategy that has been widely targeted is the modulation of adenosine receptors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Adenosine is a purine nucleotide produced by all metabolically active cells. Unlike classical neurotransmitters in the brain, adenosine is not packaged into vesicles or released from axon terminals in a Ca<sup>2+</sup>-dependent manner. Rather, extracellular adenosine in brain is derived from degradation of other purine nucleotides and from intracellular adenosine released via transmembrane transport.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Adenosine acts as a neuromodulator that coordinates responses to DA and other neurotransmitters in areas of the brain that are responsible for motor function, learning, and memory.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Adenosine exerts a tonic inhibitory effect of DA receptor signaling in forebrain motor and limbic structures. Adenosine is comprised of four distinct receptor subtypes designated A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub> belonging to the G protein-coupled receptor superfamily.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> A<sub>1</sub> and A<sub>3</sub> receptors are coupled to inhibitory G proteins, while A<sub>2A</sub> and A<sub>2B</sub> receptors are coupled to stimulatory G proteins. On the basis of in situ hybridization histochemistry and quantitative receptor autoradiography, the greatest densities of A<sub>2A</sub> receptor expression in rodent brain are found in the neostriatum with lower levels in olfactory, neocortical, and limbic system structures.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> On the basis of [<sup>11</sup>C]-TMSX positron emission tomography (PET) imaging in human subjects and on autoradiographic studies of postmortem brain sections, the distribution of A<sub>2A</sub> receptors in human brain closely matches the distribution in rodent brain, with a high concentration in the neostriatum and much lower levels in other brain regions.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">The loss of DA input into the neostriatum is a hallmark of PD and underlies many of the cardinal motor symptoms of this disorder. Also, it has been reported that overexpression of A<sub>2A</sub> receptors correlates with the motor symptoms in PD.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Adenosine A<sub>2A</sub> receptors colocalize and physically associate with D<sub>2</sub> receptors in the striatum.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> A<sub>2A</sub> and D<sub>2</sub> receptors have opposing effects on adenylate cyclase and cyclic adenosine monophosphate (cAMP) production in cells, such that activation of A<sub>2A</sub> receptors inhibits D<sub>2</sub> receptor signaling. Conversely, A<sub>2A</sub> receptor antagonists enhance D<sub>2</sub>-dependent signaling as shown by induction of immediate early gene c-fos expression in the striatopallidal pathway<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and facilitate other D<sub>2</sub>-mediated responses. Of importance to PD, pharmacological blockade of A<sub>2A</sub> receptors has shown dramatic beneficial effects in preclinical animal models of PD,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> reversing haloperidol-induced catalepsy, showing potentiation of DA-mediated responses in DA-depleted [6-hydroxydopamine (6-OHDA)-treated] animals and dramatic relief of parkinsonian symptoms in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated nonhuman primates.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> These lines of evidence suggested that A<sub>2A</sub> and D<sub>2</sub> receptors play unique and integrative roles in striatal function. A<sub>2A</sub> antagonists facilitate DA receptor signaling and thereby normalize motor function in animal models of DA dysregulation. As a result of these findings, the adenosine A<sub>2A</sub> receptor has become a sought after target for treating PD. Blockade of A<sub>2A</sub> signaling by selective A<sub>2A</sub> receptor antagonists (e.g., KW-6002,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> istradefylline; SCH-420814, preladenant<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>) was shown to be beneficial for not only enhancing the therapeutic effects of L-DOPA but also reducing dyskinesia from long-term L-DOPA treatment.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Preladenant completed phase II clinical trials for PD, and Merck (Schering-Plough) is currently recruiting for several phase III trials.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p last">Quantitative autoradiographic analyses in rodent, postmortem human brain sections,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and [<sup>11</sup>C-MPDX] PET imaging in human subjects<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> show that adenosine A<sub>1</sub> receptors are concentrated in neocortex, hippocampus, and striatum. On the basis of anatomical and in vivo microdialysis studies, A<sub>1</sub> receptors appear to be localized presynaptically of DA axon terminals where they inhibit DA release.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> A<sub>1</sub> receptor antagonists facilitate DA release in the striatum and, like A<sub>2A</sub> receptors, potentiate DA-mediated responses. Antagonism of both the A<sub>2A</sub> and the A<sub>1</sub> would be synergisticâinhibition of the A<sub>1</sub> receptor will facilitate DA release, while inhibition of the A<sub>2A</sub> receptor will enhance postsynaptic responses to DA. Interestingly, the A<sub>1</sub> receptor is also concentrated in neocortical and limbic system structures that are important for cognitive function and has been implicated in antidepressant action. Pharmacological inhibition of A<sub>1</sub> receptors enhances neurotransmitter release in the hippocampus<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and enhances performance in animal models of learning and memory.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> ASP-5854 is a dual A<sub>2A</sub>/A<sub>1</sub> antagonist having binding affinities of 1.8 and 9.0 nM for A<sub>2A</sub> and A<sub>1</sub>, respectively.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> ASP-5854 has shown very good efficacy in a number of animal models of PD,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and it has shown positive effects in two models of cognition, the scopolamine-induced memory deficits in the mouse Y-maze and the rat passive avoidance test.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In contrast, the selective A<sub>2A</sub> antagonist KW-6002 had minimal or no effect in the same models, suggesting that the A<sub>1</sub> component could provide added benefit to PD patients. These data suggest that a dual A<sub>2A</sub>/A<sub>1</sub> adenosine receptor antagonist may offer a unique and exciting approach to treating both the motor and the nonmotor disturbances of PD.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We recently published the in vivo characterization of an arylindenopyrimidine compound <b>1</b> as a dual A<sub>2A</sub>/A<sub>1</sub> receptor antagonist.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Compound <b>1</b> was identified as an ideal dual A<sub>2A</sub>/A<sub>1</sub> receptor antagonist having excellent functional in vitro activity (A<sub>2A</sub><i>K</i><sub>i</sub> = 4.1 nM; A<sub>1</sub><i>K</i><sub>i</sub> = 17.0 nM) with good pharmacokinetics (PK) and desirable brain levels. Compound <b>1</b> also showed excellent beneficial effects in several preclinical animal models of PD across a number of different species including mouse<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and rat<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> models of neuroleptic-induced catalepsy, mouse model of reserpine-induced akinesia,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> rat 6-OHDA lesion model of drug-induced rotation,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and MPTP-treated nonhuman primate model.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">Further evaluation of <b>1</b> revealed that it was genotoxic in both the Ames and the mouse lymphoma L5178Y assays following metabolic activation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Incubation of <b>1</b> with Aroclor 1254-induced rat liver S9 and human liver S9 produced at least two reactive metabolites, the endocyclic iminium ion <b>2</b> and the aryl aldehyde <b>3</b> (Scheme <a class="ref internalNav" href="#sch3" aria-label="1">1</a>). It was concluded that one of these reactive metabolites was responsible for the genotoxicity based on several mechanistic studies. Compound <b>1</b> also showed some adverse events in the 28 day GLP toxicity study in nonhuman primates, which may be related to the reactive metabolites, but that has not been confirmed. Knowing the metabolic soft spots of the molecule allowed us to design analogues that might slow down or eliminate the oxidative metabolism that occurred with compound <b>1</b>.</div><figure id="sch3" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0001.jpeg" id="GRAPHIC-d2141e682-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Metabolism of Compound <b>1</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The primary site of metabolism was occurring on the methylenes adjacent to the nitrogen inside the pyrrolidine ring. The addition of methyl groups on one, not shown, or both sides (<b>4</b>) of the nitrogen atom gave compounds that were devoid of the metabolic liability seen with <b>1</b>. It appeared that the metabolism was more influenced by the steric bulk of the methyl groups rather than the electronics as one might expect the methine carbons to be more susceptible to oxidation. Also, the methyl groups were able to block metabolism at the benzylic position. The dimethylpyrrolidine <b>4</b> maintained good functional (human cell lines) in vitro activity for both A<sub>2A</sub> and A<sub>1</sub>, but <b>4</b> had decreased in vivo activity in the haloperidol-induced catalepsy model in mouse as compared to <b>1</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Haloperidol, a neuroleptic medication that inhibits D<sub>2</sub> receptors,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> was used to induce catalepsy. In the rodent, catalepsy is characterized as a loss of voluntary motion where limbs uncharacteristically remain in placed positions, which mimics the muscular stiffness seen in PD patients. Efficacy in this model is defined as reversal of catalepsy, that is, moving from the placed positions (refer to the <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a> for a more detailed description of the mouse catalepsy model). This was the primary in vivo model that was used to evaluate compounds quickly by assessing oral and central nervous system activity. Also, the model typically required very little compound (5â10 mg), making it a robust tool with very fast turnaround. The bicyclic pyrrolidine <b>5</b> was also devoid of the metabolic liabilities and showed improved in vivo activity with an ED<sub>50</sub> of 1 mg/kg in mouse catalepsy, but this was still 5-fold less potent than <b>1</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Human Functional A<sub>2A</sub> and A<sub>1</sub> in Vitro Activity and Reversal of Neuroleptic-Induced Catalepsy in Mice</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0002.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0003.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">The in vivo activity of reversing haloperidol-induced catalepsy is reported as an ED<sub>50</sub>, % reversal of at a single dose, or not active at a single dose. Not active corresponds to <50% reversal of catalepsy. Behavioral testing was conducted 1 h after dosing of A<sub>2A</sub>/A<sub>1</sub> antagonist.</p></div></div><div></div></div><div class="NLM_p">Next, we replaced the benzylic pyrrolidine with various substituted pyridine compounds exemplified by <b>6</b>â<b>12</b>. The thought was to remove the electron-rich ring with the pyridine, a system that would still increase solubility. Compounds <b>6</b>â<b>10</b> had very potent activity for A<sub>2A</sub> and A<sub>1</sub>, while maintaining excellent activity in the mouse catalepsy model. A dose response was run using <b>6</b> in the mouse catalepsy model and showed that it had an ED<sub>50</sub> of <1 mg/kg after oral administration. Not surprisingly, the benzylic pyridines were extensively metabolized at the benzylic position, which resulted in poor plasma exposures and very short half-lives (<0.5 h). The behavioral testing was generally conducted 1 h after dosing the A<sub>2A</sub>/A<sub>1</sub> antagonist, but a duration of action study showed that <b>6</b> and <b>7</b> were active in the mouse catalepsy model at 4 and 2 h, respectively, after a 10 mg/kg po dose despite the very short half-life. The suboptimal PK profiles and benzylic metabolism prompted us to prepare the ketone <b>11</b> and the <i>gem</i>-difluoro <b>12</b> to try and block metabolism, improve stability, and increase in vivo exposure. The metabolism was eliminated, and the compounds maintained good in vitro activity, but neither <b>11</b> or <b>12</b> was active in the mouse catalepsy model after a 10 mg/kg oral dose. Although no PK or brain levels were determined for <b>11</b> or <b>12</b>, the poor physical properties, that is, solubility, may be responsible for low absorption and lack of activity. Moving the pyridine ring out by one or two methylenes results in decreased in vitro activity.</div><div class="NLM_p">Converting the benzyl amines to their corresponding amides gave compounds with excellent in vitro and in vivo activity.<a onclick="showRef(event, 'cit28c'); return false;" href="javascript:void(0);" class="ref cit28c">(28c)</a> Compound <b>13</b> is a representative compound from the amide series that had optimal potency (ED<sub>50</sub> = 0.4 mg/kg) in the mouse catalepsy model as compared to other amides that were prepared (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Cyclic amines generally gave amide compounds that were slightly more potent than acyclic amines. The idea behind preparing the amides was 2-fold: first, oxidizing the benzylic position would eliminate the oxidative metabolism at that position; second, the electron-withdrawing nature of the carbonyl would pull electron density out of the nitrogen heterocycle, making the positions Î± to the nitrogen less susceptible to oxidation. Introduction of a basic nitrogen, like the one found in the piperazine, was critical to maintain good solubility. Fortunately, this approach was successful as we observed no metabolism on the methylenes adjacent to the nitrogen of the amide nor did we see any metabolism on the methylenes adjacent to the nitrogen in the 4-position.</div><div class="NLM_p">Another strategy to eliminate the benzylic metabolism was to prepare a variety of phenyl ethers from this series.<a onclick="showRef(event, 'cit28c'); return false;" href="javascript:void(0);" class="ref cit28c">(28c)</a> Converting the benzylic methylene to an oxygen atom eliminated the metabolic potential at that position, similarly to the carbonyl from the amides. Moving the solubilizing group, nitrogen heterocycle, out a few atoms also eliminated the oxidative metabolism from occurring inside the ring as seen with compound <b>1</b>, while maintaining good activity. Compound <b>14</b> represents the optimized compound out of a variety of ethers that were synthesized. The morpholine ring gave optimal in vitro and in vivo activity and had an ED<sub>50</sub> of <0.1 mg/kg in the mouse catalepsy model (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reversal of neuroleptic-induced catalepsy in mice by compounds <b>13</b> and <b>14</b>. In this behavioral model, catalepsy was induced in male Balb/c mice by subcutaneous administration of haloperidol, a neuroleptic D<sub>2</sub> receptor antagonist. Compound <b>1</b> was used as the positive control for this model at 10 mg/kg, po. Compounds <b>13</b> (left panel) and <b>14</b> (right panel) were administered orally 30 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 1 h after dosing of <b>13</b> and <b>14</b>. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 8â12 mice per treatment group during a 60 s test session. Both compounds produced a dose-dependent reversal of haloperidol-induced catalepsy. The ED<sub>50</sub> of <b>13</b> for inhibiting haloperidol-induced catalepsy in mice was 0.4 mg/kg, po, and the minimum effective dose is shown to be 1 mg/kg, po. The ED<sub>50</sub> of <b>14</b> for inhibiting haloperidol-induced catalepsy in mice was <0.1 mg/kg, po, and the minimum effective dose is shown to be 0.1 mg/kg, po. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">The synthesis of compounds <b>4</b>â<b>13</b> started with the commercially available 6-methylindanone <b>15</b>, which was deprotonated with NaHMDS and reacted with CS<sub>2</sub> followed by MeI to afford the dithioketenacetal <b>16</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="2">2</a>).<a onclick="showRef(event, 'ref28 ref36'); return false;" href="javascript:void(0);" class="ref ref28 ref36">(28, 36)</a> Compound <b>16</b> reacts with guanidine to form an intermediate amino pyrimidine, not shown, that is then oxidized to the corresponding ketone by passing air through the solution to give <b>17</b>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The amino pyrimidine was protected using excess (Boc)<sub>2</sub>O and 4-(dimethylamino)pyridine (DMAP) to give <b>18</b>. Efforts to mono-Boc compound <b>17</b> were unsuccessful as the di-Boc compound was forming while starting material was present. Also, the reaction was very sluggish without the addition of DMAP. The phenyl substituent was installed via a modified Suzuki reaction under Liebeskind type conditions using the methylthioether as the coupling partner to afford <b>19</b>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The Suzuki reaction proceeded smoothly with the di-Boc protected amino pyrimidine but could not be accomplished on the unprotected amino pyrimidine <b>17</b> under the same conditions. Compound <b>19</b> underwent benzyl bromination to afford the corresponding bromide <b>20</b>, which was a key intermediate that was carried through paths 1â3 to prepare compounds <b>4</b>â<b>13</b>. Following path 1, the Boc groups were removed with TFA followed by alkylation with 2,5-dimethylpyrrolidine or 7-azabicyclo[2.2.1]heptane to give the desired target compounds <b>4</b> and <b>5</b>, respectively. Following path 2, the benzyl bromide <b>20</b> was reacted, under Suzuki conditions, with several pyridylboronic acids to provide their corresponding compounds <b>6</b>â<b>10</b>. The pyridyl compound <b>6</b> was oxidized using air, under basic conditions in NMP, to give the diketone <b>11</b> (see insert Scheme <a class="ref internalNav" href="#sch1" aria-label="2">2</a>). Reaction of <b>11</b> with DAST gave the <i>gem</i>-difluoro compound <b>12</b>. Following path 3, the bromide <b>20</b> was converted to the corresponding aldehyde, not shown, using NMO in the presence of molecular sieves followed by further oxidation to the acid <b>21</b> with KMnO<sub>4</sub>. The acid <b>21</b> was coupled with 1-methylpiperazine using HATU followed by removal of the Boc groups with TFA afforded the amide <b>13</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>4</b>â<b>13</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of <b>14</b> started with the commercially available 6-methoxyindanone <b>22</b>, which was condensed with benzaldehyde to afford the benzylidene <b>23</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="3">3</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The benzylidene <b>23</b> was reacted with guanidine and, upon aromatization, was oxidized to the corresponding ketone <b>24</b> using air in a one-pot reaction as described above.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The methoxy group was deprotected by LiCl in NMP at 180 Â°C to give the corresponding phenol <b>25</b>. Attempts to deprotect using BBr<sub>3</sub> were completely unsuccessful. However, EtSNa in DMF was also effective in removing the methoxy group but was not as efficient as the LiCl. The phenol was then reacted with 4-(2-chloroethyl)morpholine in the presence of <i>t</i>-BuOK to give the ether <b>14</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>14</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> PK</h3><div class="NLM_p">Compounds <b>13</b> and <b>14</b> were of high interest because of their in vivo potency in the mouse catalepsy model, shown above, and because of their different structural features. The PK data of <b>13</b> and <b>14</b> were determined in mouse, rat, and monkey and compared to the PK data of <b>1</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Compounds <b>1</b>, <b>13</b>, and <b>14</b> had moderate to high clearances in all species. In general, the compounds had good oral bioavailability and low to moderate half-lives in all species. Amide <b>13</b> had half-lives 2â4-fold higher in rodents as compared to compounds <b>1</b> and <b>14</b>. Plasma levels of <b>13</b> and <b>14</b> were good in all species and were comparable to <b>1</b> in mouse and rat but were 2â4-fold higher in monkeys as compared to <b>1</b>. The concentration of <b>14</b> found in rat brain (4161 nM) was comparable to the brain concentration (3552 nM) found using compound <b>1</b>. Interestingly, <b>13</b> had a much lower exposure in the brain (459 nM) but showed similar efficacy in the mouse catalepsy model as compared to <b>1</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The different brain exposures of <b>13</b> and <b>14</b> were compelling, and we thought that further characterization of both compounds would complement one another. Our goal was to profile both compounds to get a better understanding of what may be the ideal brain exposure and PK profile for a dual adenosine A<sub>2A</sub>/A<sub>1</sub> antagonist for the treatment of PD.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Pharmacokinetic Data for Compounds <b>1</b>, <b>13</b>, and <b>14</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compd</th><th class="colsep0 rowsep0" align="center">IV/oral dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Vss, iv (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">oral <i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">oral plasma <i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char=".">brain <i>C</i><sub>max</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="center" char=".">mouse</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">440</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">655</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">1695</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>14</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">1081</td><td class="colsep0 rowsep0" align="char" char=".">61</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="center" char=".">rat</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">1263</td><td class="colsep0 rowsep0" align="char" char=".">64</td><td class="colsep0 rowsep0" align="char" char=".">3552</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">968</td><td class="colsep0 rowsep0" align="char" char=".">45</td><td class="colsep0 rowsep0" align="char" char=".">459</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>14</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">1652</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">4161</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="center" char=".">monkey</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>1</b></td><td class="colsep0 rowsep0" align="left">1/10</td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">626</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">1459</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>14</b></td><td class="colsep0 rowsep0" align="left">2/10</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">2769</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Mouse Catalepsy</h3><div class="NLM_p">The mouse catalepsy data,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, were collected at a single time point, 1 h postdose of <b>13</b> or <b>14</b>. Another study was performed using the same model of neuroleptic-induced catalepsy in mice to examine the duration of action of <b>13</b> and <b>14</b>.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Catalepsy time was measured in haloperidol (1 mg/kg, sc)-treated mice after oral administration of <b>13</b> (10 mg/kg), <b>14</b> (10 mg/kg), vehicle, or positive control <b>1</b> (10 mg/kg). Catalepsy was measured at 30 min and 1, 2, and 4 h after oral dosing of the respective treatment groups. The results in Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> show that haloperidol induced catalepsy at each measurement period and that <b>13</b> and <b>14</b> were effective in reversing haloperidol-induced catalepsy at all measurement periods. These data suggest that in mice, the duration of action for in vivo efficacy of <b>13</b> and <b>14</b> is at least 4 h following oral administration at 10 mg/kg. Extended measurement periods past 4 h were not examined nor were lower doses of compounds <b>13</b> or <b>14</b>.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Duration of action of <b>13</b> in the mouse model of neuroleptic-induced catalepsy. Catalepsy was induced by subcutaneous administration of haloperidol. Compound <b>13</b> was administered orally 30 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 30 min and 1, 2, and 4 h after administration of vehicle, <b>13</b>, or <b>1</b> (positive control) in male Balb/c mice. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 8 mice per treatment group during a 60 s test session. Haloperidol-induced catalepsy was evident at all measurement periods. Compound <b>13</b> was effective in reversing haloperidol-induced catalepsy 30 min and 1, 2, and 4 h after oral dosing. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Duration of action of <b>14</b> in the mouse model of neuroleptic-induced catalepsy. Catalepsy was induced by subcutaneous administration of haloperidol. Compound <b>14</b> was administered orally 30 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 30 min and 1, 2, and 4 h after administration of vehicle, <b>14</b>, or <b>1</b> (positive control) in male Balb/c mice. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 8 mice per treatment group during a 60 s test session. Haloperidol-induced catalepsy was evident at all measurement periods. Compound <b>14</b> was effective in reversing haloperidol-induced catalepsy 30 min and 1, 2, and 4 h after oral dosing. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Rat Catalepsy</h3><div class="NLM_p">In vivo efficacy of <b>13</b> and <b>14</b> was examined in a rat model of neuroleptic-induced catalepsy.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> This model was carried out analogously to that described for mice except that the maximum duration for rat was 180 s as compared to 60 s for mice. Results in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> show that both <b>13</b> and <b>14</b> were effective in reversing the haloperidol-induced catalepsy having ED<sub>50</sub> values of 0.6 and 0.3 mg/kg, po, respectively, and each having minimum effective doses of 1 mg/kg, po. As shown in mice, the reversal in rat was also dose-dependent.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Reversal of neuroleptic-induced catalepsy in rats by compounds <b>13</b> and <b>14</b>. In this behavioral model, catalepsy was induced in SpragueâDawley rats by subcutaneous administration of haloperidol, a neuroleptic D<sub>2</sub> receptor antagonist. Compound <b>1</b> was used as the positive control for this model at 10 mg/kg, po. Compounds <b>13</b> (left panel) and <b>14</b> (right panel) were administered orally 60 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 1 h after dosing of <b>13</b> and <b>14</b>. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 10 rats per treatment group during a 180 s test session. Both compounds produced a dose-dependent reversal of haloperidol-induced catalepsy. The ED<sub>50</sub> values of <b>13</b> and <b>14</b> for inhibiting haloperidol-induced catalepsy in rats were 0.6 and 0.3 mg/kg, po, respectively, and the minimum effective dose was shown to be 1 mg/kg, po, for both <b>13</b> and <b>14</b>. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A study was performed using the rat model of neuroleptic-induced catalepsy to examine the duration of action of <b>14</b>. The results in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> shows that haloperidol induced catalepsy at each measurement period and that <b>14</b> was effective in reversing haloperidol-induced catalepsy at 1, 2, and 4 h after a 1 mg/kg oral dose. Positive results were also observed for <b>1</b> (positive control) at 10 mg/kg, po. These data suggest that in rats, the duration of action for in vivo efficacy of <b>14</b> is at least 4 h following oral administration.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Duration of action of <b>14</b> in the rat model of neuroleptic-induced catalepsy. Catalepsy was induced by subcutaneous administration of haloperidol. Compound <b>14</b> (1 mg/kg) was administered orally 60 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 15 min and 1, 2, and 4 h after administration of vehicle, <b>14</b>, or <b>1</b> (positive control) in SpragueâDawley rats. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 10â12 rats per treatment group during a 180 s test session. Haloperidol-induced catalepsy was evident at all measurement periods. Compound <b>14</b> was effective in reversing haloperidol-induced catalepsy 1, 2, and 4 h after oral dosing of 1 mg/kg. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Mouse and Rat Models of Reserpine-Induced Akinesia</h3><div class="NLM_p">To evaluate the potential antiparkinsonian properties of <b>13</b> and <b>14</b>, locomotor activity was studied in a mouse model of reserpine-induced akinesia.<a onclick="showRef(event, 'ref31 ref39'); return false;" href="javascript:void(0);" class="ref ref31 ref39">(31, 39)</a> Reserpine is an alkaloid that depletes monoamine by inhibiting its vesicular uptake, resulting in a dramatic reduction of spontaneous locomotor activity (akinesia). Efficacy was defined as reversal of reserpine-induced akinesia and was quantified as total distance traveled (cm) (refer to the <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a> for a more detailed description of the mouse and rat reserpine models). Locomotion was studied 60 min after oral administration of <b>13</b> or <b>14</b> (0.10, 1.0, 3.0, 6.0, or 10.0 mg/kg), <b>1</b> (10 mg/kg, positive control), or vehicle in mice that were pretreated with reserpine (0.6 mg/kg, sc) 18 h earlier (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). The total distance traveled was recorded during a 30 min measurement period. Reserpine produced a marked decrease in horizontal and vertical locomotor activity. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, reserpine-induced akinesia was reversed by <b>13</b> and <b>14</b> at 1, 3, 6, and 10 mg/kg, po, and the minimum effective dose was 1 mg/kg, po, for each compound. An analogous experiment was also performed in rats using <b>13</b> and <b>14</b> except the distance traveled was recorded during a 60 min measurement period instead of 30 min for the mouse model. Reserpine again produced a marked decrease in locomotor activity. Both <b>13</b> and <b>14</b> produced a dose-dependent reversal of akinesia with both compounds having a minimum effective dose of 1 mg/kg, po.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0011.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Reversal of reserpine-induced akinesia by <b>13</b> (left) and <b>14</b> (right) in mice. In this behavioral model, akinesia was induced by subcutaneous administration reserpine, a monoamine-depleting drug in male CF-1 mice. Compounds <b>13</b>, <b>14</b>, <b>1</b> (10 mg/kg, positive control), or vehicle were administered orally 60 min before the behavioral test in the locomotor activity boxes. Each value shows the mean (Â±SEM) of the total distance traveled during the 30 min measurement period in the behavioral test session. Reserpine produced a marked decrease in locomotor activity as compared with vehicle + vehicle-treated controls. Compounds <b>13</b> and <b>14</b> reversed reserpine-induced akinesia with similar effectiveness to the control <b>1</b>, <i>N</i> = 14â16 mice per treatment group. Asterisks indicate significant differences as compared with the reserpine + vehicle control group (**<i>P</i> < 0.01, ***<i>P</i> < 0.001, Hochberg test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> 6-OHDA Lesion Model in Rats</h3><div class="NLM_p">Compounds <b>13</b> and <b>14</b> were studied in the 6-OHDA-lesion model of drug-induced rotation in rats.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In this model, the neurotoxin 6-OHDA (12 Î¼g) is microinjected unilaterally in the medial forebrain bundle to produce a targeted degeneration of midbrain DA neurons in the pars compacta of the substantia nigra. 6-OHDA-induced neurotoxicity causes a dramatic deficit in DA neurons that is accompanied by denervation-induced supersensitivity of postsynaptic DA receptors in the striatum of the lesioned side. An imbalance in DA activity between the two sides of the brain causes asymmetry in motor behavior that can be enhanced by drug treatment. For example, drugs that stimulate postsynaptic DA receptors produce an imbalance in DA signaling that favors the lesion side and induces rotation behavior (turning) toward the side opposite (contralateral to) the lesion side (refer to the <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a> for a more detailed description of the 6-OHDA-lesion model).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">One rotation count was defined as one 360Â° turn. Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a> (left panel) shows that prior to L-DOPA administration, <b>14</b> alone was able to produce a modest, dose-dependent increase in the number of contralateral rotations observed in the 6-OHDA lesioned rats, implying that <b>14</b> was able to provide a modest enhancement of DA neurotransmission, especially via the supersensitive D<sub>2</sub> receptors at the lesioned side. Similar results were seen with compound <b>13</b> (not shown). In contrast, L-DOPA (10 mg/kg, po) was able to produce a more pronounced enhancement in the number of contralateral rotations, consistent with the known increase in DA transmission that this drug produces (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>, right panel). More importantly, a dose-dependent, synergistic effect is realized when L-DOPA is administered to animals that were dosed previously with the adenosine receptor antagonists <b>13</b> (not shown) or <b>14</b> with the minimum effective dose being 1 mg/kg, po, for both compounds. These results suggest that DA must be present in the brain for an adenosine antagonist to be optimally effective in treating PD as the modest effect of <b>13</b> or <b>14</b> alone on the behavior of animals would probably not suffice. It is known that approximately 80% of DA neurons are depleted before any PD symptoms, that is, motor dysfunction, is apparent.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Therefore, it is critical to identify PD patients at an earlier stage to maximize the benefit of adenosine receptor antagonists in treating PD. While this remains the ultimate challenge, significant efforts are being put forth to evaluate and treat PD patients to enhance quality of life.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0012.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Reversal of reserpine-induced akinesia by <b>14</b> (left) and <b>13</b> (right) in rats. In this behavioral model, akinesia was induced by subcutaneous administration reserpine, a monoamine-depleting drug in male Wistar rats. Compounds <b>13</b>, <b>14</b>, <b>1</b> (10 mg/kg, positive control), or vehicle was administered orally 60 min before the behavioral test in the locomotor activity boxes. Each value shows the mean (Â±SEM) of the total distance traveled during a 60 min measurement period in the behavioral test session. Reserpine produced a marked decrease in locomotor activity as compared with vehicle + vehicle-treated controls. Compounds <b>13</b> and <b>14</b> reversed reserpine-induced akinesia with similar effectiveness to the control <b>1</b>, <i>N</i> = 16â18 rats per treatment group. Asterisks indicate significant differences as compared with the reserpine + vehicle control group (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001, Hochberg test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0013.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>14</b> potentiates the effects of L-DOPA in the 6-OHDA-lesioned rat model of PD. Six weeks after administration of 6-OHDA, the behavioral test was started by dosing rats with L-DOPA [10 mg/kg, po coadministered with carbidopa (2.5 mg/k, sc)] alone or with each dose of <b>14</b> (0.1, 1.0, 3.0, 6.0, and 10 mg/kg, po). The effects of <b>14</b> alone at 10 mg/kg, po (indicated in both the left and the right panels as 10), were also studied in this model. For clarity, two separate groups of animals were dosed at 10 mg/kg, po. The rotational behavior was determined as each animal was tethered to a high-resolution optical sensor connected to an automated computerized system that quantifies circular motion. One rotation count was defined as one 360Â° turn. Each value represents the mean (Â±SEM) of total contralateral rotations of <i>n</i> = 16 rats per treatment group during the 2 h before and after L-DOPA administration. Asterisks in the left panel indicate significant differences as compared with vehicle control treatment group, and asterisks in the right panel indicate significant differences as compared with the L-DOPA + vehicle control treatment group (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001, Tukey's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, we have shown that the dual A<sub>2A</sub>/A<sub>1</sub> receptor antagonist <b>1</b> was metabolized into reactive intermediates that caused genotoxicity and possibly the adverse events seen in the 28 day GLP toxicity study in nonhuman primates. Optimization of the scaffold led to the identification of <b>13</b> and <b>14</b> as dual A<sub>2A</sub>/A<sub>1</sub> receptor antagonists having complementary brain PK profiles. Both <b>13</b> and <b>14</b> showed excellent efficacy across a number of animal models of PD including mouse and rat catalepsy, mouse and rat reserpine-induced akinesia, and 6-OHDA lesion model in rats. Despite the fact that <b>14</b> had â¼8-fold higher brain levels in rats as compared to <b>13</b>, both <b>13</b> and <b>14</b> exhibit very similar efficacy profiles across the various PD models. Further evaluation will be needed to differentiate or distinguish compounds <b>13</b> and <b>14</b>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21147" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21147" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Information</h3><div class="NLM_p">All proton and carbon nuclear magnetic resonance spectra were determined using a 400 MHz Bruker NMR with the appropriate internal standards. High-resolution MS was performed on a JEOL Accutof JMS-T100 LC with a DART CE ionization source operating in the positive mode. Reagent grade chemicals and solvents were purchased from Aldrich, Oakwood, or TCI. All chromatographies were carried out on a combi-flash system equipped with an automated fraction collector. All final compounds were purified to â¥95% purity as determined by Agilent 1100 series high-performance liquid chromatography (HPLC) with UV detection at 254 nm using the following method: Supelcosil ABZ+PLUS, 3.3 cm Ã 2.1 cm, 11 min; 1.2 mL/min flow rate; and 5â95% 0.1% TFA in CH<sub>3</sub>CN/0.1% TFA in H<sub>2</sub>O. Experimental procedures and spectral listings for compounds <b>1</b> and <b>16</b>â<b>20</b> were previously reported.<a onclick="showRef(event, 'cit28a'); return false;" href="javascript:void(0);" class="ref cit28a">(28a)</a></div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 2-Amino-8-((2,5-dimethylpyrrolidin-1-yl)methyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>4</b>)</h4><div class="NLM_p">Neat TFA (8 mL, 102.8 mmol) was added to a CH<sub>2</sub>Cl<sub>2</sub> solution (24 mL) of <b>20</b> (1.94 g, 3.4 mmol), and the mixture was stirred at room temperature. After 2 h, the solution was concentrated in vacuo, and saturated aqueous NaHCO<sub>3</sub> was added to the material. The resulting suspension was sonicated, and the precipitate was collected by filtration and washed with water. The collected solid was dried under high vacuum to afford 1.1 g (90%) of 2-amino-8-(bromomethyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one as a yellow solid that was used without further purification. <i>R</i><sub>t</sub> = 4.75 min. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): Î´ 8.03â8.12 (m, 2H), 7.89 (d, <i>J</i> = 0.98 Hz, 1H), 7.72 (d, <i>J</i> = 7.58 Hz, 1H), 7.46â7.62 (m, 4H), 5.88 (br. s., 2H), 4.56 (s, 2H) ppm. <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>): Î´ 187.6, 176.1, 165.9, 164.5, 144.2, 140.6, 136.4, 135.2, 133.4, 131.4, 129.7, 128.1, 124.0, 122.0, 108.0, 32.1 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>13</sub>BrN<sub>3</sub>O [(M + H)<sup>+</sup>], 366.0237; found, 366.0254.</div><div class="NLM_p last">Neat 2,5-dimethylpyrrolidine-mix of <i>cis</i>- and <i>trans</i>-isomers (1.1 mL, 9.3 mmol) was added to a THF solution (20 mL) of 2-amino-8-(bromomethyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (1.7 g, 4.6 mmol) and triethyl amine (Et<sub>3</sub>N) (1.3 mL, 9.3 mmol), and the resulting mixture was heated to 75 Â°C. After 3 h, the mixture was concentrated in vacuo, dissolved into CH<sub>2</sub>Cl<sub>2</sub>. The mixture was washed with saturated aqueous NaHCO<sub>3</sub> and brine (2Ã), dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated, and purified via column chromatography to give 1.0 g (57%) of <b>4</b>. Compound <b>4</b> was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and added dropwise to an excess of HCl in ether. The resulting precipitate was filtered off to give 1.1 g of 2-amino-8-((2,5-dimethylpyrrolidin-1-yl)methyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>4</b>) as the di-HCl salt. <i>R</i><sub>t</sub> = 5.57 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.12 (d, <i>J</i> = 9.60 Hz, 1H), 8.01 (d, <i>J</i> = 8.59 Hz, 4H), 7.87 (d, <i>J</i> = 7.58 Hz, 1H), 7.72â7.80 (m, 1H), 7.45â7.62 (m, 4H), 4.58 (d, <i>J</i> = 4.55 Hz, 2H), 3.45â3.55 (m, 2H), 2.07â2.24 (m, 2H), 1.59â1.75 (m, 2H), 1.34 (s, 3H), 1.33 (s, 3H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.6, 175.2, 165.1, 164.8, 139.7, 136.9, 136.2, 136.1, 135.5, 130.9, 129.4, 127.6, 123.8, 123.2, 110.9, 63.1, 52.6, 29.3, 16.4 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>4</sub>O [(M + H)<sup>+</sup>], 385.2023; found, 385.2036.</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 8-(7-Azabicyclo[2.2.1]heptan-7-ylmethyl)-2-amino-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>5</b>)</h4><div class="NLM_p last">The same procedure described to prepare <b>4</b> was followed except that 7-azabicyclo[2.2.1]heptane was used in place of 2,5-dimethylpyrrolidine to give the title compound in 40% yield. <i>R</i><sub>t</sub> = 3.04 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.05â8.16 (m, 3H), 8.01 (d, <i>J</i> = 7.07 Hz, 2H), 7.97 (d, <i>J</i> = 7.58 Hz, 1H), 7.75 (d, <i>J</i> = 7.58 Hz, 1H), 7.48â7.61 (m, 3H), 4.38 (d, <i>J</i> = 6.06 Hz, 2H), 3.95 (br. s., 2H), 2.24 (d, <i>J</i> = 8.59 Hz, 2H), 2.04 (d, <i>J</i> = 8.59 Hz, 2H), 1.77 (d, <i>J</i> = 8.59 Hz, 2H), 1.67 (d, <i>J</i> = 8.08 Hz, 2H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.8, 175.4, 164.8, 164.7, 139.9, 137.7, 136.8, 135.4, 135.3, 131.0, 129.5, 127.7, 123.3, 123.2, 111.0, 62.7, 48.3, 26.9, 25.1 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>23</sub>N<sub>4</sub>O [(M + H)<sup>+</sup>], 383.1866; found, 383.1848.</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 2-Amino-4-phenyl-8-(pyridin-3-ylmethyl)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>6</b>)</h4><div class="NLM_p last">A dioxane/water (4:1) solution (5 mL) of 2-amino-8-(bromomethyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (175 mg, 0.48 mmol), 3-pyridylboronic acid (94 mg, 0.77 mmol), K<sub>2</sub>CO<sub>3</sub> (133 mg, 0.96 mmol), and Pd(dppf)Cl<sub>2</sub> (39 mg, 0.05 mmol) was heated in the microwave at 120 Â°C for 10 min. The resulting mixture was diluted with THF and EtOAc, washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated, and purified to give 112 mg (64%) of <b>6</b>. Compound <b>6</b> was dissolved in THF added dropwise to an excess of HCl in ether. The resulting precipitate was filtered off to give 115 mg of 2-amino-4-phenyl-8-(pyridin-3-ylmethyl)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>6</b>) as the di-HCl salt. <i>R</i><sub>t</sub> = 3.01 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.01 (s, 1H), 8.84 (d, <i>J</i> = 5.05 Hz, 1H), 8.54 (d, <i>J</i> = 8.08 Hz, 1H), 7.91â8.12 (m, 5H), 7.73 (s, 1H), 7.65 (s, 2H), 7.46â7.59 (m, 3H), 4.39 (s, 2H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.9, 175.4, 164.6, 164.3, 145.9, 145.7, 141.7, 140.3, 140.1, 135.3, 135.2, 134.9, 133.5, 130.8, 129.4, 127.6, 127.0, 123.5, 121.4, 111.0, 37.1 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>17</sub>N<sub>4</sub>O [(M + H)<sup>+</sup>], 365.1379; found, 365.1395.</div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 5-((2-Amino-5-oxo-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-8-yl)methyl)nicotinonitrile (<b>7</b>)</h4><div class="NLM_p last">The same procedure used to prepare <b>6</b> was followed except that (5-cyanopyridin-3-yl)boronic acid was used in place of 3-pyridylboronic acid to give the title compound in 64% yield. <i>R</i><sub>t</sub> = 4.33 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.86â8.97 (m, 2H), 8.34 (s, 1H), 7.99 (d, <i>J</i> = 7.07 Hz, 3H), 7.45â7.70 (m, 7H), 4.25 (s, 2H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.9, 175.4, 164.5, 164.2, 153.6, 150.4, 146.4, 140.0, 139.9, 136.5, 135.2, 134.7, 133.4, 130.8, 129.4, 127.6, 123.4, 121.2, 116.8, 111.0, 109.0, 37.3 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>16</sub>N<sub>5</sub>O [(M + H)<sup>+</sup>], 390.1349; found, 390.1395.</div></div><div id="sec3_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-Amino-8-((5-fluoropyridin-3-yl)methyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>8</b>)</h4><div class="NLM_p last">The same procedure used to prepare <b>6</b> was followed except that (5-fluoropyridin-3-yl)boronic acid was used in place of 3-pyridylboronic acid to give the title compound in 74% yield. <i>R</i><sub>t</sub> = 3.92 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.62 (d, <i>J</i> = 6.06 Hz, 2H), 8.20 (br. s., 2H), 7.91â8.03 (m, 3H), 7.69 (s, 1H), 7.62â7.68 (m, 2H), 7.45â7.61 (m, 3H), 4.27 (s, 2H) ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>16</sub>FN<sub>4</sub>O [(M + H)<sup>+</sup>], 383.1303; found, 383.1229.</div></div><div id="sec3_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-Amino-8-((3-fluoropyridin-4-yl)methyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>9</b>)</h4><div class="NLM_p last">The same procedure used to prepare <b>6</b> was followed except that (3-fluoropyridin-4-yl)boronic acid was used in place of 3-pyridylboronic acid to give the title compound in 69% yield. <i>R</i><sub>t</sub> = 3.63 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.66 (s, 1H), 8.48 (d, <i>J</i> = 4.04 Hz, 1H), 8.02â8.15 (br. s., 2H), 7.99 (d, <i>J</i> = 7.07 Hz, 2H), 7.44â7.71 (m, 7H), 4.28 (s, 2H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.9, 175.4, 164.6, 164.3, 145.2, 144.8, 142.5, 140.0, 136.6, 135.3, 135.0, 133.4, 130.9, 129.5, 127.7, 126.4, 123.5, 121.0, 119.7, 111.0, 33.7 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>16</sub>FN<sub>4</sub>O [(M + H)<sup>+</sup>], 383.1303; found, 383.1322.</div></div><div id="sec3_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-Amino-8-((4-chloropyridin-3-yl)methyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>10</b>)</h4><div class="NLM_p last">The same procedure used to prepare <b>6</b> was followed except that (4-chloropyridin-3-yl)boronic acid was used in place of 3-pyridylboronic acid to give the title compound in 56% yield. <i>R</i><sub>t</sub> = 3.60 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.99 (s, 1H), 8.73 (d, <i>J</i> = 5.56 Hz, 1H), 8.15 (br. s., 2H), 7.90â8.03 (m, 3H), 7.45â7.68 (m, 6H), 4.40 (s, 2H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.7, 175.4, 164.2, 164.1, 147.5, 145.3, 144.6, 139.8, 134.9, 135.7, 134.7, 134.7, 133.6, 131.0, 129.5, 127.7, 126.5, 123.4, 121.0, 111.0, 35.7 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>16</sub>ClN<sub>4</sub>O [(M + H)<sup>+</sup>], 399.1007; found, 399.1013.</div></div><div id="sec3_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2-Amino-8-nicotinoyl-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>11</b>)</h4><div class="NLM_p last">Powdered NaOH (420 mg, 10.5 mmol) was added to an NMP solution (1.5 mL) of 2-amino-4-phenyl-8-(pyridin-3-ylmethyl)-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>6</b>) (400 mg, 1.1 mmol). Air was bubbled into the solution at a steady rate using a steel needle, and the mixture was heated to 80 Â°C. After 18 h, the air needle was removed, and water was added. The resulting solid was filtered off, washed with water, and dried in vacuo. The crude solid was dissolved in THF and dry packed onto silica gel. Column chromatography gave 110 mg (26%) of 2-amino-8-nicotinoyl-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>11</b>). <i>R</i><sub>t</sub> = 3.56 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.97 (s, 1H), 8.89 (d, <i>J</i> = 4.55 Hz, 1H), 8.13â8.25 (m, 3H), 8.00â8.10 (m, 4H), 7.86 (d, <i>J</i> = 7.58 Hz, 1H), 7.66 (dd, <i>J</i> = 5.31, 7.83 Hz, 1H), 7.48â7.61 (m, 3H) ppm. <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 194.1, 186.9, 175.4, 165.9, 165.5, 153.7, 150.6, 141.4, 140.1, 140.0, 137.7, 136.0, 135.2, 132.9, 131.6, 130.0, 128.3, 124.3, 123.9, 122.0, 111.7 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>15</sub>N<sub>4</sub>O<sub>2</sub> [(M + H)<sup>+</sup>], 379.1190; found, 379.1221.</div></div><div id="sec3_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Amino-8-(difluoro(pyridin-3-yl)methyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>12</b>)</h4><div class="NLM_p last">2-Amino-8-nicotinoyl-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (110 mg, 0.29 mmol) was dissolved in neat DAST (1 mL), and the mixture was heated to 70 Â°C. After 4 h, the mixture was concentrated in vacuo and partitioned between DCM and water. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated, and purified via column chromatography to give 27 mg (23%) of 2-amino-8-(difluoro(pyridin-3-yl)methyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>12</b>). <i>R</i><sub>t</sub> = 4.10 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.89 (s, 1H), 8.78 (d, <i>J</i> = 3.54 Hz, 1H), 8.15 (br. s., 1H), 8.09 (d, <i>J</i> = 7.58 Hz, 2H), 8.01 (d, <i>J</i> = 7.07 Hz, 2H), 7.92 (d, <i>J</i> = 7.58 Hz, 1H), 7.78â7.84 (m, 2H), 7.47â7.63 (m, 4H) ppm. <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.8, 175.3, 165.8, 165.5, 152.3, 146.8, 140.7, 138.5, 136.0, 134.1, 132.5, 132.4, 131.5, 130.7, 130.0, 128.2, 124.5, 124.3, 120.1, 117.8, 111.5 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>15</sub>F<sub>2</sub>N<sub>4</sub>O [(M + H)<sup>+</sup>], 401.1208; found, 401.1196.</div></div><div id="sec3_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Amino-8-(4-methylpiperazine-1-carbonyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>13</b>)</h4><div class="NLM_p last">Neat piperazine (0.4 mL, 3.6 mmol) was added to a THF solution (60 mL) of acid <b>21</b> (1.7 g, 3.3 mmol), diisopropylethylamine (1.7 mL, 9.9 mmol), and HATU (1.3 g, 3.3 mmol). The resulting mixture was heated to 40 Â°C. After 18 h, the mixture was concentrated and purified via column chromatography to give 1.8 g (91%) of bis-<i>tert</i>-butyl (8-(4-methylpiperazine-1-carbonyl)-5-oxo-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-2-yl)carbamate that was used immediately. The bis-<i>tert</i>-butyl (8-(4-methylpiperazine-1-carbonyl)-5-oxo-4-phenyl-5<i>H</i>-indeno[1,2-d]pyrimidin-2-yl)carbamate (1.8 g, 3.0 mmol) was then stirred in 25 mL of CH<sub>2</sub>Cl<sub>2</sub>/TFA (4:1). After 3 h, the mixture was concentrated, neutralized with saturated aqueous NaHCO<sub>3</sub>, and filtered to give 1 g of crude 2-amino-8-(4-methylpiperazine-1-carbonyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>13</b>). The solid was purified via column chromatography to give 893 mg (75%) of <b>13</b> as the free base, which was dissolved in THF and added to 10 mL of 1 N HCl in ether, concentrated, and dried in vacuo to give 2-amino-8-(4-methylpiperazine-1-carbonyl)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>13</b>) as the di-HCl salt. <i>R</i><sub>t</sub> = 2.63 min. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): Î´ ppm 2.34 (s, 3 H), 2.39 (br. s., 2 H), 2.52 (d, <i>J</i> = 2.20 Hz, 2 H), 3.46 (br. s., 2 H), 3.84 (br. s., 2 H), 5.86 (br. s., 2 H), 7.46â7.64 (m, 4 H), 7.78 (d, <i>J</i> = 7.58 Hz, 1 H), 7.85 (s, 1 H), 8.07 (dd, <i>J</i> = 7.83, 1.71 Hz, 2 H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.5, 175.1, 167.8, 165.0, 164.9, 140.2, 139.6, 137.0, 135.5, 131.5, 130.9, 129.4, 127.6, 123.2, 119.3, 110.9, 57.1, 51.3, 42.2 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> [(M + H)<sup>+</sup>], 400.1768; found, 400.1780.</div></div><div id="sec3_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Amino-8-(2-morpholinoethoxy)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>14</b>)</h4><div class="NLM_p last">Solid potassium <i>tert</i>-butoxide (<i>t</i>-BuOK) (9.7 g, 86.5 mmol) was added to a DMF solution (200 mL) of <b>25</b> (10.0 g, 34.6 mmol) and 4-(2-chloroethyl)morpholine hydrochloride (7.1 g, 38.1 mmol), and the resulting solution was heated to 75 Â°C. After 4 h at 75 Â°C, the mixture was cooled to room temperature diluted with tetrahydrofuran (THF) and EtOAc and washed with brine, water, and brine. The organics were dried over Na<sub>2</sub>SO<sub>4</sub> and dry packed onto silica gel. Column chromatography gave 7.0 g (50%) of the desired ether <b>14</b> as the free base, which was dissolved in THF and added to 100 mL of 2 N HCl in ether, concentrated, and dried in vacuo to give 2-amino-8-(2-morpholinoethoxy)-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>14</b>) as the di-HCl salt. <i>R</i><sub>t</sub> = 2.85 min. <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>): Î´ ppm 2.53â2.67 (m, 4 H), 2.86 (t, <i>J</i> = 5.65 Hz, 2 H), 3.66â3.83 (m, 4 H), 4.25 (t, <i>J</i> = 5.65 Hz, 2 H), 5.76 (br. s., 2 H), 7.01 (dd, <i>J</i> = 8.10, 2.45 Hz, 1 H), 7.35 (d, <i>J</i> = 2.26 Hz, 1 H), 7.43â7.57 (m, 3 H), 7.66 (d, <i>J</i> = 8.29 Hz, 1 H), 7.98â8.10 (m, 2 H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.2, 174.9, 164.1, 163.1, 162.4, 141.8, 134.6, 131.0, 129.5, 129.5, 127.7, 125.0, 118.7, 111.5, 107.2, 63.0, 62.7, 54.5, 51.5 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub> [(M + H)<sup>+</sup>], 403.1765; found, 403.1754.</div></div><div id="sec3_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2-((Bis-<i>tert</i>-butoxycarbonyl)amino)-5-oxo-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidine-8-carboxylic Acid (<b>21</b>)</h4><div class="NLM_p">Solid <i>N</i>-methyl morpholine <i>N</i>-oxide (2.5 g, 21.2 mmol) was added to a CH<sub>3</sub>CN solution (300 mL) of <b>7</b> (6.0 g, 10.6 mmol) and 4 Ã ms (10.5 g). After 18 h at room temperature, the mixture was filtered, and the filtrate was diluted with EtOAc and washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and purified via column chromatography to give 3.6 g (68%) of bis-<i>tert</i>-butyl (8-formyl-5-oxo-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-2-yl)carbamate. <i>R</i><sub>t</sub> = 6.81 min. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): Î´ 10.17 (s, 1H), 8.43 (s, 1H), 8.24 (d, <i>J</i> = 7.07 Hz, 2H), 8.13 (d, <i>J</i> = 7.58 Hz, 1H), 7.96 (d, <i>J</i> = 7.58 Hz, 1H), 7.49â7.63 (m, 3H), 1.55 (s, 18H) ppm. <sup>13</sup>C NMR (101 MHz, chloroform-<i>d</i>): Î´ 190.6, 188.0, 175.3, 150.3, 141.2, 139.3, 134.8, 134.3, 132.3, 130.3, 128.3, 124.7, 122.6, 84.2, 77.3, 77.2, 77.0, 76.7, 27.9 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>28</sub>N<sub>3</sub>O<sub>6</sub> [(M + H)<sup>+</sup>], 502.1973; found, 502.1995.</div><div class="NLM_p last">Solid KMnO<sub>4</sub> was added to an acetone/water solution (100 mL/25 mL) of bis-<i>tert</i>-butyl (8-formyl-5-oxo-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-2-yl)carbamate (3.6 g, 7.2 mmol), and the resulting mixture was heated to 55 Â°C. After 14 h, the mixture was cooled to room temperature and filtered. The filtrate was diluted with EtOAc and washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), concentrated, and purified by column chromatography to give 2.1 g (57%) of 2-((bis-<i>tert</i>-butoxycarbonyl)amino)-5-oxo-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidine-8-carboxylic acid (<b>21</b>). <i>R</i><sub>t</sub> = 6.00 min. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): Î´ 8.54â8.65 (m, 1H), 8.26â8.36 (m, 1 H), 8.17â8.24 (m, 2H), 7.78â7.89 (m, 1H), 7.48â7.63 (m, 3H), 1.53 (s, 18H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 187.5, 175.0, 163.7, 163.3, 160.4, 159.9, 150.0, 134.9, 134.0, 132.0, 131.6, 130.0, 129.9, 128.2, 127.9, 124.3, 118.7, 83.9, 27.3 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>28</sub>H<sub>28</sub>N<sub>3</sub>O<sub>7</sub> [(M + H)<sup>+</sup>], 518.1922; found, 518.1887.</div></div><div id="sec3_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>E</i>)-2-Benzylidene-6-methoxy-2,3-dihydro-1<i>H</i>-inden-1-one (<b>23</b>)</h4><div class="NLM_p last">An aqueous solution (5 mL) of NaOH (1.5 g, 38.5 mmol) was added dropwise to an ethanol (EtOH) solution (30 mL) of 6-methoxy-1-indanone (5.0 g, 30.8 mmol) and benzaldehyde (3.4 g, 32.4 mmol). A precipitate formed immediately. An additional 30 mL of EtOH was added, and the resulting slurry was stirred vigorously for 0.5 h. The slurry was cooled in an ice bath, filtered, and washed with cold EtOH. The collected solid was dried in vacuo to give 7.3 g (95%) of (<i>E</i>)-2-benzylidene-6-methoxy-2,3-dihydro-1<i>H</i>-inden-1-one (<b>23</b>). <i>R</i><sub>t</sub> = 5.39 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 7.79 (d, <i>J</i> = 7.07 Hz, 2H), 7.59 (d, <i>J</i> = 8.08 Hz, 1H), 7.43â7.56 (m, 4H), 7.31 (dd, <i>J</i> = 2.53, 8.08 Hz, 1H), 7.26 (d, <i>J</i> = 2.53 Hz, 1H), 4.06 (s, 2H), 3.84 (s, 3H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 193.1, 159.1, 142.6, 138.4, 135.8, 134.8, 132.6, 130.7, 129.7, 128.9, 127.5, 123.4, 105.5, 55.4, 31.1 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>15</sub>O<sub>2</sub> [(M + H)<sup>+</sup>], 251.1067; found, 251.1056.</div></div><div id="sec3_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Amino-8-methoxy-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>24</b>)</h4><div class="NLM_p last">Powdered NaOH (5.8 g, 146.0 mmol) was added to an EtOH solution (130 mL) of guanidine acetate (17.4 g, 146.0 mmol). After 30 min, the sodium acetate (NaOAc) was filtered off, and the filtrate was added to an EtOH suspension (80 mL) of <b>23</b> (7.3 g, 29.2 mmol). The resulting mixture was heated to reflux overnight. The homogeneous solution was cooled in ice for 30 min and filtered to give 6.0 g of crude material (<i>des</i>-ketone), which was used without further purification. The crude material (6.0 g) was dissolved in NMP (80 mL), and powdered NaOH (1.2 g, 31.1 mmol) was added. The resulting mixture was heated to 80 Â°C and air was bubbled through the solution using a steel needle. After 16 h, the mixture was cooled to room temperature, water was added, and the resulting precipitate was filtered and washed with water and cold EtOH. The red solid was dried in vacuo to give 5.0 g (56%) of 2-amino-8-methoxy-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>24</b>). <i>R</i><sub>t</sub> = 4.04 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.00 (d, <i>J</i> = 6.57 Hz, 2H), 7.92 (br. s., 2H), 7.62 (d, <i>J</i> = 8.59 Hz, 1H), 7.45â7.58 (m, 3H), 7.27 (d, <i>J</i> = 2.53 Hz, 1H), 7.15 (dd, <i>J</i> = 2.53, 8.08 Hz, 1H), 3.93 (s, 3H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.5, 174.8, 164.8, 164.2, 164.1, 142.1, 135.6, 130.6, 129.5, 128.7, 127.5, 124.9, 117.7, 111.5, 106.1, 55.9 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub> [(M + H)<sup>+</sup>], 304.1081; found, 304.1065.</div></div><div id="sec3_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Amino-8-hydroxy-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>25</b>)</h4><div class="NLM_p last">An NMP solution (25 mL) of <b>24</b> (4.0 g, 13.2 mmol), LiCl (5.6 g, 132.0 mmol), and water (0.5 mL) were heated to 180 Â°C. After 4 h, the mixture was diluted with THF and EtOAc, washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and dry packed onto silica gel. Column chromatography gave 2.4 g (63%) of 2-amino-8-hydroxy-4-phenyl-5<i>H</i>-indeno[1,2-<i>d</i>]pyrimidin-5-one (<b>25</b>). <i>R</i><sub>t</sub> = 3.58 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.76 (s, 1H), 7.99 (d, <i>J</i> = 6.57 Hz, 2H), 7.87 (br. s., 2H), 7.42â7.59 (m, 4H), 7.15 (d, <i>J</i> = 2.02 Hz, 1H), 6.95 (dd, <i>J</i> = 2.02, 8.08 Hz, 1H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 186.7, 175.0, 164.9, 163.9, 163.2, 142.4, 135.7, 130.6, 129.5, 127.6, 127.4, 125.3, 118.8, 111.6, 107.9 ppm. HRMS, <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub> [(M + H)<sup>+</sup>], 290.0924; found, 290.0923.</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Pharmacokinetic Studies</h3><div class="NLM_p last">Compound <b>1</b>, <b>13</b>, or <b>14</b> was administered to fasted SpragueâDawley rats (male), Balb/c mice (male), and Cynomolus monkeys (male and female) by a single iv or oral administration. Compound <b>1</b> was formulated in 10% solutol for the iv injection. Compound <b>1</b> was formulated in 0.5% methylcellulose and dosed orally as a solution. The iv concentrations of <b>1</b> were 2 mg/kg for mice and rats and were 1 mg/kg for monkeys. The iv concentrations of <b>13</b> and <b>14</b> were 2 mg/kg for mice, rats, and monkeys. The oral concentrations of <b>1</b> were 10 mg/kg for all species. Discrete blood samples collected from mice and rats were withdrawn from 3 to 4 animals per time point at selected intervals postdose via orbital sinus (rats) or cardiac (mice) puncture. Serial blood collections from monkeys were withdrawn by venipuncture. Plasma was obtained by centrifugation, processed by acetonitrile precipitation, and then analyzed by LC-MS/MS. The limit of quantitiation (LOQ) was 0.7â2 ng/mL. Noncompartmental analysis was performed on individual plasma concentrations using WinNonlin (version 4.0.4). For the tissue distribution studies, a 10 mg/kg solution of <b>1</b>, <b>13</b>, or <b>14</b> in 0.5% methylcellulose was administered orally to fasted SpragueâDawley rats (male). At each time point, four animals were euthanized for collection of blood, plasma, and brain. Each tissue was weighed and homogenized in methanol. The methanolic extracts were evaporated and then reconstituted in mobile phase for analysis by LC-MS/MS. Blood and plasma were treated with acetonitrile, and the supernatants were analyzed for drug concentration by LC-MS/MS.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Mouse Catalepsy Study</h3><div class="NLM_p">Haloperidol, a neuroleptic medication that inhibits D<sub>2</sub> receptors, was used to induce catalepsy. In the rodent, catalepsy is characterized as a loss of voluntary motion where limbs uncharacteristically remain in placed positions. Catalepsy was measured in haloperidol (1 mg/kg, sc)-treated mice (fasted, male Balb/c mice) after oral administration of <b>1</b> (0.01, 0.10, 1.0, or 10.0 mg/kg, po), L-DOPA [300 mg/kg; coadministered with carbidopa (75 mg/kg)], or vehicle. Compounds <b>4</b>â<b>14</b> were given orally at 10 mg/kg to the haloperidol-treated mice using <b>1</b> (10 mg/kg, po) as the positive control, and the data were reported as the percent reversal of catalepsy. Dose responses of catalepsy were measured in haloperidol (1 mg/kg, sc)-treated mice (fasted, male Balb/c mice) after oral administration <b>4</b>, <b>5</b>, <b>6</b>, <b>13</b>, or <b>14</b> (0.1, 1.0, 3.0, or 10.0 mg/kg, po), <b>1</b> (10 mg/kg, po), or vehicle. Animals were randomly assigned to treatment groups, and behavioral testing was performed blind to treatment. Control mice received the respective sc and po vehicles. Haloperidol was dissolved in 0.3% tartaric acid in 0.9% saline. L-DOPA was diluted in 0.5% methylcellulose and dosed as a suspension. Compounds <b>1</b>, <b>13</b>, and <b>14</b> were diluted in 0.5% methylcellulose and dosed orally. Compounds <b>1</b>, <b>13</b>, and <b>14</b> were administered orally 30 min after haloperidol. Behavioral testing was conducted 1 h after dosing of <b>1</b>, <b>13</b>, and <b>14</b>. The behavioral test trial (maximum duration of 60 s) began by placing the forepaws of fasted, male Balb/c mice on a horizontal bar elevated 3.5 cm above the bench. The cataleptic state was regarded as over, and the trial ended when the animal came off the bar by either placing its forepaws on the bench or climbing onto the bar with all of its limbs. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 8â12 mice per treatment group during a 60 s test session. Asterisks indicate significant differences as compared with the haloperidol + vehicle control group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</div><div class="NLM_p last">A separate study was performed using the same model of neuroleptic-induced catalepsy to examine the duration of action of <b>13</b> and <b>14</b> in mice. Catalepsy time was measured in haloperidol (1 mg/kg, sc)-treated mice (fasted, male Balb/c mice) after oral administration of <b>13</b> (0 or 10 mg/kg), <b>14</b> (0 or 10 mg/kg), <b>1</b> (10 mg/kg), or vehicle. Compounds <b>1</b>, <b>13</b>, and <b>14</b> were diluted in 0.5% methylcellulose. Catalepsy was measured repeatedly 30 min and 1, 2, and 4 h after oral dosing of the respective groups. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 8 mice per treatment group during a 60 s test session. Asterisks indicate significant differences as compared with the haloperidol + vehicle control group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Rat Catalepsy Study</h3><div class="NLM_p">Haloperidol, a neuroleptic medication that inhibits D<sub>2</sub> receptors, was used to induce catalepsy. In the rodent, catalepsy is characterized as a loss of voluntary motion where limbs remain in placed positions. The time to descend from the bar was measured in haloperidol (1 mg/kg, sc)-treated male SpragueâDawley rats (fasted) after oral administration of <b>13</b> or <b>14</b> (0.10, 1.0, 3.0, or 10.0 mg/kg), <b>1</b> (10 mg/kg), or vehicle. Animals were randomly assigned to treatment groups, and behavioral testing was performed blind to treatment. Control rats received the respective sc and po vehicles. Haloperidol was dissolved in 0.3% tartaric acid in 0.9% saline. Compound <b>1</b> was diluted in 0.5% methylcellulose and dosed as a solution. Compounds <b>13</b> and <b>14</b> were diluted in 20% HPÎ²CD and dosed as a solution. Compounds <b>1</b>, <b>13</b>, and <b>14</b> were administered orally 30 min after haloperidol. Behavioral testing was conducted 1 h after dosing of <b>1</b>, <b>13</b>, and <b>14</b>. The behavioral test trial (maximum duration of 180 s) began by placing the forepaws of male SpragueâDawley rats on a horizontal bar elevated 3.5 cm above the bench. The cataleptic state was regarded as over, and the trial ended when the animal came off the bar by either placing its forepaws on the bench or climbing onto the bar with all of its limbs. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 10â16 rats per treatment group during a 180 s test session. Asterisks indicate significant differences as compared with the haloperidol + vehicle control group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</div><div class="NLM_p last">A separate study was performed using the same model of neuroleptic-induced catalepsy to examine the duration of action of <b>14</b> in rats. Catalepsy time was measured in haloperidol (1 mg/kg, sc)-treated rats (fasted, male SpragueâDawley rats) after oral administration of <b>14</b> (0 or 1.0 mg/kg), <b>1</b> (10 mg/kg), or vehicle. Compound <b>1</b> was diluted in 0.5% methylcellulose and dosed as a solution. Compound <b>14</b> was diluted in 20% HPÎ²CD and dosed as a solution. Compounds <b>1</b> and <b>14</b> were administered orally 30 min after haloperidol. Catalepsy was measured repeatedly 15 min and 1, 2, and 4 h after oral dosing of the respective groups. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 10 rats per treatment group during a 180 s test session. Asterisks indicate significant differences as compared with the haloperidol + vehicle control group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Reserpine-Induced Akinesia Study in Mice</h3><div class="NLM_p last">Reserpine is an alkaloid that depletes monoamines by inhibiting their vesicular uptake, resulting in a dramatic reduction of spontaneous locomotor activity (akinesia). Efficacy is defined as reversal of reserpine-induced akinesia. Locomotion was studied in open field activity boxes (L, 17.5 in; W, 17.5 in; and H, 12 in), each containing 20 equally spaced pairs of horizontal infrared photocell beams along one axis. The activity was measured automatically by a PC running the activity analysis software. One activity count corresponded to the consecutive interruption of two infrared beams placed 2.5 cm apart and 2 cm above the cage floor, and the total distance traveled was quantified in cm. Locomotion was studied 60 min after oral administration of compound <b>13</b> or <b>14</b> (0.1, 1.0, 3.0, 6.0, and 30 mg/kg, po), <b>1</b> (10 mg/kg), or vehicle in mice that were pretreated with reserpine (0.6 mg/kg, sc) 18 h earlier. Mice used were fasted male CF-1 mice. Animals were randomly assigned to treatment groups. Control mice received the respective sc and po vehicles. Reserpine was diluted in 0.5% acetic acid in distilled water and dosed sc. Compounds <b>13</b>, <b>14</b>, and <b>1</b> were diluted in 0.5% methylcellulose and dosed as a solution. Reserpine produced a marked decrease in horizontal and vertical locomotor activity. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, reserpine-induced akinesia was reversed by <b>13</b> and <b>14</b> at 1.0, 3.0, 6.0, and 10 mg/kg, po. Akinesia was also reversed by <b>1</b> at 10 mg/kg as the positive control. In Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, each value represents the mean (Â±SEM) of the total distance traveled of <i>n</i> = 14â16 mice per treatment group during the 30 min measurement period in the behavioral test session. Asterisks indicate significant differences as compared with the reserpine + vehicle control group (**<i>P</i> < 0.01, ***<i>P</i> < 0.001, Hochberg test of multiple comparisons).</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Reserpine-Induced Akinesia Study in Rats</h3><div class="NLM_p last">Reserpine is an alkaloid that depletes monoamines by inhibiting their vesicular uptake, resulting in a dramatic reduction of spontaneous locomotor activity (akinesia). Efficacy is defined as reversal of reserpine-induced akinesia. Locomotion was studied in open field activity boxes (L, 17.5 in; W, 17.5 in; and H, 12 in), each containing 20 equally spaced pairs of horizontal infrared photocell beams along one axis. A PC running the activity analysis software measured activity automatically. One activity count corresponded to the consecutive interruption of two infrared beams placed 2.5 cm apart and 2 cm above the cage floor, and the total distance traveled was quantified in cm. Locomotion was studied 60 min after oral administration of <b>13</b> (0.1, 1.0, 3.0, 6.0, and 10 mg/kg, po), <b>14</b> (0.1, 1.0, 3.0, and 10 mg/kg, po), <b>1</b> (10 mg/kg), or vehicle in rats that were pretreated with reserpine (0.6 mg/kg, sc) 18 h earlier. Animals were randomly assigned to treatment groups. Control rats received the respective sc and po vehicles. Rats used were fasted, male Wistar rats. Reserpine was diluted in 1% acetic acid in distilled water, <b>13</b> and <b>14</b> were diluted in 20% HPbCD, and <b>1</b> was diluted in 0.5% methylcellulose. Reserpine produced a marked decrease in motor activity. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, reserpine-induced akinesia was reversed by <b>13</b> at 1.0, 3.0, 6.0, and 10 mg/kg, po, and by <b>14</b> at 1.0, 3.0, and 10 mg/kg, po. Akinesia was also reversed by <b>1</b> at 10 mg/kg as the positive control. In Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, each value represents the mean (Â±SEM) of the total distance traveled of <i>n</i> = 16â18 rats per treatment group during the 60 min measurement period in the behavioral test session. Asterisks indicate significant differences as compared with the reserpine + vehicle control group (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001, Hochberg test of multiple comparisons).</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Rat 6-OHDA Lesion Model of Drug-Induced Rotation</h3><div class="NLM_p last">The neurotoxin 6-OHDA (12 Î¼g) is microinjected unilaterally in the medial forebrain bundle to produce a targeted degeneration of midbrain DA neurons in the pars compacta of the substantia nigra. Fasted, male SpragueâDawley rats weighing 227â260 g at the time of surgery were used in this study. 6-OHDA-induced neurotoxicity is relatively selective for monoaminergic neurons because DA and noradrenergic transporters preferentially take it up. 6-OHDA accumulates in the cytosol of neurons and generates reactive oxygen species, which then inhibit mitochondrial respiratory enzymes leading to metabolic deficits and DA cell death. Degeneration of dopaminergic neurons in the injected side of the brain is accompanied by denervation-induced supersensitivity of postsynaptic DA receptors in the striatum of the lesioned side. An imbalance in DA activity between the two sides of the brain causes asymmetry in motor behavior that can be enhanced by drug treatment. For example, drugs that stimulate postsynaptic DA receptors produce and imbalance in DA signaling that favors the lesion side and induces rotation behavior (turning) toward the side opposite (contralateral to) the lesion side. Three weeks after administration of 6-OHDA, rats were challenged with drugs acting on the dopaminergic system and studied in a behavioral test chamber. Each animal was tethered to high-resolution optical sensor connected to an automated computerized system that quantifies circular motion. One rotation count was defined as one 360Â° turn. To test the effects of neuronal loss on drug responsiveness, motor asymmetry was examined in a screening test with subcutaneous administration of a postsynaptic DA agonist, apomorphine (0.05 mg/kg, sc). This test was repeated 1 week later and then followed 2 weeks later with a behavioral test to L-DOPA (10 mg/kg, po) coadministered with carbidopa (2.5 mg/kg, po). Animals showing an average response of at least 125 contralateral rotations in 1 h after apomorphine were included in further studies. Sixteen animals selected equidistant from the median L-DOPA response were used to test the effects of compound <b>1</b> on rotational behavior. To exclude a priming effect of L-DOPA, L-DOPA [10 mg/kg, po, coadministered with carbidopa (2.5 mg/kg, po)] was administered alone or with each dose of <b>13</b> or <b>14</b> (0.1, 1.0, 3.0, 6.0, and 10.0 mg/kg, po) to all animals on separate testing days in a randomized order, with each rat serving as its own control. The effects of <b>13</b> and <b>14</b> alone were also studied in the model. This within-subjects repeated measure design was carried out with at least two nondrug days elapsing between drug-testing sessions. Control rats received the respective po vehicles. Compounds <b>13</b> and <b>14</b> were diluted in 20% HPÎ²CD and dosed as solutions. L-DOPA and carbidopa were diluted in 0.5% methylcellulose and coadministered as suspensions. Each behavioral test session began with a 30 min interval of acclimation in the test chamber, followed by administration of <b>13</b>, <b>14</b>, or vehicle and measurement of behavior for 60 min. Thereafter, the behavioral effects of L-DOPA (coadministered with carbidopa) or vehicle were measured for 120 min. Each value represents the mean (Â±SEM) of total contralateral rotations of <i>n</i> = 16 rats per treatment group during the 2 h before and after L-DOPA administration. Asterisks indicate significant differences as compared with the L-DOPA + vehicle control treatment group (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001) Tukey's test of multiple comparisons).</div></div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian C. Shook</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#593b2a3136363219302d2a77333733773a3634"><span class="__cf_email__" data-cfemail="dab8a9b2b5b5b19ab3aea9f4b0b4b0f4b9b5b7">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefanie Rassnick</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathaniel Wallace</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Crooke</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Ault</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Devraj Chakravarty</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Kent Barbay</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aihua Wang</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark T. Powell</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristi Leonard</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vernon Alford</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert H. Scannevin</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Carroll</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Lampron</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lori Westover</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heng-Keang Lim</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ronald Russell</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shawn Branum</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth M. Wells</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Damon</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Youells</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xun Li</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Derek A. Beauchamp</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth Rhodes</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul F. Jackson</span> - <span class="hlFld-Affiliation affiliation">Janssen Research and
Development, L.L.C., Welsh and McKean Roads, P.O. Box
776, Spring House, Pennsylvania
19477, United States</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm201640m" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i37" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i37"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i38" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i38"> Abbreviations Used</h2><tr><td class="NLM_term">6-OHDA</td><td class="NLM_def"><p class="first last">6-hydroxydopamine</p></td></tr><tr><td class="NLM_term">MPTP</td><td class="NLM_def"><p class="first last">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson's disease</p></td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">L-DOPA</td><td class="NLM_def"><p class="first last">levodopamine</p></td></tr><tr><td class="NLM_term">MAO-B</td><td class="NLM_def"><p class="first last">monoamine oxidase type B</p></td></tr><tr><td class="NLM_term">COMT</td><td class="NLM_def"><p class="first last">catechol <i>O</i>-methyl-transferase</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-(dimethylamino)pyridine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 41 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lozano, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchison, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostrovsky, J. O.</span><span> </span><span class="NLM_article-title">New developments in understanding the etiology of Parkinson's disease and in its treatment</span> <span class="citation_source-journal">Curr. Opin. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">â</span> <span class="NLM_lpage">790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=783-790&author=A.+M.+Lozanoauthor=A.+E.+Langauthor=W.+D.+Hutchisonauthor=J.+O.+Dostrovsky&title=New+developments+in+understanding+the+etiology+of+Parkinson%27s+disease+and+in+its+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLozano%26aufirst%3DA.%2BM.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DHutchison%26aufirst%3DW.%2BD.%26aulast%3DDostrovsky%26aufirst%3DJ.%2BO.%26atitle%3DNew%2520developments%2520in%2520understanding%2520the%2520etiology%2520of%2520Parkinson%2527s%2520disease%2520and%2520in%2520its%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1998%26volume%3D8%26spage%3D783%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Fink, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivkees, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterfreund, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reppert, S. M.</span><span> </span><span class="NLM_article-title">Molecular cloning of the rat A<sub>2</sub> adenosine receptor: Selective co-expression with D<sub>2</sub> dopamine receptors in rat striatum</span> <span class="citation_source-journal">Mol. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">â</span> <span class="NLM_lpage">195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0169-328X%2892%2990173-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=1279342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVelt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1992&pages=186-195&author=J.+S.+Finkauthor=D.+R.+Weaverauthor=S.+A.+Rivkeesauthor=R.+A.+Peterfreundauthor=A.+E.+Pollackauthor=E.+M.+Adlerauthor=S.+M.+Reppert&title=Molecular+cloning+of+the+rat+A2+adenosine+receptor%3A+Selective+co-expression+with+D2+dopamine+receptors+in+rat+striatum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum</span></div><div class="casAuthors">Fink, J. Stephen; Weaver, David R.; Rivkees, Scott A.; Peterfreund, Robert A.; Pollack, Alexia E.; Adler, Elizabeth M.; Reppert, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-95</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    </div><div class="casAbstract">A cDNA fragment homologous to other G protein-coupled receptors was isolated from rat brain using the PCR method and demonstrated to be abundantly expressed in striatum.  Using this fragment as a probe, a 2.1 kb full-length cDNA was isolated from a rat striatal cDNA library.  This cDNA encodes a protein of 410 amino acids and is highly homologous to previously isolated adenosine receptor cDNA.  Expression of this cDNA in COS cells revealed high affinity (Kd = 38.6 nM) and saturable binding of the A2 adenosine receptor-selective ligand [3H]CGS 21680.  Agonist displacement profile of [3H]CGS 21680 binding was consistent with an adenosine receptor of the A2 subtype (NECA > (R)-PIA > CPA > (S)-PIA).  In situ hybridization demonstrated that rat A2 adenosine receptor mRNA was co-expressed in the same striatal neurons as D2 dopamine receptor mRNA, and never co-expressed with striatal D1 dopamine receptor mRNA.  Several lines of evidence have previously suggested that dopamine-induced changes in motor behavior can be modulated by adenosine analogs acting at the A2 subtype of adenosine receptor in the forebrain.  The co-expression of D2 dopamine and A2 adenosine receptors in a subset of striatal cells provides an anatomical basis for dopaminergic-adenosinergic interactions on motor behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Daq1pagx8bVg90H21EOLACvtfcHk0lizeVBDpcflxQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVelt7o%253D&md5=c625968121ce9599d80d0d7cad3e1b56</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0169-328X%2892%2990173-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0169-328X%252892%252990173-9%26sid%3Dliteratum%253Aachs%26aulast%3DFink%26aufirst%3DJ.%2BS.%26aulast%3DWeaver%26aufirst%3DD.%2BR.%26aulast%3DRivkees%26aufirst%3DS.%2BA.%26aulast%3DPeterfreund%26aufirst%3DR.%2BA.%26aulast%3DPollack%26aufirst%3DA.%2BE.%26aulast%3DAdler%26aufirst%3DE.%2BM.%26aulast%3DReppert%26aufirst%3DS.%2BM.%26atitle%3DMolecular%2520cloning%2520of%2520the%2520rat%2520A2%2520adenosine%2520receptor%253A%2520Selective%2520co-expression%2520with%2520D2%2520dopamine%2520receptors%2520in%2520rat%2520striatum%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D1992%26volume%3D14%26spage%3D186%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Schiffmann, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderhaeghen, J. J.</span><span> </span><span class="NLM_article-title">Distribution of adenosine A<sub>2</sub>receptor mRNA in the human brain</span> <span class="citation_source-journal">Neurosci. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=1991&pages=177-181&author=S.+N.+Schiffmannauthor=F.+Lipertauthor=G.+Vassartauthor=J.+J.+Vanderhaeghen&title=Distribution+of+adenosine+A2receptor+mRNA+in+the+human+brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26aulast%3DLipert%26aufirst%3DF.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DVanderhaeghen%26aufirst%3DJ.%2BJ.%26atitle%3DDistribution%2520of%2520adenosine%2520A2receptor%2520mRNA%2520in%2520the%2520human%2520brain%26jtitle%3DNeurosci.%2520Lett.%26date%3D1991%26volume%3D130%26spage%3D177%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Olanow, C. W.</span><span> </span><span class="NLM_article-title">MAO-B inhibitors in Parkinson's disease</span> <span class="citation_source-journal">Adv. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">â</span> <span class="NLM_lpage">671</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=8420207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK3sXktF2lurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1993&pages=666-671&author=C.+W.+Olanow&title=MAO-B+inhibitors+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">MAO-B inhibitors in Parkinson's disease</span></div><div class="casAuthors">Olanow, C. Warren</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Neurology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">Parkinson's Disease</span>),
    <span class="NLM_cas:pages">666-71</span>CODEN:
                <span class="NLM_cas:coden">ADNRA3</span>;
        ISSN:<span class="NLM_cas:issn">0091-3952</span>.
    </div><div class="casAbstract">A review with 46 ref.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFDRpN_SkdrVg90H21EOLACvtfcHk0lhbCdksjkPnzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktF2lurw%253D&md5=e90fcc306d9c58991fe71c94a48e5fba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26atitle%3DMAO-B%2520inhibitors%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DAdv.%2520Neurol.%26date%3D1993%26volume%3D60%26spage%3D666%26epage%3D671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gordin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, D. J.</span><span> </span><span class="NLM_article-title">Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease</span> <span class="citation_source-journal">J. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">254</span><span class="NLM_x">, </span> <span class="NLM_fpage">IV/37</span><span class="NLM_x">â</span> <span class="NLM_lpage">IV/48</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2007&pages=IV%2F37-IV%2F48&author=A.+Gordinauthor=D.+J.+Brooks&title=Clinical+pharmacology+and+therapeutic+use+of+COMT+inhibition+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGordin%26aufirst%3DA.%26aulast%3DBrooks%26aufirst%3DD.%2BJ.%26atitle%3DClinical%2520pharmacology%2520and%2520therapeutic%2520use%2520of%2520COMT%2520inhibition%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DJ.%2520Neurol.%26date%3D2007%26volume%3D254%26spage%3DIV%252F37%26epage%3DIV%252F48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Olanow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span> </span><span class="NLM_article-title">COMT inhibitors in Parkinson's disease. Can they prevent and/or reverse levodopa-induced motor complications?</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S72</span><span class="NLM_x">â</span> <span class="NLM_lpage">S81</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2004&pages=S72-S81&author=C.+W.+Olanowauthor=F.+Stocchi&title=COMT+inhibitors+in+Parkinson%27s+disease.+Can+they+prevent+and%2For+reverse+levodopa-induced+motor+complications%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DStocchi%26aufirst%3DF.%26atitle%3DCOMT%2520inhibitors%2520in%2520Parkinson%2527s%2520disease.%2520Can%2520they%2520prevent%2520and%252For%2520reverse%2520levodopa-induced%2520motor%2520complications%253F%26jtitle%3DNeurology%26date%3D2004%26volume%3D62%26spage%3DS72%26epage%3DS81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ramlackhansingh, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkheimer, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavese, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, D. J.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor availability in dyskinetic and nondyskinetic patients with Parkinsonâs disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1811</span><span class="NLM_x">â</span> <span class="NLM_lpage">1816</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=1811-1816&author=A.+F.+Ramlackhansinghauthor=S.+K.+Boseauthor=I.+Ahmedauthor=F.+E.+Turkheimerauthor=N.+Paveseauthor=D.+J.+Brooks&title=Adenosine+A2A+receptor+availability+in+dyskinetic+and+nondyskinetic+patients+with+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRamlackhansingh%26aufirst%3DA.%2BF.%26aulast%3DBose%26aufirst%3DS.%2BK.%26aulast%3DAhmed%26aufirst%3DI.%26aulast%3DTurkheimer%26aufirst%3DF.%2BE.%26aulast%3DPavese%26aufirst%3DN.%26aulast%3DBrooks%26aufirst%3DD.%2BJ.%26atitle%3DAdenosine%2520A2A%2520receptor%2520availability%2520in%2520dyskinetic%2520and%2520nondyskinetic%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurology%26date%3D2011%26volume%3D76%26spage%3D1811%26epage%3D1816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Antonini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clilia, R.</span><span> </span><span class="NLM_article-title">Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: Incidence, neurobiological basis, management and prevention</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">â</span> <span class="NLM_lpage">488</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.2165%2F00002018-200932060-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=19459715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVyls7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=475-488&author=A.+Antoniniauthor=R.+Clilia&title=Behavioural+adverse+effects+of+dopaminergic+treatments+in+Parkinson%27s+disease%3A+Incidence%2C+neurobiological+basis%2C+management+and+prevention"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention</span></div><div class="casAuthors">Antonini, Angelo; Cilia, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">475-488</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Treatment of Parkinson's disease has traditionally focused on the management of motor disability while behavioral disturbances have received less attention.  Recently, impulse control disorders and aberrant repetitive behaviors have surged to clin. relevance as they occur during dopamine replacement treatment (mainly with dopamine agonists) and worsen patient and caregiver quality of life.  Patients are unable to adequately est. the neg. consequences of their actions and are prone to entertain compulsive reward-seeking activities.  This review aims to summarize current evidence on the epidemiol. of behavioral disturbances in Parkinson's disease, recent insights into their neurobiol. basis and to discuss strategies for management and prevention.  Studies from 1990 through to Dec. 2008 were retrieved via searches of the Cochrane Database of Systematic Reviews and PubMed.  The mechanisms underlying the development of behavioral disturbances in Parkinson's disease are debated but current evidence points to specific risk factors: male sex, young age at onset, underlying personality traits characterized by high impulsivity and novelty seeking, and personal or family history of addictive disorders.  Specifically, in predisposed individuals dopamine replacement therapy leads to overstimulation of dopamine receptors within the mesocorticolimbic pathways and in turn to the development of addictive behaviors, such as impulse control disorders and compulsive medication intake.  Since these disturbances affect individuals who have often unremarkable psychiatric history and no cognitive impairment, their identification and management is complex.  Compulsive medication intake (described as 'hedonistic homeostatic dysregulation' or 'dopamine dysregulation syndrome') is commonly assocd. with fluctuations in advanced disease, while impulse control disorders frequently occur in early Parkinson's disease and within normal-range medication dosages.  Management primarily requires redn. of dopaminergic therapy but psychosocial support is often required.  Use of selective serotonin reuptake inhibitors in the dose used for obsessive compulsive disorders may help, while benefit from atypical antipsychotics is limited in most cases.  Deep brain stimulation should be considered with caution in these subjects.  Prevention is based on the identification of at-risk individuals and active monitoring.  Given the social and potentially medical-legal consequences of these behaviors, we encourage treating physicians to discuss risks with patients before treatment is initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMVy-djioeu7Vg90H21EOLACvtfcHk0lhancigyacpIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVyls7o%253D&md5=91c7cb882454bfa47f2d0e4dbfae7c32</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.2165%2F00002018-200932060-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200932060-00004%26sid%3Dliteratum%253Aachs%26aulast%3DAntonini%26aufirst%3DA.%26aulast%3DClilia%26aufirst%3DR.%26atitle%3DBehavioural%2520adverse%2520effects%2520of%2520dopaminergic%2520treatments%2520in%2520Parkinson%2527s%2520disease%253A%2520Incidence%252C%2520neurobiological%2520basis%252C%2520management%2520and%2520prevention%26jtitle%3DDrug%2520Saf.%26date%3D2009%26volume%3D32%26spage%3D475%26epage%3D488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hansard, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheetham, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Dopamine, but not norepinephrine or serotonin reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">â</span> <span class="NLM_lpage">958</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1124%2Fjpet.102.039743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=12438514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD38Xptlamt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=952-958&author=M.+J.+Hansardauthor=L.+A.+Smithauthor=M.+J.+Jacksonauthor=S.+C.+Cheethamauthor=P.+Jenner&title=Dopamine%2C+but+not+norepinephrine+or+serotonin+reuptake+inhibition+reverses+motor+deficits+in+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine-treated+primates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates</span></div><div class="casAuthors">Hansard, Matthew J.; Smith, Lance A.; Jackson, Michael J.; Cheetham, Sharon C.; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">952-958</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Monoamine reuptake inhibitors that do not discriminate between the transporters for dopamine (DA), norepinephrine (NE), or 5-hydroxytryptamine (5-HT, serotonin) can reverse locomotor deficits and motor disability in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.  DA reuptake inhibition is presumed to be primarily responsible, but the role played by inhibition of NE and 5-HT reuptake is unknown.  This work evaluated the efficacy of a range of monoamine reuptake inhibitors either alone or in combination in MPTP-treated common marmosets to det. the actions required for effective antiparkinsonian activity.  Monoamine reuptake inhibitors not discriminating between the DA, NE, and 5-HT transporters [1-[1-(3,4-dichlororphenyl)cyclobutyl]-2-(3-diaminethylaminopropylthio)ethanone monocitrate (BTS 74 398) and nomifensine] reversed locomotor deficits and motor disability in MPTP-treated marmosets but bupropion was without effect.  The selective DA reuptake inhibitor 1-(2-(bis-(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (GBR 12909) also reversed these motor deficits.  The relative efficacy of the compds. (BTS 74 398 > GBR 12909 > nomifensine Â» bupropion) paralleled their previously detd. potency in inhibiting DA uptake in vitro and in vivo.  In contrast, the selective NE reuptake inhibitor nisoxetine and the 5-HT reuptake inhibitor sertraline administered alone failed to improve motor function and tended to worsen the deficits.  Coadministration of nisoxetine attenuated the improvement in motor deficits produced by GBR 12909.  Coadministration of sertraline also abolished the reversal of motor deficits produced by GBR 12909.  Coadministration of both sertraline and nisoxetine similarly abolished the improvement of motor deficits produced by GBR 12909.  Mols. possessing potent DA reuptake inhibitory activity may be useful in the treatment of the motor symptoms of Parkinson's disease.  In contrast, there seems to be no role for NE or 5-HT reuptake inhibitors, and they may impair antiparkinsonian activity mediated through dopaminergic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprkAiG5hgKS7Vg90H21EOLACvtfcHk0lhancigyacpIQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xptlamt7g%253D&md5=f5b88eadd0c931fe318d49b4701b8760</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039743%26sid%3Dliteratum%253Aachs%26aulast%3DHansard%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BA.%26aulast%3DJackson%26aufirst%3DM.%2BJ.%26aulast%3DCheetham%26aufirst%3DS.%2BC.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DDopamine%252C%2520but%2520not%2520norepinephrine%2520or%2520serotonin%2520reuptake%2520inhibition%2520reverses%2520motor%2520deficits%2520in%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine-treated%2520primates%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D952%26epage%3D958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Antonini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolosa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poewe, W. H.</span><span> </span><span class="NLM_article-title">A reassessment of risks and benefits of dopamine agonists in Parkinson's disease</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">â</span> <span class="NLM_lpage">937</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FS1474-4422%2809%2970225-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=19709931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Kitr7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=929-937&author=A.+Antoniniauthor=E.+Tolosaauthor=Y.+Mizunoauthor=M.+Yamamotoauthor=W.+H.+Poewe&title=A+reassessment+of+risks+and+benefits+of+dopamine+agonists+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">A reassessment of risks and benefits of dopamine agonists in Parkinson's disease</span></div><div class="casAuthors">Antonini, Angelo; Tolosa, Eduardo; Mizuno, Yoshikuni; Yamamoto, Mitsutoshi; Poewe, Werner H.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">929-937</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurologists have several choices of drugs that have been shown to be effective for the treatment of the symptoms of Parkinson's disease.  Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa.  However, before starting any treatment, the overall benefit-to-risk ratio to individual patients must be considered.  For the dopamine agonists, the available evidence on their symptomatic efficacy, effect on long-term levodopa-related motor complications, putative effect on progression of disease, and adverse event profile must be taken into account.  Recently, the occurrence of adverse events such as leg edema, daytime somnolence, impulse control disorders, and fibrosis have increasingly been recognized.  The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks vs. benefits for individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Rc8SOX7hMrVg90H21EOLACvtfcHk0lhplokCW-6v_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Kitr7I&md5=3126e343054967641c318000aab5d2fe</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2809%2970225-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252809%252970225-X%26sid%3Dliteratum%253Aachs%26aulast%3DAntonini%26aufirst%3DA.%26aulast%3DTolosa%26aufirst%3DE.%26aulast%3DMizuno%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DPoewe%26aufirst%3DW.%2BH.%26atitle%3DA%2520reassessment%2520of%2520risks%2520and%2520benefits%2520of%2520dopamine%2520agonists%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DLancet%2520Neurol.%26date%3D2009%26volume%3D8%26spage%3D929%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span> </span><span class="NLM_article-title">Dopamine agonists in Parkinsonâs disease</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">â</span> <span class="NLM_lpage">677</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1586%2F14737175.8.4.671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=18416667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFSht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=671-677&author=M.+Yamamotoauthor=A.+H.+V.+Schapira&title=Dopamine+agonists+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonists in Parkinson's disease</span></div><div class="casAuthors">Yamamoto, Mitsutoshi; Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson's disease (PD) throughout its course.  As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications.  As an adjunct to levodopa, they improve motor control and limit the need for levodopa in those patients in whom this may be considered relevant.  The non-ergot dopamine agonists in particular have a good safety profile, although as with other agonists, sedation, and cognitive and behavioral problems may be limiting in some patients.  Pramipexole has shown benefit in improving depressive symptoms in PD.  Ropinirole and pramipexole have both demonstrated a redn. in the rate of loss of nigrostriatal innervation as detd. by imaging in PD patients, when compared with levodopa.  Thus, dopamine agonists contribute to several dimensions of the management of PD and have become an integral part of the disease treatment algorithm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxVM_IekUXprVg90H21EOLACvtfcHk0lhplokCW-6v_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFSht70%253D&md5=9a145ab9c49de374322fb02fe543d4ad</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1586%2F14737175.8.4.671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.8.4.671%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DDopamine%2520agonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2008%26volume%3D8%26spage%3D671%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonists and Parkinson's disease</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">â</span> <span class="NLM_lpage">567</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn2000537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=555-567&author=B.+C.+Shookauthor=P.+F.+Jackson&title=Adenosine+A2A+receptor+antagonists+and+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists and Parkinson's Disease</span></div><div class="casAuthors">Shook, Brian C.; Jackson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">555-567</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This Review summarizes and updates the work on adenosine A2A receptor antagonists for Parkinson's disease from 2006 to the present.  There have been numerous publications, patent applications, and press releases within this time frame that highlight new medicinal chem. approaches to this attractive and promising target to treat Parkinson's disease.  The Review is broken down by scaffold type and will discuss the efforts to optimize particular scaffolds for activity, pharmacokinetics, and other drug discovery parameters.  The majority of approaches focus on prepg. selective A2A antagonists, but a few approaches to dual A2A/A1 antagonists will also be highlighted.  The in vivo profiles of compds. will be highlighted and discussed to compare activities across different chem. series.  A clin. report and update will be given on compds. that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9jbqVC-a6P7Vg90H21EOLACvtfcHk0lhplokCW-6v_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D&md5=81746259f96dd1a270f12c3cb2dbe1d3</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fcn2000537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn2000537%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520and%2520Parkinson%2527s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D555%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Neustadt, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamford, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertorelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredduzzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen-Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, K.</span><span> </span><span class="NLM_article-title">Potent and selective adenosine A<sub>2A</sub> antagonists 1,2,4-triazolo[1,5-c]pyrimidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">â</span> <span class="NLM_lpage">971</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=967-971&author=B.+R.+Neustadtauthor=H.+Liuauthor=J.+Haoauthor=W.+J.+Greenleeauthor=A.+W.+Stamfordauthor=C.+Fosterauthor=L.+Arikauthor=J.+Lachowiczauthor=H.+Zhangauthor=R.+Bertorelliauthor=S.+Fredduzziauthor=G.+Vartyauthor=M.+Cohen-Williamsauthor=K.+Ng&title=Potent+and+selective+adenosine+A2A+antagonists+1%2C2%2C4-triazolo%5B1%2C5-c%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DArik%26aufirst%3DL.%26aulast%3DLachowicz%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DVarty%26aufirst%3DG.%26aulast%3DCohen-Williams%26aufirst%3DM.%26aulast%3DNg%26aufirst%3DK.%26atitle%3DPotent%2520and%2520selective%2520adenosine%2520A2A%2520antagonists%25201%252C2%252C4-triazolo%255B1%252C5-c%255Dpyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D967%26epage%3D971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Slee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorjani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueter, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malany, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joswig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Palomino, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gual, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, J.</span><span> </span><span class="NLM_article-title">Identification of novel, water soluble, 2-amino-N-pyrimin-4-ylacetamides as A<sub>2A</sub> receptor antagonists with in vivo activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">400</span><span class="NLM_x">â</span> <span class="NLM_lpage">406</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070623o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=400-406&author=D.+H.+Sleeauthor=X.+Zhangauthor=M.+Moorjaniauthor=E.+Linauthor=M.+C.+Lanierauthor=Y.+Chenauthor=J.+K.+Rueterauthor=S.+M.+Lechnerauthor=S.+Markisonauthor=S.+Malanyauthor=T.+Joswigauthor=M.+Santosauthor=R.+S.+Grossauthor=J.+P.+Williamsauthor=J.+C.+Castro-Palominoauthor=M.+I.+Crespoauthor=M.+Pratauthor=S.+Gualauthor=J.+L.+Diazauthor=J.+Wenauthor=Z.+O%27Brienauthor=J.+Saunders&title=Identification+of+novel%2C+water+soluble%2C+2-amino-N-pyrimin-4-ylacetamides+as+A2A+receptor+antagonists+with+in+vivo+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1021%2Fjm070623o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070623o%26sid%3Dliteratum%253Aachs%26aulast%3DSlee%26aufirst%3DD.%2BH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMoorjani%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DLanier%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DRueter%26aufirst%3DJ.%2BK.%26aulast%3DLechner%26aufirst%3DS.%2BM.%26aulast%3DMarkison%26aufirst%3DS.%26aulast%3DMalany%26aufirst%3DS.%26aulast%3DJoswig%26aufirst%3DT.%26aulast%3DSantos%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DR.%2BS.%26aulast%3DWilliams%26aufirst%3DJ.%2BP.%26aulast%3DCastro-Palomino%26aufirst%3DJ.%2BC.%26aulast%3DCrespo%26aufirst%3DM.%2BI.%26aulast%3DPrat%26aufirst%3DM.%26aulast%3DGual%26aufirst%3DS.%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DO%2527Brien%26aufirst%3DZ.%26aulast%3DSaunders%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520novel%252C%2520water%2520soluble%252C%25202-amino-N-pyrimin-4-ylacetamides%2520as%2520A2A%2520receptor%2520antagonists%2520with%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D400%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brescia, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuinness, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, I.</span><span> </span><span class="NLM_article-title">Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A<sub>2A</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">â</span> <span class="NLM_lpage">1402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1399-1402&author=Y.+Shaoauthor=A.+G.+Coleauthor=M.+R.+Bresciaauthor=L.+Y.+Qinauthor=J.+Duoauthor=T.+M.+Staufferauthor=L.+L.+Rokoszauthor=B.+F.+McGuinnessauthor=I.+Henderson&title=Synthesis+and+SAR+studies+of+trisubstituted+purinones+as+potent+and+selective+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DY.%26aulast%3DCole%26aufirst%3DA.%2BG.%26aulast%3DBrescia%26aufirst%3DM.%2BR.%26aulast%3DQin%26aufirst%3DL.%2BY.%26aulast%3DDuo%26aufirst%3DJ.%26aulast%3DStauffer%26aufirst%3DT.%2BM.%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DMcGuinness%26aufirst%3DB.%2BF.%26aulast%3DHenderson%26aufirst%3DI.%26atitle%3DSynthesis%2520and%2520SAR%2520studies%2520of%2520trisubstituted%2520purinones%2520as%2520potent%2520and%2520selective%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1399%26epage%3D1402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Vu, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumaravel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phadke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engber, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span> </span><span class="NLM_article-title">Piperazine derivatives of 1,2,4-triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A<sub>2A</sub> receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4291</span><span class="NLM_x">â</span> <span class="NLM_lpage">4299</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0498405" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4291-4299&author=C.+B.+Vuauthor=B.+Pengauthor=G.+Kumaravelauthor=G.+Smitsauthor=X.+Jinauthor=D.+Phadkeauthor=T.+Engberauthor=C.+Huangauthor=J.+Reillyauthor=S.+Tamauthor=D.+Grantauthor=G.+Hetuauthor=L.+Chenauthor=J.+Zhangauthor=R.+C.+Petter&title=Piperazine+derivatives+of+1%2C2%2C4-triazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazine+as+potent+and+selective+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=10.1021%2Fjm0498405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0498405%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DC.%2BB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DKumaravel%26aufirst%3DG.%26aulast%3DSmits%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DPhadke%26aufirst%3DD.%26aulast%3DEngber%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DGrant%26aufirst%3DD.%26aulast%3DHetu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26atitle%3DPiperazine%2520derivatives%2520of%25201%252C2%252C4-triazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazine%2520as%2520potent%2520and%2520selective%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4291%26epage%3D4299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Latini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedata, F.</span><span> </span><span class="NLM_article-title">Adenosine in the central nervous system: release mechanisms and extracellular concentrations</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">â</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1046%2Fj.1471-4159.2001.00607.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=11701750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotlSht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2001&pages=463-484&author=S.+Latiniauthor=F.+Pedata&title=Adenosine+in+the+central+nervous+system%3A+release+mechanisms+and+extracellular+concentrations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine in the central nervous system: release mechanisms and extracellular concentrations</span></div><div class="casAuthors">Latini, Serena; Pedata, Felicita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-484</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine has several functions within the CNS that involve an inhibitory tone of neurotransmission and neuroprotective actions in pathol. conditions.  The understanding of adenosine prodn. and release in the brain is therefore of fundamental importance and has been extensively studied.  Conflicting results are often obtained regarding the cellular source of adenosine, the stimulus that induces release and the mechanism for release, in relation to different exptl. approaches used to study adenosine prodn. and release.  A neuronal origin of adenosine has been demonstrated through electrophysiol. approaches showing that neurons can release significant quantities of adenosine, sufficient to activate adenosine receptors and to modulate synaptic functions.  Specific actions of adenosine are mediated by different receptor subtypes (A1, A2A, A2B and A3), which are activated by various ranges of adenosine concns.  Another important issue is the measurement of adenosine concns. in the extracellular fluid under different conditions in order to know the degree of receptor stimulation and understand adenosine central actions.  For this purpose, several exptl. approaches have been used both in vivo and in vitro, which provide an estn. of basal adenosine levels in the range of 50-200 nM.  The purpose of this review is to describe pathways of adenosine prodn. and metab., and to summarize characteristics of adenosine release in the brain in response to different stimuli.  Finally, studies performed to evaluate adenosine concns. under physiol. and hypoxic/ischemic conditions will be described to evaluate the degree of adenosine receptor activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD81oBeM405rVg90H21EOLACvtfcHk0ljxdWv31Xf1pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotlSht7Y%253D&md5=c9636f206b3dbf0e3e2aa1c9ac9bb9fc</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2001.00607.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2001.00607.x%26sid%3Dliteratum%253Aachs%26aulast%3DLatini%26aufirst%3DS.%26aulast%3DPedata%26aufirst%3DF.%26atitle%3DAdenosine%2520in%2520the%2520central%2520nervous%2520system%253A%2520release%2520mechanisms%2520and%2520extracellular%2520concentrations%26jtitle%3DJ.%2520Neurochem.%26date%3D2001%26volume%3D79%26spage%3D463%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dunwiddie, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masino, S. A.</span><span> </span><span class="NLM_article-title">The role and regulation of adenosine in the central nervous system</span> <span class="citation_source-journal">Annu. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">â</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1146%2Fannurev.neuro.24.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=11283304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3MXls1Siu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2001&pages=31-55&author=T.+V.+Dunwiddieauthor=S.+A.+Masino&title=The+role+and+regulation+of+adenosine+in+the+central+nervous+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">The role and regulation of adenosine in the central nervous system</span></div><div class="casAuthors">Dunwiddie, Thomas V.; Masino, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-55</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 166 refs.  Adenosine is a modulator that has a pervasive and generally inhibitory effect on neuronal activity.  Tonic activation of adenosine receptors by adenosine that is normally present in the extracellular space in brain tissue leads to inhibitory effects that appear to be mediated by both adenosine A1 and A2A receptors.  Relief from this tonic inhibition by receptor antagonists such as caffeine accounts for the excitatory actions of these agents.  Characterization of the effects of adenosine receptor agonists and antagonists has led to numerous hypotheses concerning the role of this nucleoside.  Previous work has established a role for adenosine in a diverse array of neural phenomena, which include regulation of sleep and the level of arousal, neuroprotection, regulation of seizure susceptibility, locomotor effects, analgesia, mediation of the effects of ethanol, and chronic drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0o-Qitx0a6LVg90H21EOLACvtfcHk0ljxdWv31Xf1pg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXls1Siu7c%253D&md5=b9e0a3a4bc0c6cc23cc0ab9728d4b410</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.24.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.24.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DDunwiddie%26aufirst%3DT.%2BV.%26aulast%3DMasino%26aufirst%3DS.%2BA.%26atitle%3DThe%2520role%2520and%2520regulation%2520of%2520adenosine%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2001%26volume%3D24%26spage%3D31%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Stiles, G. L.</span><span> </span><span class="NLM_article-title">Adenosine receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">6451</span><span class="NLM_x">â</span> <span class="NLM_lpage">6454</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=6451-6454&author=G.+L.+Stiles&title=Adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStiles%26aufirst%3DG.%2BL.%26atitle%3DAdenosine%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D6451%26epage%3D6454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rosin, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robeva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodard, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyenet, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, J.</span><span> </span><span class="NLM_article-title">Immunohistochemical localization of adenosine A<sub>2A</sub> receptors in rat central nervous system</span> <span class="citation_source-journal">J. Comp. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">â</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1002%2F%28SICI%291096-9861%2819981116%29401%3A2%3C163%3A%3AAID-CNE2%3E3.0.CO%3B2-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=9822147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK1cXntlanu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1998&pages=163-186&author=D.+L.+Rosinauthor=A.+Robevaauthor=R.+L.+Woodardauthor=P.+G.+Guyenetauthor=J.+Linden&title=Immunohistochemical+localization+of+adenosine+A2A+receptors+in+rat+central+nervous+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system</span></div><div class="casAuthors">Rosin, Diane L.; Robeva, Anna; Woodard, Robin L.; Guyenet, Patrice G.; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Comparative Neurology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-186</span>CODEN:
                <span class="NLM_cas:coden">JCNEAM</span>;
        ISSN:<span class="NLM_cas:issn">0021-9967</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The A2A adenosine receptor (A2A-AR) transcript and radioligand binding sites have a distinct distribution in rat brain, restricted primarily to the striatum, nucleus accumbens, and olfactory tubercles.  The authors describe here the use of purified recombinant human A2A-ARs to generate a monoclonal antibody that has been used to better resolve the distribution of A2A-ARs in rat brain.  The antibody can detect 1 ng of purified recombinant receptor by Western blotting and is potent (EC50 = 0.62 Î¼g/mL) and highly selective for the A12A-AR subtype.  By Western blotting, the apparent mol. mass of recombinant and rat striatal receptors shifts upon deglycosylation from 43-48 to 42 kilodaltons.  Analyses of chimeric A1/A2A-ARs and synthesis of a blocking peptide pinpointed the epitope (SQPLPGER) of the antibody to the center of the third intracellular loop of the receptor.  Incubation of rat striatal membranes with antibody reduces receptor coupling to G-proteins.  In rat brain, dense A2A-AR-like immunoreactivity that is eliminated by the blocking peptide was found in the neuropil of the striatum, nucleus accumbens (rostral pole, core, and shell), cell bridges of the striatum, olfactory tubercles, and areas of extended amygdala with somewhat lighter labeling in the globus pallidus and nucleus of the solitary tract.  Light perikaryal labeling was found in other areas of the brain, including the cortex, hippocampus, thalamus, cerebellum, and portions of the hindbrain.  The obsd. distribution of A2A-AR immunoreactivity throughout the neuraxis is consistent with the receptors' role in modulating dopaminergic neurotransmission and central control of cardiovascular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFUvkZHeam7Vg90H21EOLACvtfcHk0lhM1FGOo_Kppw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntlanu7Y%253D&md5=297b00a8d21c3430128983539209aa65</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-9861%2819981116%29401%3A2%3C163%3A%3AAID-CNE2%3E3.0.CO%3B2-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-9861%252819981116%2529401%253A2%253C163%253A%253AAID-CNE2%253E3.0.CO%253B2-D%26sid%3Dliteratum%253Aachs%26aulast%3DRosin%26aufirst%3DD.%2BL.%26aulast%3DRobeva%26aufirst%3DA.%26aulast%3DWoodard%26aufirst%3DR.%2BL.%26aulast%3DGuyenet%26aufirst%3DP.%2BG.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DImmunohistochemical%2520localization%2520of%2520adenosine%2520A2A%2520receptors%2520in%2520rat%2520central%2520nervous%2520system%26jtitle%3DJ.%2520Comp.%2520Neurol.%26date%3D1998%26volume%3D401%26spage%3D163%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svenningsson, P.</span><span> </span><span class="NLM_article-title">Striatal adenosine A<sub>2A</sub> receptors-where are they? What do they do? Comments</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">â</span> <span class="NLM_lpage">47</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1998&pages=46-47&author=B.+B.+Fredholmauthor=P.+Svenningsson&title=Striatal+adenosine+A2A+receptors-where+are+they%3F+What+do+they+do%3F+Comments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DSvenningsson%26aufirst%3DP.%26atitle%3DStriatal%2520adenosine%2520A2A%2520receptors-where%2520are%2520they%253F%2520What%2520do%2520they%2520do%253F%2520Comments%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1998%26volume%3D19%26spage%3D46%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ishiwata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span> </span><span class="NLM_article-title">First visualization of adenosine A<sub>2A</sub> receptors in the human brain by positron emission tomography with [<sup>11</sup>C]TMSX</span> <span class="citation_source-journal">Synapse</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">â</span> <span class="NLM_lpage">136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2005&pages=133-136&author=K.+Ishiwataauthor=M.+Mishinaauthor=Y.+Kimuraauthor=K.+Odaauthor=T.+Sasakiauthor=K.+Ishii&title=First+visualization+of+adenosine+A2A+receptors+in+the+human+brain+by+positron+emission+tomography+with+%5B11C%5DTMSX"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DMishina%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DK.%26atitle%3DFirst%2520visualization%2520of%2520adenosine%2520A2A%2520receptors%2520in%2520the%2520human%2520brain%2520by%2520positron%2520emission%2520tomography%2520with%2520%255B11C%255DTMSX%26jtitle%3DSynapse%26date%3D2005%26volume%3D55%26spage%3D133%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Svenningsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedvall, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span> </span><span class="NLM_article-title">Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study</span> <span class="citation_source-journal">Synapse</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">â</span> <span class="NLM_lpage">335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=322-335&author=P.+Svenningssonauthor=H.+Hallauthor=G.+Sedvallauthor=B.+B.+Fredholm&title=Distribution+of+adenosine+receptors+in+the+postmortem+human+brain%3A+an+extended+autoradiographic+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DHall%26aufirst%3DH.%26aulast%3DSedvall%26aufirst%3DG.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DDistribution%2520of%2520adenosine%2520receptors%2520in%2520the%2520postmortem%2520human%2520brain%253A%2520an%2520extended%2520autoradiographic%2520study%26jtitle%3DSynapse%26date%3D1997%26volume%3D27%26spage%3D322%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Varani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenzi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casetta, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLennan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granieri, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borea, P. A.</span><span> </span><span class="NLM_article-title">A<sub>2A</sub> adenosine receptor overexpression and functionality, as well as TNF-Î± levels, correlate with motor symptoms in Parkinson's disease</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">â</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=587-598&author=K.+Varaniauthor=F.+Vincenziauthor=A.+Tosiauthor=S.+Gessiauthor=I.+Casettaauthor=G.+Granieriauthor=P.+Fazioauthor=E.+Leungauthor=S.+MacLennanauthor=E.+Granieriauthor=P.+A.+Borea&title=A2A+adenosine+receptor+overexpression+and+functionality%2C+as+well+as+TNF-%CE%B1+levels%2C+correlate+with+motor+symptoms+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DVincenzi%26aufirst%3DF.%26aulast%3DTosi%26aufirst%3DA.%26aulast%3DGessi%26aufirst%3DS.%26aulast%3DCasetta%26aufirst%3DI.%26aulast%3DGranieri%26aufirst%3DG.%26aulast%3DFazio%26aufirst%3DP.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DMacLennan%26aufirst%3DS.%26aulast%3DGranieri%26aufirst%3DE.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DA2A%2520adenosine%2520receptor%2520overexpression%2520and%2520functionality%252C%2520as%2520well%2520as%2520TNF-%25CE%25B1%2520levels%252C%2520correlate%2520with%2520motor%2520symptoms%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DFASEB%2520J.%26date%3D2010%26volume%3D24%26spage%3D587%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Pollack, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, J. S.</span><span> </span><span class="NLM_article-title">Adenosine antagonists potentiate D2 dopamine dependent activation of Fos in the striatopallidal pathway</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">â</span> <span class="NLM_lpage">728</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1995&pages=721-728&author=A.+E.+Pollackauthor=J.+S.+Fink&title=Adenosine+antagonists+potentiate+D2+dopamine+dependent+activation+of+Fos+in+the+striatopallidal+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPollack%26aufirst%3DA.%2BE.%26aulast%3DFink%26aufirst%3DJ.%2BS.%26atitle%3DAdenosine%2520antagonists%2520potentiate%2520D2%2520dopamine%2520dependent%2520activation%2520of%2520Fos%2520in%2520the%2520striatopallidal%2520pathway%26jtitle%3DNeuroscience%26date%3D1995%26volume%3D68%26spage%3D721%26epage%3D728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Duty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Animal models of Parkinson's disease: A source of novel treatments and clues to the cause of the disease</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">1357</span><span class="NLM_x">â</span> <span class="NLM_lpage">1391</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1111%2Fj.1476-5381.2011.01426.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=21486284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1357-1391&author=S.+Dutyauthor=P.+Jenner&title=Animal+models+of+Parkinson%27s+disease%3A+A+source+of+novel+treatments+and+clues+to+the+cause+of+the+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease</span></div><div class="casAuthors">Duty, Susan; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1391</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness.  Models based on specific pathogenic mechanisms may subsequently lead to the development of neuroprotective agents for PD that stop or slow disease progression.  The array of available rodent models is large and ranges from acute pharmacol. models, such as the reserpine- or haloperidol-treated rats that display one or more parkinsonian signs, to models exhibiting destruction of the dopaminergic nigro-striatal pathway, such as the classical 6-hydroxydopamine (6-OHDA) rat and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models.  All of these have provided test beds in which new mols. for treating the motor symptoms of PD can be assessed.  In addn., the emergence of abnormal involuntary movements (AIMs) with repeated treatment of 6-OHDA-lesioned rats with L-DOPA has allowed for examn. of the mechanisms responsible for treatment-related dyskinesia in PD, and the detection of mols. able to prevent or reverse their appearance.  Other toxin-based models of nigro-striatal tract degeneration include the systemic administration of the pesticides rotenone and paraquat, but while providing clues to disease pathogenesis, these are not so commonly used for drug development.  The MPTP-treated primate model of PD, which closely mimics the clin. features of PD and in which all currently used anti-parkinsonian medications have been shown to be effective, is undoubtedly the most clin.-relevant of all available models.  The MPTP-treated primate develops clear dyskinesia when repeatedly exposed to L-DOPA, and these parkinsonian animals have shown responses to novel dopaminergic agents that are highly predictive of their effect in man.  Whether non-dopaminergic drugs show the same degree of predictability of response is a matter of debate.  As our understanding of the pathogenesis of PD has improved, so new rodent models produced by agents mimicking these mechanisms, including proteasome inhibitors such as PSI, lactacystin and epoximycin or inflammogens like lipopolysaccharide (LPS) have been developed.  A further generation of models aimed at mimicking the genetic causes of PD has also sprung up.  While these newer models have provided further clues to the disease pathol., they have so far been less commonly used for drug development.  There is little doubt that the availability of exptl. animal models of PD has dramatically altered dopaminergic drug treatment of the illness and the prevention and reversal of drug-related side effects that emerge with disease progression and chronic medication.  However, so far, we have made little progress in moving into other pharmacol. areas for the treatment of PD, and we have not developed models that reflect the progressive nature of the illness and its complexity in terms of the extent of pathol. and biochem. change.  Only when this occurs are we likely to make progress in developing agents to stop or slow the disease progression.  The overarching question that draws all of these models together in the quest for better drug treatments for PD is how well do they recapitulate the human condition and how predictive are they of successful translation of drugs into the clinic.  This article aims to clarify the current position and highlight the strengths and weaknesses of available models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoptecPrVBnv7Vg90H21EOLACvtfcHk0lhTQmfhVYPcQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM&md5=587852b53e518988f9ab89436aa23326</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01426.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01426.x%26sid%3Dliteratum%253Aachs%26aulast%3DDuty%26aufirst%3DS.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DAnimal%2520models%2520of%2520Parkinson%2527s%2520disease%253A%2520A%2520source%2520of%2520novel%2520treatments%2520and%2520clues%2520to%2520the%2520cause%2520of%2520the%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1357%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beilstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonsalla, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzchild, M. A.</span><span> </span><span class="NLM_article-title">Neuroprotection by caffeine and A<sub>2A</sub> adenosine receptor inactivation in a model of Parkinson's disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">RC143/1</span><span class="NLM_x">â</span> <span class="NLM_lpage">RC143/6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=RC143%2F1-RC143%2F6&author=J.+F.+Chenauthor=K.+Xuauthor=J.+P.+Petzerauthor=R.+Staalauthor=Y.+H.+Xuauthor=M.+Beilsteinauthor=P.+K.+Sonsallaauthor=K.+Castagnoliauthor=N.+Castagnoliauthor=M.+A.+Schwarzchild&title=Neuroprotection+by+caffeine+and+A2A+adenosine+receptor+inactivation+in+a+model+of+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DStaal%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DY.%2BH.%26aulast%3DBeilstein%26aufirst%3DM.%26aulast%3DSonsalla%26aufirst%3DP.%2BK.%26aulast%3DCastagnoli%26aufirst%3DK.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DSchwarzchild%26aufirst%3DM.%2BA.%26atitle%3DNeuroprotection%2520by%2520caffeine%2520and%2520A2A%2520adenosine%2520receptor%2520inactivation%2520in%2520a%2520model%2520of%2520Parkinson%2527s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2001%26volume%3D21%26spage%3DRC143%252F1%26epage%3DRC143%252F6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Grondin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedard, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahar, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregoire, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span> </span><span class="NLM_article-title">Antiparkinsonian effect of a new adenosine A<sub>2A</sub> receptor antagonist in MPTP-treated monkeys</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1673</span><span class="NLM_x">â</span> <span class="NLM_lpage">1677</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1999&pages=1673-1677&author=R.+Grondinauthor=P.+J.+Bedardauthor=A.+J.+Taharauthor=L.+Gregoireauthor=A.+Moriauthor=H.+Kase&title=Antiparkinsonian+effect+of+a+new+adenosine+A2A+receptor+antagonist+in+MPTP-treated+monkeys"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrondin%26aufirst%3DR.%26aulast%3DBedard%26aufirst%3DP.%2BJ.%26aulast%3DTahar%26aufirst%3DA.%2BJ.%26aulast%3DGregoire%26aufirst%3DL.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DKase%26aufirst%3DH.%26atitle%3DAntiparkinsonian%2520effect%2520of%2520a%2520new%2520adenosine%2520A2A%2520receptor%2520antagonist%2520in%2520MPTP-treated%2520monkeys%26jtitle%3DNeurology%26date%3D1999%26volume%3D52%26spage%3D1673%26epage%3D1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ongini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monopoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Impagnatiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredduzzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzchild, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. F.</span><span> </span><span class="NLM_article-title">Dual actions of A<sub>2A</sub> adenosine receptor antagonists on motor dysfunction and neurodegenerative processes</span> <span class="citation_source-journal">Drug Dev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2001&pages=379-386&author=E.+Onginiauthor=A.+Monopoliauthor=F.+Impagnatielloauthor=S.+Fredduzziauthor=M.+Schwarzchildauthor=J.+F.+Chen&title=Dual+actions+of+A2A+adenosine+receptor+antagonists+on+motor+dysfunction+and+neurodegenerative+processes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOngini%26aufirst%3DE.%26aulast%3DMonopoli%26aufirst%3DA.%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DSchwarzchild%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26atitle%3DDual%2520actions%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520on%2520motor%2520dysfunction%2520and%2520neurodegenerative%2520processes%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2001%26volume%3D52%26spage%3D379%26epage%3D386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwana, Y.</span><span> </span><span class="NLM_article-title">Neuroprotection by adenosine A<sub>2A</sub> receptor blockade in experimental models of Parkinson's disease</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1046%2Fj.0022-3042.2001.00694.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=11902116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD38XptV2jsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2002&pages=262-270&author=K.+Ikedaauthor=M.+Kurokawaauthor=S.+Aoyamaauthor=Y.+Kuwana&title=Neuroprotection+by+adenosine+A2A+receptor+blockade+in+experimental+models+of+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16dR"><div class="casContent"><span class="casTitleNuber">16d</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease</span></div><div class="casAuthors">Ikeda, Ken; Kurokawa, Masako; Aoyama, Shiro; Kuwana, Yoshihisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-270</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Adenosine A2A receptors are abundant in the caudate-putamen and involved in the motor control in several species.  In MPTP-treated monkeys, A2A receptor-blockade with an antagonist alleviates parkinsonian symptoms without provoking dyskinesia, suggesting this receptor may offer a new target for the antisymptomatic therapy of Parkinson's disease.  In the present study, a significant neuroprotective effect of A2A receptor antagonists is shown in exptl. models of Parkinson's disease.  Oral administration of A2A receptor antagonists protected against the loss of nigral dopaminergic neuronal cells induced by 6-hydroxydopamine in rats.  A2A antagonists also prevented the functional loss of dopaminergic nerve terminals in the striatum and the ensuing gliosis caused by MPTP in mice.  The neuroprotective property of A2A receptor antagonists may be exerted by altering the packaging of these neurotoxins into vesicles, thus reducing their effective intracellular concn.  We therefore conclude that the adenosine A2A receptor may provide a novel target for the long-term medication of Parkinson's disease, because blockade of this receptor exerts both acutely antisymptomatic and chronically neuroprotective activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb8toXJpqCzLVg90H21EOLACvtfcHk0liSWCmrnkGwfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptV2jsQ%253D%253D&md5=68ddb10b0be184393df31567d2acc7ca</span></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=10.1046%2Fj.0022-3042.2001.00694.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0022-3042.2001.00694.x%26sid%3Dliteratum%253Aachs%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DKurokawa%26aufirst%3DM.%26aulast%3DAoyama%26aufirst%3DS.%26aulast%3DKuwana%26aufirst%3DY.%26atitle%3DNeuroprotection%2520by%2520adenosine%2520A2A%2520receptor%2520blockade%2520in%2520experimental%2520models%2520of%2520Parkinson%2527s%2520disease%26jtitle%3DJ.%2520Neurochem.%26date%3D2002%26volume%3D80%26spage%3D262%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, R. K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwana, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">â</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1002%2Fana.410430415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=9546333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK1cXisFyisbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1998&pages=507-513&author=T.+Kandaauthor=M.+J.+Jacksonauthor=L.+A.+Smithauthor=R.+K.+B.+Pearceauthor=J.+Nakamuraauthor=H.+Kaseauthor=Y.+Kuwanaauthor=P.+Jenner&title=Adenosine+A2A+antagonist%3A+a+novel+antiparkinsonian+agent+that+does+not+provoke+dyskinesia+in+parkinsonian+monkeys"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys</span></div><div class="casAuthors">Kanda, Tomoyuki; Jackson, Michael J.; Smith, Lance A.; Pearce, Ronald K. B.; Nakamura, Joji; Kase, Hiroshi; Kuwana, Yoshihisa; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">507-513</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Treatment of Parkinson's disease with L-DOPA therapy leads to long-term complications, including loss of drug efficacy and the onset of dyskinesia.  Adenosine A2A receptors in the striatum are selectively localized to GABAergic output neurons of the striato-pallidal pathway and may avoid such problems.  The novel adenosine A2A receptor antagonist KW-6002 was examd. for antiparkinsonian activity in MPTP-treated primates.  Oral administration of KW-6002 reversed motor disability in MPTP-treated common marmosets in a dose-dependent manner.  However, KW-6002 only modestly increased overall locomotor activity and did not cause abnormal movement, such as stereotypy.  The ability of KW-6002 to reverse motor disability was maintained on repeated daily administration for 21 days, and no tolerance was obsd.  KW-6002 induced little or no dyskinesia in MPTP-treated primates previously primed to exhibit dyskinesia by prior exposure to L-DOPA.  Thus, selective adenosine A2A receptor antagonists represent a new class of antiparkinsonian agents that do not produce hyperactivity or induce dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQ20y4EvPvLVg90H21EOLACvtfcHk0lg8fOIEUmHO3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFyisbw%253D&md5=36af21fdde02b63c588e3ca03785dafe</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1002%2Fana.410430415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.410430415%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BA.%26aulast%3DPearce%26aufirst%3DR.%2BK.%2BB.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DKuwana%26aufirst%3DY.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DAdenosine%2520A2A%2520antagonist%253A%2520a%2520novel%2520antiparkinsonian%2520agent%2520that%2520does%2520not%2520provoke%2520dyskinesia%2520in%2520parkinsonian%2520monkeys%26jtitle%3DAnn.%2520Neurol.%26date%3D1998%26volume%3D43%26spage%3D507%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Koga, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwana, Y.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">â</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FS0014-2999%2800%2900745-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=11090641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1ygsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2000&pages=249-255&author=K.+Kogaauthor=M.+Kurokawaauthor=M.+Ochiauthor=J.+Nakamuraauthor=Y.+Kuwana&title=Adenosine+A2A+receptor+antagonists+KF17837+and+KW-6002+potentiate+rotation+induced+by+dopaminergic+drugs+in+hemi-Parkinsonian+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats</span></div><div class="casAuthors">Koga, K.; Kurokawa, M.; Ochi, M.; Nakamura, J.; Kuwana, Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-255</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The effects of novel adenosine A2A receptor antagonists KF17837 ((E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione) and KW-6002 ((E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione), on rotational behavior induced by apomorphine or L-DOPA (l-3,4-dihydroxyphenylalanine) were investigated in rats with unilateral 6-hydroxydopamine lesions.  Both KF17837 and KW-6002 slightly induced rotational behavior per se.  However, KF17837 and KW-6002 significantly increased the total counts of turning induced by apomorphine at doses of 3 mg/kg, p.o. and 10 mg/kg, p.o., and at doses of 1 mg/kg, p.o. and higher, resp.  KF17837 and KW-6002 also potentiated the rotational behavior induced by L-DOPA at a dose of 3 mg/kg, p.o.  Furthermore, i.c.v. injection (10 Î¼g/20 Î¼l) of a selective adenosine A2 receptor agonist CGS 21680 {2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine} partially prevented the rotational behavior induced by apomorphine and this inhibition was reversed by KW-6002 (1 mg/kg, p.o.).  The increase in total counts of apomorphine-induced turning by the adenosine A2A receptor antagonists seems to be mainly attributable to prolongation of turning duration rather than enhancement of intensity.  These results suggest that these adenosine A2A receptor antagonists may be useful to ameliorate shortening in the duration of dopaminergic drug response in patients with advanced Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZbOArDCv31rVg90H21EOLACvtfcHk0lg8fOIEUmHO3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1ygsb0%253D&md5=1763bbd6e38fbfc8bf3f9ab1b3f12374</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2800%2900745-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252800%252900745-7%26sid%3Dliteratum%253Aachs%26aulast%3DKoga%26aufirst%3DK.%26aulast%3DKurokawa%26aufirst%3DM.%26aulast%3DOchi%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKuwana%26aufirst%3DY.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520KF17837%2520and%2520KW-6002%2520potentiate%2520rotation%2520induced%2520by%2520dopaminergic%2520drugs%2520in%2520hemi-Parkinsonian%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D408%26spage%3D249%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neustadt, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamford, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ongini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monopoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertorelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, K. I.</span><span> </span><span class="NLM_article-title">Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1376</span><span class="NLM_x">â</span> <span class="NLM_lpage">1380</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1376-1380&author=B.+R.+Neustadtauthor=J.+Haoauthor=N.+Lindoauthor=W.+J.+Greenleeauthor=A.+W.+Stamfordauthor=D.+Tulshianauthor=E.+Onginiauthor=J.+Hunterauthor=A.+Monopoliauthor=R.+Bertorelliauthor=C.+Fosterauthor=L.+Arikauthor=J.+Lachowiczauthor=K.+Ngauthor=K.+I.+Feng&title=Potent%2C+selective%2C+and+orally+active+adenosine+A2A+receptor+antagonists%3A+arylpiperazine+derivatives+of+pyrazolo%5B4%2C3-e%5D-1%2C2%2C4-triazolo%5B1%2C5-c%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DLindo%26aufirst%3DN.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DOngini%26aufirst%3DE.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DMonopoli%26aufirst%3DA.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DArik%26aufirst%3DL.%26aulast%3DLachowicz%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DK.%2BI.%26atitle%3DPotent%252C%2520selective%252C%2520and%2520orally%2520active%2520adenosine%2520A2A%2520receptor%2520antagonists%253A%2520arylpiperazine%2520derivatives%2520of%2520pyrazolo%255B4%252C3-e%255D-1%252C2%252C4-triazolo%255B1%252C5-c%255Dpyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1376%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hodgson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertorelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varty, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forlani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredduzzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen-Williams, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Impagnatiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolussi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parra, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neustadt, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamford, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reggiani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J. C.</span><span> </span><span class="NLM_article-title">Characterization of the potent and highly selective 2A receptor antagonists preladenant and SCH 412348 [7-[2-[4â2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">â</span> <span class="NLM_lpage">303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1124%2Fjpet.108.149617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=19332567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=294-303&author=R.+A.+Hodgsonauthor=R.+Bertorelliauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=A.+Forlaniauthor=S.+Fredduzziauthor=M.+E.+Cohen-Williamsauthor=G.+A.+Higginsauthor=F.+Impagnatielloauthor=E.+Nicolussiauthor=L.+E.+Parraauthor=C.+Fosterauthor=Y.+Zhaiauthor=B.+R.+Neustadtauthor=A.+W.+Stamfordauthor=E.+M.+Parkerauthor=A.+Reggianiauthor=J.+C.+Hunter&title=Characterization+of+the+potent+and+highly+selective+2A+receptor+antagonists+preladenant+and+SCH+412348+%5B7-%5B2-%5B4%E2%80%932%2C4-difluorophenyl%5D-1-piperazinyl%5Dethyl%5D-2-%282-furanyl%29-7H-pyrazolo%5B4%2C3-e%5D%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-c%5Dpyrimidin-5-amine%5D+in+rodent+models+of+movement+disorders+and+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span></div><div class="casAuthors">Hodgson, Robert A.; Bertorelli, Rosalia; Varty, Geoffrey B.; Lachowicz, Jean E.; Forlani, Angelo; Fredduzzi, Silva; Cohen-Williams, Mary E.; Higgins, Guy A.; Impagnatiello, Francesco; Nicolussi, Elisa; Parra, Leonard E.; Foster, Carolyn; Zhai, Ying; Neustadt, Bernie R.; Stamford, Andrew W.; Parker, Eric M.; Reggiani, Angelo; Hunter, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adenosine A2A receptor has been implicated in the underlying biol. of various neurol. and psychiatric disorders, including Parkinson's disease (PD) and depression.  Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] are potent competitive antagonists of the human A2A receptor (Ki = 1.1 and 0.6 nM, resp.) and have > 1000-fold selectivity over all other adenosine receptors, making these compds. the most selective A2A receptor antagonists reported to date.  Both compds. attenuate hypolocomotion induced by the A2A receptor agonist CGS-21680 [2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine], suggesting that they inhibit A2A receptor activity in vivo.  Their high degree of selectivity and robust in vivo activity make preladenant and SCH 412348 useful tools to investigate the role of the A2A receptor system in animal models of PD and depression.  Oral administration of preladenant and SCH 412348 (0.1-1 mg/kg) to rats potentiated 3,4-dihydroxy-L-phenylalanine (L-Dopa)-induced contralateral rotations after 6-hydroxydopamine lesions in the medial forebrain bundle and potently attenuated the cataleptic effects of haloperidol.  Preladenant (1 mg/kg) inhibited L-Dopa-induced behavioral sensitization after repeated daily administration, which suggests a reduced risk of the development of dyskinesias.  Finally, preladenant and SCH 412348 exhibited antidepressant-like profiles in models of behavioral despair, namely the mouse tail suspension test and the mouse and rat forced swim test.  These studies demonstrate that preladenant and SCH 412348 are potent and selective A2A receptor antagonists and provide further evidence of the potential therapeutic benefits of A2A receptor inhibition in PD (with reduced risk of dyskinesias) and depression (one of the primary nonmotor symptoms of PD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNkJMOfNlLc7Vg90H21EOLACvtfcHk0lif2AB2dl_-DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D&md5=b8ce809c2d57a994d201ecca4daa39a3</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.149617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.149617%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DForlani%26aufirst%3DA.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DCohen-Williams%26aufirst%3DM.%2BE.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DNicolussi%26aufirst%3DE.%26aulast%3DParra%26aufirst%3DL.%2BE.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DReggiani%26aufirst%3DA.%26aulast%3DHunter%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520the%2520potent%2520and%2520highly%2520selective%25202A%2520receptor%2520antagonists%2520preladenant%2520and%2520SCH%2520412348%2520%255B7-%255B2-%255B4%25E2%2580%25932%252C4-difluorophenyl%255D-1-piperazinyl%255Dethyl%255D-2-%25282-furanyl%2529-7H-pyrazolo%255B4%252C3-e%255D%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-c%255Dpyrimidin-5-amine%255D%2520in%2520rodent%2520models%2520of%2520movement%2520disorders%2520and%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D294%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwana, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Combined use of the adenosine A<sub>2A</sub> antagonist KW-6002 with L-DOPA or with selective D<sub>1</sub> or D<sub>2</sub> dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys</span> <span class="citation_source-journal">Exp. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">â</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1006%2Fexnr.2000.7350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=10739638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitVWqsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2000&pages=321-327&author=T.+Kandaauthor=M.+J.+Jacksonauthor=L.+A.+Smithauthor=R.+K.+Pearceauthor=J.+Nakamuraauthor=H.+Kaseauthor=Y.+Kuwanaauthor=P.+Jenner&title=Combined+use+of+the+adenosine+A2A+antagonist+KW-6002+with+L-DOPA+or+with+selective+D1+or+D2+dopamine+agonists+increases+antiparkinsonian+activity+but+not+dyskinesia+in+MPTP-treated+monkeys"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys</span></div><div class="casAuthors">Kanda, Tomoyuki; Jackson, Michael J.; Smith, Lance A.; Pearce, Ronald K. B.; Nakamura, Joji; Kase, Hiroshi; Kuwana, Yoshihisa; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">321-327</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The novel selective adenosine A2A receptor antagonist KW-6002 improves motor disability in MPTP-treated parkinsonian marmosets without provoking dyskinesia.  In this study we have investigated whether KW-6002 in combination with l-DOPA or selective D1 or D2 dopamine receptor agonists enhances antiparkinsonian activity in MPTP-treated common marmosets.  Combination of KW-6002 with the selective dopamine D2 receptor agonist quinpirole or the D1 receptor agonist SKF80723 produced an additive improvement in motor disability.  Coadministration of KW-6002 with a low dose of l-DOPA also produced an additive improvement in motor disability, and increased locomotor activity.  The ability of KW-6002 to enhance antiparkinsonian activity was more marked with l-DOPA and quinpirole than with the D1 agonist.  However, despite producing an enhanced antiparkinsonian response KW-6002 did not exacerbate l-DOPA-induced dyskinesia in MPTP-treated common marmosets previously primed to exhibit dyskinesia by prior exposure to l-DOPA.  Selective adenosine A2A receptor antagonists, such as KW-6002, may be one means of reducing the dosage of l-DOPA used in treating Parkinson's disease and are potentially a novel approach to treating the illness both as monotherapy and in combination with dopaminergic drugs.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsA7cu-aJS8rVg90H21EOLACvtfcHk0li7fDwyHwvFYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitVWqsLY%253D&md5=28db343f66ae2a8179d7113246f39ae7</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1006%2Fexnr.2000.7350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.2000.7350%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BA.%26aulast%3DPearce%26aufirst%3DR.%2BK.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DKuwana%26aufirst%3DY.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DCombined%2520use%2520of%2520the%2520adenosine%2520A2A%2520antagonist%2520KW-6002%2520with%2520L-DOPA%2520or%2520with%2520selective%2520D1%2520or%2520D2%2520dopamine%2520agonists%2520increases%2520antiparkinsonian%2520activity%2520but%2520not%2520dyskinesia%2520in%2520MPTP-treated%2520monkeys%26jtitle%3DExp.%2520Neurol.%26date%3D2000%26volume%3D162%26spage%3D321%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hauser, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubble, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, D. D.</span><span> </span><span class="NLM_article-title">Randomized trial of adenosine A<sub>2A</sub> receptor antagonist istradefylline in advanced PD</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">â</span> <span class="NLM_lpage">303</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2003&pages=297-303&author=R.+A.+Hauserauthor=J.+P.+Hubbleauthor=D.+D.+Truong&title=Randomized+trial+of+adenosine+A2A+receptor+antagonist+istradefylline+in+advanced+PD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DR.%2BA.%26aulast%3DHubble%26aufirst%3DJ.%2BP.%26aulast%3DTruong%26aufirst%3DD.%2BD.%26atitle%3DRandomized%2520trial%2520of%2520adenosine%2520A2A%2520receptor%2520antagonist%2520istradefylline%2520in%2520advanced%2520PD%26jtitle%3DNeurology%26date%3D2003%26volume%3D61%26spage%3D297%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bara-Jimenez, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherzai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibbiani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouradian, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, T. N.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonist treatment of Parkinsonâs disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">296</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2003&pages=293-296&author=W.+Bara-Jimenezauthor=A.+Sherzaiauthor=T.+Dimitrovaauthor=A.+Favitauthor=F.+Bibbianiauthor=M.+Gillespieauthor=M.+J.+Morrisauthor=M.+M.+Mouradianauthor=T.+N.+Chase&title=Adenosine+A2A+receptor+antagonist+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBara-Jimenez%26aufirst%3DW.%26aulast%3DSherzai%26aufirst%3DA.%26aulast%3DDimitrova%26aufirst%3DT.%26aulast%3DFavit%26aufirst%3DA.%26aulast%3DBibbiani%26aufirst%3DF.%26aulast%3DGillespie%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DM.%2BJ.%26aulast%3DMouradian%26aufirst%3DM.%2BM.%26aulast%3DChase%26aufirst%3DT.%2BN.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonist%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurology%26date%3D2003%26volume%3D61%26spage%3D293%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">For the current status of preladenant, go to <a href="http://clinicaltrials.gov" class="extLink">clinicaltrials.gov</a> and use the following identifiers: NCT01155479, NCT01227265, NCT01155466, NCT01294800, NCT01215227, and NCT01323855.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukumitsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiwata, K.</span><span> </span><span class="NLM_article-title">Quantitative analysis of adenosine A<sub>1</sub>receptors in human brain using positron emission tomography and [1-methyl-<sup>11</sup>C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine</span> <span class="citation_source-journal">Nuclear Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">â</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2Fj.nucmedbio.2004.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=15607479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyqsbzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2004&pages=975-981&author=Y.+Kimuraauthor=K.+Ishiiauthor=N.+Fukumitsuauthor=K.+Odaauthor=T.+Sasakiauthor=K.+Kawamuraauthor=K.+Ishiwata&title=Quantitative+analysis+of+adenosine+A1receptors+in+human+brain+using+positron+emission+tomography+and+%5B1-methyl-11C%5D8-dicyclopropylmethyl-1-methyl-3-propylxanthine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1 -methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine</span></div><div class="casAuthors">Kimura, Yuichi; Ishii, Kenji; Fukumitsu, Nobuyoshi; Oda, Keiichi; Sasaki, Toru; Kawamura, Kazunori; Ishiwata, Kiichi</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">975-981</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Fully quant. anal. of the adenosine A1 receptor (A1R) in the brain with 11C-MPDX and positron emission tomog. is reported.  The kinetics is described using a two-tissue three-compartment model, and estd. binding potentials correspond well with the ests. made by Logan plot.  The image of the binding potential of the MPDX is physiol. reasonable.  We conclude that MPDX is applicable to the visualization of the A1Rs in the brain with Logan plot.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj_Ng1prMQZbVg90H21EOLACvtfcHk0lgyouQfIjEnzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyqsbzL&md5=b0bd06a1abeef2f6850e12a4f6afb6dd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2004.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2004.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DFukumitsu%26aufirst%3DN.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DIshiwata%26aufirst%3DK.%26atitle%3DQuantitative%2520analysis%2520of%2520adenosine%2520A1receptors%2520in%2520human%2520brain%2520using%2520positron%2520emission%2520tomography%2520and%2520%255B1-methyl-11C%255D8-dicyclopropylmethyl-1-methyl-3-propylxanthine%26jtitle%3DNuclear%2520Med.%2520Biol.%26date%3D2004%26volume%3D31%26spage%3D975%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ballarin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiriz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrosio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahy, N.</span><span> </span><span class="NLM_article-title">Effect of locally infused 2-cholroadenosine, an A<sub>1</sub> receptor agonist, on spontaneous and evoked dopamine release in rat neostriatum</span> <span class="citation_source-journal">Neurosci. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">185</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">â</span> <span class="NLM_lpage">32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1995&pages=29-32&author=M.+Ballarinauthor=J.+Reirizauthor=S.+Ambrosioauthor=N.+Mahy&title=Effect+of+locally+infused+2-cholroadenosine%2C+an+A1+receptor+agonist%2C+on+spontaneous+and+evoked+dopamine+release+in+rat+neostriatum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBallarin%26aufirst%3DM.%26aulast%3DReiriz%26aufirst%3DJ.%26aulast%3DAmbrosio%26aufirst%3DS.%26aulast%3DMahy%26aufirst%3DN.%26atitle%3DEffect%2520of%2520locally%2520infused%25202-cholroadenosine%252C%2520an%2520A1%2520receptor%2520agonist%252C%2520on%2520spontaneous%2520and%2520evoked%2520dopamine%2520release%2520in%2520rat%2520neostriatum%26jtitle%3DNeurosci.%2520Lett.%26date%3D1995%26volume%3D185%26spage%3D29%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Moore, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, D.</span><span> </span><span class="NLM_article-title">Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">14397</span><span class="NLM_x">â</span> <span class="NLM_lpage">14402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=14397-14402&author=K.+A.+Mooreauthor=R.+A.+Nicollauthor=D.+Schmitz&title=Adenosine+gates+synaptic+plasticity+at+hippocampal+mossy+fiber+synapses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DK.%2BA.%26aulast%3DNicoll%26aufirst%3DR.%2BA.%26aulast%3DSchmitz%26aufirst%3DD.%26atitle%3DAdenosine%2520gates%2520synaptic%2520plasticity%2520at%2520hippocampal%2520mossy%2520fiber%2520synapses%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%26date%3D2003%26volume%3D100%26spage%3D14397%26epage%3D14402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rebola, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinheiro, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malva, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, R. A.</span><span> </span><span class="NLM_article-title">Subcellular localization of adenosine A<sub>1</sub> receptors in nerve terminal and synapses of the rat hippocampus</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">987</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">â</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FS0006-8993%2803%2903247-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=14499945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1aqsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=987&publication_year=2003&pages=49-58&author=N.+Rebolaauthor=P.+C.+Pinheiroauthor=C.+R.+Oliveiraauthor=J.+O.+Malvaauthor=R.+A.+Cunha&title=Subcellular+localization+of+adenosine+A1+receptors+in+nerve+terminal+and+synapses+of+the+rat+hippocampus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular localization of adenosine A1 receptors in nerve terminals and synapses of the rat hippocampus</span></div><div class="casAuthors">Rebola, Nelson; Pinheiro, Paulo C.; Oliveira, Catarina R.; Malva, Joao O.; Cunha, Rodrigo A.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">987</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-58</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Adenosine is a neuromodulator in the CNS that mainly acts through pre- and postsynaptic A1 receptors to inhibit the release of excitatory neurotransmitters and NMDA receptor function.  This might result from a highly localized distribution of A1 receptors in the active zone and postsynaptic d. of CNS synapses that we now investigated in the rat hippocampus.  The binding d. of the selective A1 receptor antagonist, [3H]1,3-dipropyl-8-cyclopentylxanthine ([3H]DPCPX), was enriched in membranes from Percoll-purified nerve terminals (Bmax=1839Â±52 fmol/mg protein) compared to total membranes from the hippocampus (Bmax=984Â±31 fmol/mg protein), the same occurring with A1 receptor immunoreactivity.  [3H]DPCPX binding occurred mainly to the plasma membrane rather than to intracellular sites, since the binding of the membrane permeable A1 receptor ligand [3H]DPCPX to intact hippocampal nerve terminals (Bmax=1901Â±192 fmol/mg protein) was markedly reduced (Bmax=321Â±30 fmol/mg protein) by the membrane impermeable adenosine receptor antagonist, 8-sulfophenyltheophilline (25 Î¼M).  Further subcellular fractionation of hippocampal nerve terminals revealed that A1 receptor immunoreactivity was strategically located in the active zone of presynaptic nerve terminals, as expected to understand the efficiency of A1 receptors to depress neurotransmitter release.  A1 Receptors were also present in nerve terminals outside the active zone in accordance with the existence of a presynaptic A1 receptor reserve.  Finally, A1 receptor immunoreactivity was evident in the postsynaptic d. together with NMDA receptor subunits 1, 2A and 2B and with N-and P/Q-type calcium channel immunoreactivity, emphasizing the importance of A1 receptors in the control of dendritic integration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXNS9YJIv75rVg90H21EOLACvtfcHk0lgyouQfIjEnzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1aqsr8%253D&md5=3400357993c99c6aa97d2def8af5b8ca</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2803%2903247-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252803%252903247-5%26sid%3Dliteratum%253Aachs%26aulast%3DRebola%26aufirst%3DN.%26aulast%3DPinheiro%26aufirst%3DP.%2BC.%26aulast%3DOliveira%26aufirst%3DC.%2BR.%26aulast%3DMalva%26aufirst%3DJ.%2BO.%26aulast%3DCunha%26aufirst%3DR.%2BA.%26atitle%3DSubcellular%2520localization%2520of%2520adenosine%2520A1%2520receptors%2520in%2520nerve%2520terminal%2520and%2520synapses%2520of%2520the%2520rat%2520hippocampus%26jtitle%3DBrain%2520Res.%26date%3D2003%26volume%3D987%26spage%3D49%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Maemoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takuma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noriko, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsuya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoharu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoru, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atsushi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nobuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitaro, M.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of FR194921, a new potent, selective, orally active antagonist for central adenosine A<sub>1</sub> receptors</span> <span class="citation_source-journal">J. Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">â</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1254%2Fjphs.FP0040359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=15351792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFyjs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=42-52&author=T.+Maemotoauthor=T.+Mihoauthor=M.+Takumaauthor=U.+Norikoauthor=M.+Hideakiauthor=H.+Katsuyaauthor=Y.+Takayukiauthor=S.+Kiyoharuauthor=K.+Satoruauthor=A.+Atsushiauthor=I.+Akinoriauthor=M.+Nobuyaauthor=M.+Seitaro&title=Pharmacological+characterization+of+FR194921%2C+a+new+potent%2C+selective%2C+orally+active+antagonist+for+central+adenosine+A1+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors</span></div><div class="casAuthors">Maemoto, Takuya; Tada, Miho; Mihara, Takuma; Ueyama, Noriko; Matsuoka, Hideaki; Harada, Katsuya; Yamaji, Takayuki; Shirakawa, Kiyoharu; Kuroda, Satoru; Akahane, Atsushi; Iwashita, Akinori; Matsuoka, Nobuya; Mutoh, Seitaro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-52</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">Adenosine A1 receptors in the brain are believed to play an important role in brain functioning.  We have discovered a novel adenosine A1 receptor antagonist, FR194921 (2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone), and characterized the pharmacol. activity in the present study.  FR194921 showed potent and selective affinity for the adenosine A1 receptor without affinity for A2A and A3 receptors and did not show any species differences in binding affinity profile among human, rat, and mouse.  Pharmacokinetic study in rats revealed that FR194921 was orally active and highly brain penetrable.  Oral administration of FR194921 dose-dependently ameliorated the hypolocomotion induced by the A1 receptor agonist N6-cyclopentyladenosine in rats, indicating this compd. exerts A1-antagonistic action in vivo.  In the passive avoidance test, scopolamine (1 mg/kg)-induced memory deficits were significantly ameliorated by FR194921 (0.32, 1 mg/kg).  In two animal models of anxiety, the social interaction test and elevated plus maze, FR194921 showed specific anxiolytic activity without significantly influencing general behavior.  In contrast, FR194921 did not show antidepressant activity even at a dose of 32 mg/kg in the rat forced swimming test.  These results indicate that the novel, potent, and selective adenosine A1 receptor antagonist FR194921 exerts both cognitive-enhancing and anxiolytic activity, suggesting the therapeutic potential of this compd. for dementia and anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpor8cuLg5xVrVg90H21EOLACvtfcHk0liKUnwFSmFBpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFyjs78%253D&md5=1828b4e7afe4c25a61aa0fa094f64c38</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1254%2Fjphs.FP0040359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.FP0040359%26sid%3Dliteratum%253Aachs%26aulast%3DMaemoto%26aufirst%3DT.%26aulast%3DMiho%26aufirst%3DT.%26aulast%3DTakuma%26aufirst%3DM.%26aulast%3DNoriko%26aufirst%3DU.%26aulast%3DHideaki%26aufirst%3DM.%26aulast%3DKatsuya%26aufirst%3DH.%26aulast%3DTakayuki%26aufirst%3DY.%26aulast%3DKiyoharu%26aufirst%3DS.%26aulast%3DSatoru%26aufirst%3DK.%26aulast%3DAtsushi%26aufirst%3DA.%26aulast%3DAkinori%26aufirst%3DI.%26aulast%3DNobuya%26aufirst%3DM.%26aulast%3DSeitaro%26aufirst%3DM.%26atitle%3DPharmacological%2520characterization%2520of%2520FR194921%252C%2520a%2520new%2520potent%252C%2520selective%252C%2520orally%2520active%2520antagonist%2520for%2520central%2520adenosine%2520A1%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D96%26spage%3D42%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Yonishi, S.; Aoki, S.; Matsushima, Y.; Akahane, A.</span><span> </span><span class="NLM_article-title">Preparation of pyrazines as adenosine A<sub>1</sub> and A<sub>2A</sub> receptor antagonists and their pharmaceutical compositions</span>. PCT Int. Appl. WO 2005040151,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=S.+Yonishi&author=S.+Aoki&author=Y.+Matsushima&author=A.+Akahane&title=Preparation+of+pyrazines+as+adenosine+A1+and+A2A+receptor+antagonists+and+their+pharmaceutical+compositions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYonishi%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520pyrazines%2520as%2520adenosine%2520A1%2520and%2520A2A%2520receptor%2520antagonists%2520and%2520their%2520pharmaceutical%2520compositions%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span> </span><span class="NLM_article-title">A novel adenosine A<sub>1</sub> and A<sub>2A</sub> receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">â</span> <span class="NLM_lpage">161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2008&pages=152-161&author=T.+Miharaauthor=A.+Iwashitaauthor=N.+Matsuoka&title=A+novel+adenosine+A1+and+A2A+receptor+antagonist+ASP5854+ameliorates+motor+impairment+in+MPTP-treated+marmosets%3A+Comparison+with+existing+anti-Parkinson%27s+disease+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMihara%26aufirst%3DT.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3DA%2520novel%2520adenosine%2520A1%2520and%2520A2A%2520receptor%2520antagonist%2520ASP5854%2520ameliorates%2520motor%2520impairment%2520in%2520MPTP-treated%2520marmosets%253A%2520Comparison%2520with%2520existing%2520anti-Parkinson%2527s%2520disease%2520drugs%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2008%26volume%3D194%26spage%3D152%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span> </span><span class="NLM_article-title">Brain adenosine A2A receptor occupancy by a novel A<sub>1</sub>/A<sub>2A</sub> receptor antagonist, ASP5854, in rhesus monkeys: Relationship to anticataleptic effect</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1183</span><span class="NLM_x">â</span> <span class="NLM_lpage">1188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=1183-1188&author=T.+Miharaauthor=A.+Nodaauthor=H.+Araiauthor=K.+Miharaauthor=A.+Iwashitaauthor=Y.+Murakamiauthor=T.+Matsuyaauthor=S.+Miyoshiauthor=S.+Nishimuraauthor=N.+Matsuoka&title=Brain+adenosine+A2A+receptor+occupancy+by+a+novel+A1%2FA2A+receptor+antagonist%2C+ASP5854%2C+in+rhesus+monkeys%3A+Relationship+to+anticataleptic+effect"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMihara%26aufirst%3DT.%26aulast%3DNoda%26aufirst%3DA.%26aulast%3DArai%26aufirst%3DH.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DMatsuya%26aufirst%3DT.%26aulast%3DMiyoshi%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3DBrain%2520adenosine%2520A2A%2520receptor%2520occupancy%2520by%2520a%2520novel%2520A1%252FA2A%2520receptor%2520antagonist%252C%2520ASP5854%252C%2520in%2520rhesus%2520monkeys%253A%2520Relationship%2520to%2520anticataleptic%2520effect%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2008%26volume%3D49%26spage%3D1183%26epage%3D1188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Mihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarimizu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akahane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of a novel, potent adenosine A<sub>1</sub> and A<sub>2A</sub> receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinsonâs disease and cognition</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">â</span> <span class="NLM_lpage">719</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1124%2Fjpet.107.121962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=17684118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ynsb%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=708-719&author=T.+Miharaauthor=K.+Miharaauthor=J.+Yarimizuauthor=Y.+Mitaniauthor=R.+Matsudaauthor=H.+Yamamotoauthor=S.+Aokiauthor=A.+Akahaneauthor=A.+Iwashitaauthor=N.+Matsuoka&title=Pharmacological+characterization+of+a+novel%2C+potent+adenosine+A1+and+A2A+receptor+dual+antagonist%2C+5-%5B5-amino-3-%284-fluorophenyl%29pyrazin-2-yl%5D-1-isopropylpyridine-2%281H%29-one+%28ASP5854%29%2C+in+models+of+Parkinson%E2%80%99s+disease+and+cognition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition</span></div><div class="casAuthors">Mihara, Takuma; Mihara, Kayoko; Yarimizu, Junko; Mitani, Yasuyuki; Matsuda, Ritsuko; Yamamoto, Hiroko; Aoki, Satoshi; Akahane, Atsushi; Iwashita, Akinori; Matsuoka, Nobuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">708-719</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Central adenosine A2A receptor is a promising target for drugs to treat Parkinson's disease (PD), and the central blockade of adenosine A1 receptor improves cognitive function.  In the present study, we investigated the effect of a novel adenosine A1 and A2A dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one(ASP5854),in animal models of PD and cognition.  The binding affinities of ASP5854 for human A1 and A2A receptors were 9.03 and 1.76 nM, resp., with higher specificity and no species differences.  ASP5854 also showed antagonistic action on A1 and A2A agonist-induced increases of intracellular Ca2+ concn.  ASP5854 ameliorated A2A agonist 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)- and haloperidol-induced catalepsy in mice, with the min. EDs of 0.32 and 0.1 mg/kg, resp., and it also improved haloperidol-induced catalepsy in rats at doses higher than 0.1 mg/kg.  In unilateral 6-hydroxydopamine-lesioned rats, ASP5854 significantly potentiated 7-dihydroxyphenylalanine (L-DOPA)-induced rotational behavior at doses higher than 0.032 mg/kg.  ASP5854 also significantly restored the striatal dopamine content reduced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment in mice at doses higher than 0.1 mg/kg.  Furthermore, in the rat passive avoidance test, ASP5854 significantly reversed the scopolamine-induced memory deficits, whereas the specific adenosine A2A antagonist 8-((E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) did not.  Scopolamine- or 5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801)-induced impairment of spontaneous alternation in the mouse Y-maze test was ameliorated by ASP5854, whereas KW-6002 did not exert improvement at therapeutically relevant dosages.  These results demonstrate that the novel, selective, and orally active dual adenosine A1 and A2A receptors antagonist ASP5854 improves motor impairments, is neuroprotective via A2A antagonism, and also enhances cognitive function through A1 antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKhOITDQ8dxrVg90H21EOLACvtfcHk0lgOIyqIcXVG6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ynsb%252FF&md5=2d9770179a47a228d825a49feab70ef2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.121962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.121962%26sid%3Dliteratum%253Aachs%26aulast%3DMihara%26aufirst%3DT.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DYarimizu%26aufirst%3DJ.%26aulast%3DMitani%26aufirst%3DY.%26aulast%3DMatsuda%26aufirst%3DR.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DAkahane%26aufirst%3DA.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3DPharmacological%2520characterization%2520of%2520a%2520novel%252C%2520potent%2520adenosine%2520A1%2520and%2520A2A%2520receptor%2520dual%2520antagonist%252C%25205-%255B5-amino-3-%25284-fluorophenyl%2529pyrazin-2-yl%255D-1-isopropylpyridine-2%25281H%2529-one%2520%2528ASP5854%2529%252C%2520in%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520cognition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D708%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupert, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heintzelman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullington, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchamp, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demarest, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span> </span><span class="NLM_article-title">In Vivo Characterization of a Dual Adenosine A<sub>2A</sub>/A<sub>1</sub> Receptor Antagonist in Animal Models of Parkinson's Disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8104</span><span class="NLM_x">â</span> <span class="NLM_lpage">8115</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100971t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8104-8115&author=B.+C.+Shookauthor=S.+Rassnickauthor=M.+C.+Osborneauthor=S.+Davisauthor=L.+Westoverauthor=J.+Bouletauthor=D.+Hallauthor=K.+C.+Rupertauthor=G.+R.+Heintzelmanauthor=K.+Hansenauthor=D.+Chakravartyauthor=J.+L.+Bullingtonauthor=R.+Russellauthor=S.+Branumauthor=K.+M.+Wellsauthor=S.+Damonauthor=S.+Youellsauthor=X.+Liauthor=D.+A.+Beauchampauthor=D.+Palmerauthor=M.+Reyesauthor=K.+Demarestauthor=Y.-T.+Tangauthor=K.+Rhodesauthor=P.+F.+Jackson&title=In+Vivo+Characterization+of+a+Dual+Adenosine+A2A%2FA1+Receptor+Antagonist+in+Animal+Models+of+Parkinson%27s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fjm100971t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100971t%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DOsborne%26aufirst%3DM.%2BC.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DWestover%26aufirst%3DL.%26aulast%3DBoulet%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DRupert%26aufirst%3DK.%2BC.%26aulast%3DHeintzelman%26aufirst%3DG.%2BR.%26aulast%3DHansen%26aufirst%3DK.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DBullington%26aufirst%3DJ.%2BL.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DBranum%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DK.%2BM.%26aulast%3DDamon%26aufirst%3DS.%26aulast%3DYouells%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DBeauchamp%26aufirst%3DD.%2BA.%26aulast%3DPalmer%26aufirst%3DD.%26aulast%3DReyes%26aufirst%3DM.%26aulast%3DDemarest%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DY.-T.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DIn%2520Vivo%2520Characterization%2520of%2520a%2520Dual%2520Adenosine%2520A2A%252FA1%2520Receptor%2520Antagonist%2520in%2520Animal%2520Models%2520of%2520Parkinson%2527s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8104%26epage%3D8115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupert, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heintzelman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullington, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magliaro, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osbourne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demarest, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span> </span><span class="NLM_article-title">Methylene amine substituted arylindenopyrimidines as potent adenosine A<sub>2A</sub>/A<sub>1</sub> antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2864</span><span class="NLM_x">â</span> <span class="NLM_lpage">2867</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2864-2867&author=B.+C.+Shookauthor=S.+Rassnickauthor=D.+Hallauthor=K.+C.+Rupertauthor=G.+R.+Heintzelmanauthor=K.+Hansenauthor=D.+Chakravartyauthor=J.+L.+Bullingtonauthor=R.+Scannevinauthor=B.+Magliaroauthor=L.+Westoverauthor=K.+Carrollauthor=L.+Lampronauthor=R.+Russellauthor=S.+Branumauthor=K.+Wellsauthor=S.+Damonauthor=S.+Youellsauthor=X.+Liauthor=M.+Osbourneauthor=K.+Demarestauthor=Y.+Tangauthor=K.+Rhodesauthor=P.+F.+Jackson&title=Methylene+amine+substituted+arylindenopyrimidines+as+potent+adenosine+A2A%2FA1+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DRupert%26aufirst%3DK.%2BC.%26aulast%3DHeintzelman%26aufirst%3DG.%2BR.%26aulast%3DHansen%26aufirst%3DK.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DBullington%26aufirst%3DJ.%2BL.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DMagliaro%26aufirst%3DB.%26aulast%3DWestover%26aufirst%3DL.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DLampron%26aufirst%3DL.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DBranum%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DK.%26aulast%3DDamon%26aufirst%3DS.%26aulast%3DYouells%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DOsbourne%26aufirst%3DM.%26aulast%3DDemarest%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DMethylene%2520amine%2520substituted%2520arylindenopyrimidines%2520as%2520potent%2520adenosine%2520A2A%252FA1%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2864%26epage%3D2867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ault, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crooke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbay, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alford, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupert, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heintzelman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullington, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchamp, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span> </span><span class="NLM_article-title">Optimization of arylindenopyrimidines as potent adenosine A<sub>2A</sub>/A<sub>1</sub> antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2868</span><span class="NLM_x">â</span> <span class="NLM_lpage">2871</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2868-2871&author=B.+C.+Shookauthor=S.+Rassnickauthor=D.+Chakravartyauthor=N.+Wallaceauthor=M.+Aultauthor=J.+Crookeauthor=J.+K.+Barbayauthor=A.+Wangauthor=K.+Leonardauthor=M.+T.+Powellauthor=V.+Alfordauthor=D.+Hallauthor=K.+C.+Rupertauthor=G.+R.+Heintzelmanauthor=K.+Hansenauthor=J.+L.+Bullingtonauthor=R.+Scannevinauthor=K.+Carrollauthor=L.+Lampronauthor=L.+Westoverauthor=R.+Russellauthor=S.+Branumauthor=K.+Wellsauthor=S.+Damonauthor=S.+Youellsauthor=D.+Beauchampauthor=X.+Liauthor=K.+Rhodesauthor=P.+F.+Jackson&title=Optimization+of+arylindenopyrimidines+as+potent+adenosine+A2A%2FA1+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DWallace%26aufirst%3DN.%26aulast%3DAult%26aufirst%3DM.%26aulast%3DCrooke%26aufirst%3DJ.%26aulast%3DBarbay%26aufirst%3DJ.%2BK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLeonard%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DM.%2BT.%26aulast%3DAlford%26aufirst%3DV.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DRupert%26aufirst%3DK.%2BC.%26aulast%3DHeintzelman%26aufirst%3DG.%2BR.%26aulast%3DHansen%26aufirst%3DK.%26aulast%3DBullington%26aufirst%3DJ.%2BL.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DLampron%26aufirst%3DL.%26aulast%3DWestover%26aufirst%3DL.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DBranum%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DK.%26aulast%3DDamon%26aufirst%3DS.%26aulast%3DYouells%26aufirst%3DS.%26aulast%3DBeauchamp%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DOptimization%2520of%2520arylindenopyrimidines%2520as%2520potent%2520adenosine%2520A2A%252FA1%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2868%26epage%3D2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Zarrindast, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modabber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabetkasai, M.</span><span> </span><span class="NLM_article-title">Influence on different adenosine receptor subtypes on catalepsy in mice</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1993&pages=257-261&author=M.+R.+Zarrindastauthor=M.+Modabberauthor=M.+Sabetkasai&title=Influence+on+different+adenosine+receptor+subtypes+on+catalepsy+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZarrindast%26aufirst%3DM.%2BR.%26aulast%3DModabber%26aufirst%3DM.%26aulast%3DSabetkasai%26aufirst%3DM.%26atitle%3DInfluence%2520on%2520different%2520adenosine%2520receptor%2520subtypes%2520on%2520catalepsy%2520in%2520mice%26jtitle%3DPsychopharmacology%26date%3D1993%26volume%3D113%26spage%3D257%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Mandhane, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopde, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2</sub> receptors modulate haloperidol-induced catalepsy in rats</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x"> (</span><span class="NLM_issue">2/3</span><span class="NLM_x">) </span> <span class="NLM_fpage">135</span><span class="NLM_x">â</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FS0014-2999%2897%2983039-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=9218695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK2sXjsVKgt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=1997&pages=135-141&issue=2%2F3&author=S.+N.+Mandhaneauthor=C.+T.+Chopdeauthor=A.+K.+Ghosh&title=Adenosine+A2+receptors+modulate+haloperidol-induced+catalepsy+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats</span></div><div class="casAuthors">Mandhane, Sanjay N.; Chopde, Chandrabhan T.; Ghosh, Anuradha K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">135-141</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The effect of adenosine A1 and A2 receptor agonists and antagonists was investigated on haloperidol-induced catalepsy in rats.  Pretreatment (i.p.) with the non-selective adenosine receptor antagonist, theophylline, or the selective adenosine A2 receptor antagonist, 3,7-dimethyl-1-propargylxanthine (DMPX), significantly reversed haloperidol-induced catalepsy, whereas the selective adenosine A1 receptor antagonists, 8-phenyltheophylline and 8-cyclopentyl-1,3-dipropylxanthine produced no effect.  Similar administration of the adenosine A2 receptor agonists, 5'-(N-cyclopropyl)carboxamidoadenosine and 5'-N-ethylcarboxamidoadenosine (NECA), and the mixed agonists with predominantly A1 site of action, N6-(2-phenylisopropyl)adenosine or 2-chloroadenosine, potentiated haloperidol-induced catalepsy.  Higher doses of the adenosine agonists produced catalepsy when given alone.  However, N6-cyclopentyladenosine, a highly selective adenosine A1 receptor agonist, was ineffective in these respects.  The per se cataleptic effect of adenosine agonists was blocked by DMPX and the centrally acting anticholinergic agent, scopolamine.  Scopolamine also attenuated the potentiation of haloperidol-induced catalepsy by adenosine agonists.  Further, i.c.v. administration of NECA and DMPX produced a similar effect as that produced after their systemic administration.  These findings demonstrate the differential influence of adenosine A1 and A2 receptors on haloperidol-induced catalepsy and support the hypothesis that the functional interaction between adenosine and dopamine mechanisms might occur through adenosine A2 receptors at the level of cholinergic neurons.  The results suggest that adenosine A2, but not A1, receptor antagonists may be of potential use in the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_yuXIH62xu7Vg90H21EOLACvtfcHk0lgrd1w_uLjLJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsVKgt70%253D&md5=369d9508f13df6a3a9e3ce41bf83fa13</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2983039-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252983039-7%26sid%3Dliteratum%253Aachs%26aulast%3DMandhane%26aufirst%3DS.%2BN.%26aulast%3DChopde%26aufirst%3DC.%2BT.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26atitle%3DAdenosine%2520A2%2520receptors%2520modulate%2520haloperidol-induced%2520catalepsy%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D328%26issue%3D2%252F3%26spage%3D135%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Cooper, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsden, C. D.</span><span> </span><span class="NLM_article-title">L-Dopa esters as potential prodrugs: Behavioral activity in experimental models of Parkinson's disease</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">â</span> <span class="NLM_lpage">635</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1111%2Fj.2042-7158.1987.tb03441.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=2888854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaL2sXmtFWnt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1987&pages=627-635&author=D.+R.+Cooperauthor=C.+Marrelauthor=H.+van+de+Waterbeemdauthor=B.+Testaauthor=P.+Jennerauthor=C.+D.+Marsden&title=L-Dopa+esters+as+potential+prodrugs%3A+Behavioral+activity+in+experimental+models+of+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">L-Dopa esters as potential prodrugs:  behavioral activity in experimental models of Parkinson's disease</span></div><div class="casAuthors">Cooper, D. R.; Marrel, C.; Van de Waterbeemd, H.; Testa, B.; Jenner, P.; Marsden, C. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-35</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    </div><div class="casAbstract">The behavioral activity of 13 ester prodrugs of L-dopa (I; R = Me, Et, Pr, CH2CH(OH)Me, CHMeCH2OMe, cyclohexyl, tetrahydropyranylmethyl, CH2Ph, substituted benzyl, phenylethyl, phenoxyethyl, substituted phenylethyl) was evaluated on 2 exptl. animal models of Parkinson's disease; reverse of reserpine-induced akinesia in mice and induction of circling behavior in rats with 6-hydroxydopamine lesion of the medial forebrain bundle.  In general, I did not have markedly greater activity or a more sustained effect than L-dopa itself and thus would be unlikely to offer major therapeutic advantages on intermittent oral dosage.  However, their various physiochem. properties may make them more suitable i.v. or s.c. infusions.  Structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx_hPJDd522bVg90H21EOLACvtfcHk0lgrd1w_uLjLJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmtFWnt7k%253D&md5=06e8a60094d1a7d55c4017a2ff462cd3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1987.tb03441.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1987.tb03441.x%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DD.%2BR.%26aulast%3DMarrel%26aufirst%3DC.%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DTesta%26aufirst%3DB.%26aulast%3DJenner%26aufirst%3DP.%26aulast%3DMarsden%26aufirst%3DC.%2BD.%26atitle%3DL-Dopa%2520esters%2520as%2520potential%2520prodrugs%253A%2520Behavioral%2520activity%2520in%2520experimental%2520models%2520of%2520Parkinson%2527s%2520disease%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D1987%26volume%3D39%26spage%3D627%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ungerstedt, U.</span><span> </span><span class="NLM_article-title">6-Hydroxydopamine-induced generation of central monoamine neurons</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">â</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0014-2999%2868%2990164-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=5718510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaF1MXns1eisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1968&pages=107-110&author=U.+Ungerstedt&title=6-Hydroxydopamine-induced+generation+of+central+monoamine+neurons"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">6-Hydroxydopamine-induced degeneration of central monoamine neurons</span></div><div class="casAuthors">Ungerstedt, Urban</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-10</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">6-Hydroxydopamine (I) (2 or 8 Î¼g.) injected into the nucleus caudatus putamen, the zona compacta of the substantia nigra, and the area dorsolateral to the nucleus interpedunclaris of rats caused degeneration of dopamine and noradrenaline cell bodies, axons, and terminals in the vicinity of the injection site.  The degeneration of the nigroneostriatal dopamine neuron system occurring after I injections into the substantia nigra produced marked motor disturbances.  Intracerebral administration of I may be used as a tool for anatomical and functional studies on central monoamine neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI9wsRougpvrVg90H21EOLACvtfcHk0lgrd1w_uLjLJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXns1eisw%253D%253D&md5=57298843164b07af35ca21b4624826c4</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2868%2990164-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252868%252990164-7%26sid%3Dliteratum%253Aachs%26aulast%3DUngerstedt%26aufirst%3DU.%26atitle%3D6-Hydroxydopamine-induced%2520generation%2520of%2520central%2520monoamine%2520neurons%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1968%26volume%3D5%26spage%3D107%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ungerstedt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuthnott, G. W.</span><span> </span><span class="NLM_article-title">Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1970</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">â</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0006-8993%2870%2990187-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=5494536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A280%3ADyaE3M%252Fotl2msA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1970&pages=485-493&author=U.+Ungerstedtauthor=G.+W.+Arbuthnott&title=Quantitative+recording+of+rotational+behavior+in+rats+after+6-hydroxy-dopamine+lesions+of+the+nigrostriatal+dopamine+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system</span></div><div class="casAuthors">Ungerstedt U; Arbuthnott G W</div><div class="citationInfo"><span class="NLM_cas:title">Brain research</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-93</span>
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxWjpxbmSViUg6wdEZmT2rfW6udTcc2ebpIzkoZ_NVyLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3M%252Fotl2msA%253D%253D&md5=e31a2eee4f4fff68329c0ab8a8a62788</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2870%2990187-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252870%252990187-3%26sid%3Dliteratum%253Aachs%26aulast%3DUngerstedt%26aufirst%3DU.%26aulast%3DArbuthnott%26aufirst%3DG.%2BW.%26atitle%3DQuantitative%2520recording%2520of%2520rotational%2520behavior%2520in%2520rats%2520after%25206-hydroxy-dopamine%2520lesions%2520of%2520the%2520nigrostriatal%2520dopamine%2520system%26jtitle%3DBrain%2520Res.%26date%3D1970%26volume%3D24%26spage%3D485%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Luthman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredriksson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundstroem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, T.</span><span> </span><span class="NLM_article-title">Selective lesion of central dopamine or moradenaline neuron systems in the neonatal rat: Motor behavior and monoamine alteration at adult stage</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">â</span> <span class="NLM_lpage">277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1989&pages=267-277&author=J.+Luthmanauthor=A.+Fredrikssonauthor=E.+Sundstroemauthor=G.+Jonssonauthor=T.+Archer&title=Selective+lesion+of+central+dopamine+or+moradenaline+neuron+systems+in+the+neonatal+rat%3A+Motor+behavior+and+monoamine+alteration+at+adult+stage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuthman%26aufirst%3DJ.%26aulast%3DFredriksson%26aufirst%3DA.%26aulast%3DSundstroem%26aufirst%3DE.%26aulast%3DJonsson%26aufirst%3DG.%26aulast%3DArcher%26aufirst%3DT.%26atitle%3DSelective%2520lesion%2520of%2520central%2520dopamine%2520or%2520moradenaline%2520neuron%2520systems%2520in%2520the%2520neonatal%2520rat%253A%2520Motor%2520behavior%2520and%2520monoamine%2520alteration%2520at%2520adult%2520stage%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D1989%26volume%3D33%26spage%3D267%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bankiewicz, K. S.</span><span> </span><span class="NLM_article-title">MPTP-induced parkinsonism in nonhuman primates</span> <span class="citation_source-journal">Methods Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">â</span> <span class="NLM_lpage">182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FB978-0-12-185263-4.50018-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK38XisFejt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1991&pages=168-182&author=K.+S.+Bankiewicz&title=MPTP-induced+parkinsonism+in+nonhuman+primates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">MPTP-induced parkinsonism in nonhuman primates</span></div><div class="casAuthors">Bankiewicz, Krzysztof S.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Neurosciences</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Lesions Transplant.</span>),
    <span class="NLM_cas:pages">168-82</span>CODEN:
                <span class="NLM_cas:coden">MENEE5</span>;
        ISSN:<span class="NLM_cas:issn">1043-9471</span>.
    </div><div class="casAbstract">A review with 45 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx3yh0hBeYerVg90H21EOLACvtfcHk0ljVPAVmG7YmsA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisFejt7s%253D&md5=d3848e6d09f0015f716ca9cdca6933ea</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-185263-4.50018-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-185263-4.50018-2%26sid%3Dliteratum%253Aachs%26aulast%3DBankiewicz%26aufirst%3DK.%2BS.%26atitle%3DMPTP-induced%2520parkinsonism%2520in%2520nonhuman%2520primates%26jtitle%3DMethods%2520Neurosci.%26date%3D1991%26volume%3D7%26spage%3D168%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jakowec, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzinger, G. M.</span><span> </span><span class="NLM_article-title">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced lesion model of Parkinson's disease, with emphasis on mice and nonhuman primates</span> <span class="citation_source-journal">Comp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">â</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=15575363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVejsrrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2004&pages=497-513&author=M.+W.+Jakowecauthor=G.+M.+Petzinger&title=1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine-induced+lesion+model+of+Parkinson%27s+disease%2C+with+emphasis+on+mice+and+nonhuman+primates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates</span></div><div class="casAuthors">Jakowec, Michael W.; Petzinger, Giselle M.</div><div class="citationInfo"><span class="NLM_cas:title">Comparative Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">497-513</span>CODEN:
                <span class="NLM_cas:coden">COMEFT</span>;
        ISSN:<span class="NLM_cas:issn">1532-0820</span>.
    
            (<span class="NLM_cas:orgname">American Association for Laboratory Animal Science</span>)
        </div><div class="casAbstract">A review.  Animal models play a crit. role in our understanding of the cause of human diseases and provide an opportunity to evaluate new therapeutic treatments.  The usefulness of an animal model is dependent, in part, on how closely it resembles neurochem., neuropathol., and behavioral features of the human condition.  Other considerations that may enhance the value of a model include expense, availability, reproducibility, animal morbidity and mortality, and investigator experience.  Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by slow movements, tremor, and walking impairment due to loss of midbrain nigrostriatal neurons and depletion of striatal dopamine.  In the PD research field, a no. of neurotoxic, pharmacol., and transgenic animal models are available for research studies.  We will focus on the advantages and disadvantages of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse and nonhuman primate models of PD.  Our goal is to guide researchers in the appropriateness of the MPTP models in their studies by balancing understanding of the models, objectives of the study, and health and safety of the animals.  In addn., the tech. use and safe handling of MPTP are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1AbpYksctuLVg90H21EOLACvtfcHk0ljqE9cZggjm4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVejsrrE&md5=268362f3d9a889531b0d888f0c86a96f</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJakowec%26aufirst%3DM.%2BW.%26aulast%3DPetzinger%26aufirst%3DG.%2BM.%26atitle%3D1-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine-induced%2520lesion%2520model%2520of%2520Parkinson%2527s%2520disease%252C%2520with%2520emphasis%2520on%2520mice%2520and%2520nonhuman%2520primates%26jtitle%3DComp.%2520Med.%26date%3D2004%26volume%3D54%26spage%3D497%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Campos-Romo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojeda-Flores, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Briseno, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Ruiz, J.</span><span> </span><span class="NLM_article-title">Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the hallway task</span> <span class="citation_source-journal">J. Neurosci. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">â</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2Fj.jneumeth.2008.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=19022292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFeisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2009&pages=361-368&author=A.+Campos-Romoauthor=R.+Ojeda-Floresauthor=P.+Moreno-Brisenoauthor=J.+Fernandez-Ruiz&title=Quantitative+evaluation+of+MPTP-treated+nonhuman+parkinsonian+primates+in+the+hallway+task"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33cR"><div class="casContent"><span class="casTitleNuber">33c</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task</span></div><div class="casAuthors">Campos-Romo, Aurelio; Ojeda-Flores, Rafael; Moreno-Briseno, Pablo; Fernandez-Ruiz, Juan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Methods</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-368</span>CODEN:
                <span class="NLM_cas:coden">JNMEDT</span>;
        ISSN:<span class="NLM_cas:issn">0165-0270</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a progressive neurodegenerative disorder.  An exptl. model of this disease is produced in nonhuman primates by the administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  In this work, we put forward a new quant. evaluation method that uses video recordings to measure the displacement, gate, gross and fine motor performance of freely moving subjects.  Four Vervet monkeys (Cercopithecus aethiops) were trained in a behavioral observation hallway while being recorded with digital video cameras from four different angles.  After MPTP intoxication the animals were tested without any drug and after 30 and 90 min of Levodopa/Carbidopa administration.  Using a personal computer the following behaviors were measured and evaluated from the video recordings: displacement time across the hallway, reaching time towards rewards, ingestion time, no. of attempts to obtain rewards, no. of rewards obtained, and level of the highest shelf reached for rewards.  Our results show that there was an overall behavioral deterioration after MPTP administration and an overall improvement after Levodopa/Carbidopa treatment.  This demonstrates that the HALLWAY task is a sensitive and objective method that allows detailed behavioral evaluation of freely moving monkeys in the MPTP Parkinson's disease model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruYimo678roLVg90H21EOLACvtfcHk0ljqE9cZggjm4Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFeisQ%253D%253D&md5=e824a38d96e1e6d37bac316822174a89</span></div><a href="/servlet/linkout?suffix=cit33c&amp;dbid=16384&amp;doi=10.1016%2Fj.jneumeth.2008.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneumeth.2008.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DCampos-Romo%26aufirst%3DA.%26aulast%3DOjeda-Flores%26aufirst%3DR.%26aulast%3DMoreno-Briseno%26aufirst%3DP.%26aulast%3DFernandez-Ruiz%26aufirst%3DJ.%26atitle%3DQuantitative%2520evaluation%2520of%2520MPTP-treated%2520nonhuman%2520parkinsonian%2520primates%2520in%2520the%2520hallway%2520task%26jtitle%3DJ.%2520Neurosci.%2520Methods%26date%3D2009%26volume%3D177%26spage%3D361%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Lim, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensenhauser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shook, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopaul, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. C.</span><span> </span><span class="NLM_article-title">Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent adenosine A<sub>2A</sub>/A<sub>1</sub> antagonist by minimizing bioactivation to an iminium ion reactive intermediate</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1012</span><span class="NLM_x">â</span> <span class="NLM_lpage">1030</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx1004437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1012-1030&author=H.-K.+Limauthor=J.+Chenauthor=C.+Sensenhauserauthor=K.+Cookauthor=R.+Prestonauthor=T.+Thomasauthor=B.+Shookauthor=P.+F.+Jacksonauthor=S.+Rassnickauthor=K.+Rhodesauthor=V.+Gopaulauthor=R.+Salterauthor=J.+Silvaauthor=D.+C.+Evans&title=Overcoming+the+genotoxicity+of+a+pyrrolidine+substituted+arylindenopyrimidine+as+a+potent+adenosine+A2A%2FA1+antagonist+by+minimizing+bioactivation+to+an+iminium+ion+reactive+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Ftx1004437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx1004437%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DH.-K.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSensenhauser%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DK.%26aulast%3DPreston%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DShook%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DGopaul%26aufirst%3DV.%26aulast%3DSalter%26aufirst%3DR.%26aulast%3DSilva%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26atitle%3DOvercoming%2520the%2520genotoxicity%2520of%2520a%2520pyrrolidine%2520substituted%2520arylindenopyrimidine%2520as%2520a%2520potent%2520adenosine%2520A2A%252FA1%2520antagonist%2520by%2520minimizing%2520bioactivation%2520to%2520an%2520iminium%2520ion%2520reactive%2520intermediate%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1012%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Hyttel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnt, J.</span><span> </span><span class="NLM_article-title">Receptor-binding profiles of neuroleptics</span> <span class="citation_source-journal">Psychopharmacol. Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">â</span> <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1007%2F978-3-642-70140-5_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=2860665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaL2MXlvVyrurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1985&pages=9-18&author=J.+Hyttelauthor=J.+J.+Larsenauthor=A.+V.+Christensenauthor=J.+Arnt&title=Receptor-binding+profiles+of+neuroleptics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-binding profiles of neuroleptics</span></div><div class="casAuthors">Hyttel, J.; Larsen, J. J.; Christensen, A. V.; Arnt, J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology, Supplementum</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">Dyskinesia</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">PSSUE5</span>;
        ISSN:<span class="NLM_cas:issn">0179-8456</span>.
    </div><div class="casAbstract">A review with 33 refs. of the dopaminergic receptor binding blockade by neuroleptics in relation to antipsychotic activity and side-effects of neuroleptics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBA2EApKaKZ7Vg90H21EOLACvtfcHk0linZ020q10Oeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvVyrurk%253D&md5=fb425b1ed020812fdd72f602a9e398e4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-70140-5_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-70140-5_2%26sid%3Dliteratum%253Aachs%26aulast%3DHyttel%26aufirst%3DJ.%26aulast%3DLarsen%26aufirst%3DJ.%2BJ.%26aulast%3DChristensen%26aufirst%3DA.%2BV.%26aulast%3DArnt%26aufirst%3DJ.%26atitle%3DReceptor-binding%2520profiles%2520of%2520neuroleptics%26jtitle%3DPsychopharmacol.%2520Suppl.%26date%3D1985%26volume%3D2%26spage%3D9%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Kraus, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sy, J. O.</span><span> </span><span class="NLM_article-title">A synthetic approach to rocaglamide via reductive cyclization of Î´-keto nitriles</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">83</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00262a022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1989&pages=77-83&author=G.+A.+Krausauthor=J.+O.+Sy&title=A+synthetic+approach+to+rocaglamide+via+reductive+cyclization+of+%CE%B4-keto+nitriles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjo00262a022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00262a022%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DG.%2BA.%26aulast%3DSy%26aufirst%3DJ.%2BO.%26atitle%3DA%2520synthetic%2520approach%2520to%2520rocaglamide%2520via%2520reductive%2520cyclization%2520of%2520%25CE%25B4-keto%2520nitriles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1989%26volume%3D54%26spage%3D77%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Heintzelman, G. R.; Bullington, J. L.; Rupert, K. C.</span><span> </span><span class="NLM_article-title">Preparation of arylindenopyridines and arylindenopyrimidines and their use as adenosine A<sub>2A</sub> receptor antagonists</span>. PCT Int. Appl. WO 2005042500,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=G.+R.+Heintzelman&author=J.+L.+Bullington&author=K.+C.+Rupert&title=Preparation+of+arylindenopyridines+and+arylindenopyrimidines+and+their+use+as+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeintzelman%26aufirst%3DG.%2BR.%26atitle%3DPreparation%2520of%2520arylindenopyridines%2520and%2520arylindenopyrimidines%2520and%2520their%2520use%2520as%2520adenosine%2520A2A%2520receptor%2520antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebeskind, L. S.</span><span> </span><span class="NLM_article-title">Copper-mediated, palladium-catalyzed coupling of thiol ester with aliphatic organoboron reagents</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3554</span><span class="NLM_x">â</span> <span class="NLM_lpage">3557</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo049964p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3554-3557&author=Y.+Yuauthor=L.+S.+Liebeskind&title=Copper-mediated%2C+palladium-catalyzed+coupling+of+thiol+ester+with+aliphatic+organoboron+reagents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1021%2Fjo049964p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo049964p%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLiebeskind%26aufirst%3DL.%2BS.%26atitle%3DCopper-mediated%252C%2520palladium-catalyzed%2520coupling%2520of%2520thiol%2520ester%2520with%2520aliphatic%2520organoboron%2520reagents%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3554%26epage%3D3557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kusturin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebeskind, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sample, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweitzer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srogl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, W. L.</span><span> </span><span class="NLM_article-title">Switchable catalysis: Modular synthesis of functionalized pyrimidones via selective sulfide and halide cross-coupling chemistry</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4349</span><span class="NLM_x">â</span> <span class="NLM_lpage">4352</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol035649y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=4349-4352&author=C.+Kusturinauthor=L.+S.+Liebeskindauthor=H.+Rahmanauthor=K.+Sampleauthor=B.+Schweitzerauthor=J.+Sroglauthor=W.+L.+Neumann&title=Switchable+catalysis%3A+Modular+synthesis+of+functionalized+pyrimidones+via+selective+sulfide+and+halide+cross-coupling+chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1021%2Fol035649y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol035649y%26sid%3Dliteratum%253Aachs%26aulast%3DKusturin%26aufirst%3DC.%26aulast%3DLiebeskind%26aufirst%3DL.%2BS.%26aulast%3DRahman%26aufirst%3DH.%26aulast%3DSample%26aufirst%3DK.%26aulast%3DSchweitzer%26aufirst%3DB.%26aulast%3DSrogl%26aufirst%3DJ.%26aulast%3DNeumann%26aufirst%3DW.%2BL.%26atitle%3DSwitchable%2520catalysis%253A%2520Modular%2520synthesis%2520of%2520functionalized%2520pyrimidones%2520via%2520selective%2520sulfide%2520and%2520halide%2520cross-coupling%2520chemistry%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D4349%26epage%3D4352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit38c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Liebeskind, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srogl, J.</span><span> </span><span class="NLM_article-title">Heteroaromatic thioether-boronic acid cross-coupling under neutral reaction conditions</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">979</span><span class="NLM_x">â</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol0200091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38c&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1Gktb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=979-981&author=L.+S.+Liebeskindauthor=J.+Srogl&title=Heteroaromatic+thioether-boronic+acid+cross-coupling+under+neutral+reaction+conditions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38cR"><div class="casContent"><span class="casTitleNuber">38c</span><div class="casTitle"><span class="NLM_cas:atitle">Heteroaromatic Thioether-Boronic Acid Cross-Coupling under Neutral Reaction Conditions</span></div><div class="casAuthors">Liebeskind, Lanny S.; Srogl, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">979-981</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ï-Deficient heteroarom. thioethers undergo efficient palladium-catalyzed cross-coupling with boronic acids, mediated by copper(I) thiophene-2-carboxylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmqoxHMYfLbVg90H21EOLACvtfcHk0lgAwtdjGBw1hQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1Gktb0%253D&md5=ce42d2952572e0b36f0f60e6037a18f6</span></div><a href="/servlet/linkout?suffix=cit38c&amp;dbid=16384&amp;doi=10.1021%2Fol0200091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0200091%26sid%3Dliteratum%253Aachs%26aulast%3DLiebeskind%26aufirst%3DL.%2BS.%26aulast%3DSrogl%26aufirst%3DJ.%26atitle%3DHeteroaromatic%2520thioether-boronic%2520acid%2520cross-coupling%2520under%2520neutral%2520reaction%2520conditions%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26spage%3D979%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Marsden, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolphin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvoisin, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarsy, D.</span><span> </span><span class="NLM_article-title">Role of noradrenaline in levodopa reversal of reserpine akinesia</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">â</span> <span class="NLM_lpage">525</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0006-8993%2874%2990643-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaE2MXlsVA%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1974&pages=521-525&author=C.+D.+Marsdenauthor=A.+Dolphinauthor=R.+C.+Duvoisinauthor=P.+Jennerauthor=D.+Tarsy&title=Role+of+noradrenaline+in+levodopa+reversal+of+reserpine+akinesia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Role of noradrenaline in levodopa reversal of reserpine akinesia</span></div><div class="casAuthors">Marsden, C. D.; Dolphin, A.; Duvoisin, R. C.; Jenner, P.; Tarsy, D.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-5</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Pretreatment of reserpinized rats with 25 mg FLA-63/kg, a dopamine Î²-hydroxylase inhibitor, or with 20 mg phenoxybenzamine/kg, a noradrenaline (I) [51-41-2] receptor blocker, decreased the levodopa [59-92-7] (500 mg/kg) reversal of akinesia induced by reserpine [50-55-5].  Some spontaneous activity did occur after levodopa administration in animals pretreated with FLA-63 or phenoxybenzamine but this activity was unlike that of reserpinized animals treated with levodopa alone.  Other compds. which blocked both central dopamine [51-61-6] and I receptors in the brain also decreased the levodopa effect, whereas pimozide, which primarily blocks only dopamine receptors, had no effect on the response to levodopa.  Thus, levodopa reversal of reserpine akinesia may require the formation of  I as well as dopamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQMLyHwjYI7rVg90H21EOLACvtfcHk0lgAwtdjGBw1hQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXlsVA%253D&md5=68b938889d6e3945f83bbcaa2539642c</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2874%2990643-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252874%252990643-X%26sid%3Dliteratum%253Aachs%26aulast%3DMarsden%26aufirst%3DC.%2BD.%26aulast%3DDolphin%26aufirst%3DA.%26aulast%3DDuvoisin%26aufirst%3DR.%2BC.%26aulast%3DJenner%26aufirst%3DP.%26aulast%3DTarsy%26aufirst%3DD.%26atitle%3DRole%2520of%2520noradrenaline%2520in%2520levodopa%2520reversal%2520of%2520reserpine%2520akinesia%26jtitle%3DBrain%2520Res.%26date%3D1974%26volume%3D17%26spage%3D521%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Starr, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, B. S.</span><span> </span><span class="NLM_article-title">Comparison of the effects NMDA and AMPA antagonist on the locomotor activity induced by selective D<sub>1</sub> and D<sub>2</sub> dopamine agonists in reserpine-treated mice</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1994&pages=495-504&author=M.+S.+Starrauthor=B.+S.+Starr&title=Comparison+of+the+effects+NMDA+and+AMPA+antagonist+on+the+locomotor+activity+induced+by+selective+D1+and+D2+dopamine+agonists+in+reserpine-treated+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStarr%26aufirst%3DM.%2BS.%26aulast%3DStarr%26aufirst%3DB.%2BS.%26atitle%3DComparison%2520of%2520the%2520effects%2520NMDA%2520and%2520AMPA%2520antagonist%2520on%2520the%2520locomotor%2520activity%2520induced%2520by%2520selective%2520D1%2520and%2520D2%2520dopamine%2520agonists%2520in%2520reserpine-treated%2520mice%26jtitle%3DPsychopharmacology%26date%3D1994%26volume%3D114%26spage%3D495%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Robinson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. B.</span><span> </span><span class="NLM_article-title">The rotational behavior model: Asymmetry in the effects of unilateral 6-OHDA lesions of the substantia nigra in rats</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0006-8993%2883%2991129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=6405975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaL3sXitV2rtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1983&pages=127-131&author=T.+E.+Robinsonauthor=J.+B.+Becker&title=The+rotational+behavior+model%3A+Asymmetry+in+the+effects+of+unilateral+6-OHDA+lesions+of+the+substantia+nigra+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The rotational behavior model:  asymmetry in the effects of unilateral 6-OHDA lesions of the substantia nigra in rats</span></div><div class="casAuthors">Robinson, Terry E.; Becker, Jill B.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-31</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">The d-amphetamine  [51-64-9]-induced rotational behavior of rats with dopamine  [51-61-6] depletion in the dominant striatum was in the opposite direction of that obsd. in rats with damage to the nondominant striatum.  Thus, when using the 6-hydroxydopamine (6-OHDA) lesion rotation model, the intrinsic asymmetry in the nigrostriatal dopaminergic system should be taken into consideration with respect to the side of lesion placement, since different results may be obtained depending on the side of the lesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG7YxiJKMBTbVg90H21EOLACvtfcHk0liEUISrxtNVdQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXitV2rtbg%253D&md5=b90687387f1f528f0b5ed09e84084344</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2883%2991129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252883%252991129-0%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DT.%2BE.%26aulast%3DBecker%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520rotational%2520behavior%2520model%253A%2520Asymmetry%2520in%2520the%2520effects%2520of%2520unilateral%25206-OHDA%2520lesions%2520of%2520the%2520substantia%2520nigra%2520in%2520rats%26jtitle%3DBrain%2520Res.%26date%3D1983%26volume%3D264%26spage%3D127%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Damier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agid, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graybiel, A. M.</span><span> </span><span class="NLM_article-title">The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease</span> <span class="citation_source-journal">Brain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1437</span><span class="NLM_x">â</span> <span class="NLM_lpage">1448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1999&pages=1437-1448&author=P.+Damierauthor=E.+C.+Hirschauthor=Y.+Agidauthor=A.+M.+Graybiel&title=The+substantia+nigra+of+the+human+brain.+II.+Patterns+of+loss+of+dopamine-containing+neurons+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDamier%26aufirst%3DP.%26aulast%3DHirsch%26aufirst%3DE.%2BC.%26aulast%3DAgid%26aufirst%3DY.%26aulast%3DGraybiel%26aufirst%3DA.%2BM.%26atitle%3DThe%2520substantia%2520nigra%2520of%2520the%2520human%2520brain.%2520II.%2520Patterns%2520of%2520loss%2520of%2520dopamine-containing%2520neurons%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DBrain%26date%3D1999%26volume%3D122%26spage%3D1437%26epage%3D1448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b','cit6c'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b','cit8c','cit8d','cit8e'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12a','cit12b'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c','cit16d'],'ref17':['cit17a','cit17b'],'ref18':['cit18a','cit18b'],'ref19':['cit19a','cit19b','cit19c'],'ref20':[],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28a','cit28b','cit28c'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b','cit32c'],'ref33':['cit33a','cit33b','cit33c'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38a','cit38b','cit38c'],'ref39':['cit39a','cit39b'],'ref40':['cit40'],'ref41':['cit41']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Stefanie Hagenow, Anna Affini, Elsa Y. Pioli, Sonja Hinz, Yan Zhao, Gregory Porras, Vigneshwaran Namasivayam, Christa E. MÃ¼ller, Jian-Sheng Lin, Erwan Bezard, <span class="NLM_string-name hlFld-ContribAuthor">Holger Stark</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinsonâs Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8246-8262. <a href="https://doi.org/10.1021/acs.jmedchem.0c00914" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00914%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAdenosine%252BA2AR%25252FA1R%252BAntagonists%252BEnabling%252BAdditional%252BH3R%252BAntagonism%252Bfor%252Bthe%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DHagenow%26aufirst%3DStefanie%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D25012021%26date%3D09062021%26volume%3D64%26issue%3D12%26spage%3D8246%26epage%3D8262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ritapa Chaudhuri, Semantee Bhattacharya, Jyotirmayee Dash, <span class="NLM_string-name hlFld-ContribAuthor">Santanu Bhattacharya</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Update on Targeting c-MYC G-Quadruplexes by Small Molecules for Anticancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 42-70. <a href="https://doi.org/10.1021/acs.jmedchem.0c01145" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01145</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01145%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BUpdate%252Bon%252BTargeting%252Bc-MYC%252BG-Quadruplexes%252Bby%252BSmall%252BMolecules%252Bfor%252BAnticancer%252BTherapeutics%26aulast%3DChaudhuri%26aufirst%3DRitapa%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D03072020%26date%3D23122020%26volume%3D64%26issue%3D1%26spage%3D42%26epage%3D70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ajinkya A.  Patravale</span>, <span class="hlFld-ContribAuthor ">Anil H.  Gore</span>, <span class="hlFld-ContribAuthor ">Dipti R.  Patil</span>, <span class="hlFld-ContribAuthor ">Govind B.  Kolekar</span>, <span class="hlFld-ContribAuthor ">Madhukar B.  Deshmukh</span>, and <span class="hlFld-ContribAuthor ">Prashant V.  Anbhule</span>  . </span><span class="cited-content_cbyCitation_article-title">Trouble-Free Multicomponent Method for Combinatorial Synthesis of 2-Amino-4-phenyl-5-H-indeno[1,2-d]pyrimidine-5-one and Their Screening against Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Industrial & Engineering Chemistry Research</span><span> <strong>2014,</strong> <em>53 </em>
                                    (42)
                                     , 16568-16578. <a href="https://doi.org/10.1021/ie5013618" title="DOI URL">https://doi.org/10.1021/ie5013618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ie5013618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fie5013618%26sid%3Dliteratum%253Aachs%26jtitle%3DIndustrial%2520%2526%2520Engineering%2520Chemistry%2520Research%26atitle%3DTrouble-Free%252BMulticomponent%252BMethod%252Bfor%252BCombinatorial%252BSynthesis%252Bof%252B2-Amino-4-phenyl-5-H-indeno%25255B1%25252C2-d%25255Dpyrimidine-5-one%252Band%252BTheir%252BScreening%252Bagainst%252BCancer%252BCell%252BLines%26aulast%3DPatravale%26aufirst%3DAjinkya%2BA.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D01042014%26date%3D23092014%26date%3D15092014%26date%3D13102014%26date%3D22102014%26date%3D23092014%26volume%3D53%26issue%3D42%26spage%3D16568%26epage%3D16578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John R.  Atack</span>, <span class="hlFld-ContribAuthor ">Brian C.  Shook</span>, <span class="hlFld-ContribAuthor ">Stefanie  Rassnick</span>, <span class="hlFld-ContribAuthor ">Paul F.  Jackson</span>, <span class="hlFld-ContribAuthor ">Kenneth  Rhodes</span>, <span class="hlFld-ContribAuthor ">Wilhelmus H.  Drinkenburg</span>, <span class="hlFld-ContribAuthor ">Abdallah  Ahnaou</span>, <span class="hlFld-ContribAuthor ">Paula  te Riele</span>, <span class="hlFld-ContribAuthor ">Xavier  Langlois</span>, <span class="hlFld-ContribAuthor ">Brian  Hrupka</span>, <span class="hlFld-ContribAuthor ">Patrick  De Haes</span>, <span class="hlFld-ContribAuthor ">Herman  Hendrickx</span>, <span class="hlFld-ContribAuthor ">Nancy  Aerts</span>, <span class="hlFld-ContribAuthor ">Koen  Hens</span>, <span class="hlFld-ContribAuthor ">Annemie  Wellens</span>, <span class="hlFld-ContribAuthor ">Jef  Vermeire</span>, and <span class="hlFld-ContribAuthor ">Anton A. H. P.  Megens</span>  . </span><span class="cited-content_cbyCitation_article-title">JNJ-40255293, a Novel Adenosine A2A/A1 Antagonist with Efficacy in Preclinical Models of Parkinsonâs Disease. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2014,</strong> <em>5 </em>
                                    (10)
                                     , 1005-1019. <a href="https://doi.org/10.1021/cn5001606" title="DOI URL">https://doi.org/10.1021/cn5001606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cn5001606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcn5001606%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DJNJ-40255293%25252C%252Ba%252BNovel%252BAdenosine%252BA2A%25252FA1%252BAntagonist%252Bwith%252BEfficacy%252Bin%252BPreclinical%252BModels%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DAtack%26aufirst%3DJohn%2BR.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D27072014%26date%3D08092014%26date%3D24092014%26date%3D15102014%26date%3D09092014%26volume%3D5%26issue%3D10%26spage%3D1005%26epage%3D1019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuel  de Lera Ruiz</span>, <span class="hlFld-ContribAuthor ">Yeon-Hee  Lim</span>, and <span class="hlFld-ContribAuthor ">Junying  Zheng</span>  . </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor as a Drug Discovery Target. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (9)
                                     , 3623-3650. <a href="https://doi.org/10.1021/jm4011669" title="DOI URL">https://doi.org/10.1021/jm4011669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4011669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4011669%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAdenosine%252BA2A%252BReceptor%252Bas%252Ba%252BDrug%252BDiscovery%252BTarget%26aulast%3Dde%2BLera%2BRuiz%26aufirst%3DManuel%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D31072013%26date%3D15112013%26date%3D08052014%26date%3D28102013%26volume%3D57%26issue%3D9%26spage%3D3623%26epage%3D3650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianing  Li</span>, <span class="hlFld-ContribAuthor ">Amanda L.  Jonsson</span>, <span class="hlFld-ContribAuthor ">Thijs  Beuming</span>, <span class="hlFld-ContribAuthor ">John C.  Shelley</span>, and <span class="hlFld-ContribAuthor ">Gregory A.  Voth</span>  . </span><span class="cited-content_cbyCitation_article-title">Ligand-Dependent Activation and Deactivation of the Human Adenosine A2A Receptor. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2013,</strong> <em>135 </em>
                                    (23)
                                     , 8749-8759. <a href="https://doi.org/10.1021/ja404391q" title="DOI URL">https://doi.org/10.1021/ja404391q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja404391q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja404391q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DLigand-Dependent%252BActivation%252Band%252BDeactivation%252Bof%252Bthe%252BHuman%252BAdenosine%252BA2A%252BReceptor%26aulast%3DLi%26aufirst%3DJianing%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D02052013%26date%3D29052013%26date%3D12062013%26date%3D16052013%26volume%3D135%26issue%3D23%26spage%3D8749%26epage%3D8759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alison J.  Foster</span>, <span class="hlFld-ContribAuthor ">Lucy H.  Prime</span>, <span class="hlFld-ContribAuthor ">Frida  Gustafsson</span>, <span class="hlFld-ContribAuthor ">David G.  Temesi</span>, <span class="hlFld-ContribAuthor ">Emre M.  Isin</span>, <span class="hlFld-ContribAuthor ">Johanna  MidlÃ¶v</span>, <span class="hlFld-ContribAuthor ">Neal  Castagnoli, Jr.</span>, and <span class="hlFld-ContribAuthor ">J. Gerry  Kenna</span>  . </span><span class="cited-content_cbyCitation_article-title">Bioactivation of the Cannabinoid Receptor Antagonist Rimonabant to a Cytotoxic Iminium Ion Metabolite. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2013,</strong> <em>26 </em>
                                    (1)
                                     , 124-135. <a href="https://doi.org/10.1021/tx300418w" title="DOI URL">https://doi.org/10.1021/tx300418w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/tx300418w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Ftx300418w%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DBioactivation%252Bof%252Bthe%252BCannabinoid%252BReceptor%252BAntagonist%252BRimonabant%252Bto%252Ba%252BCytotoxic%252BIminium%252BIon%252BMetabolite%26aulast%3DFoster%26aufirst%3DAlison%2BJ.%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D09102012%26date%3D12122012%26date%3D18012013%26volume%3D26%26issue%3D1%26spage%3D124%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Isabelle  Waku</span>, <span class="hlFld-ContribAuthor ">Mylena S.  MagalhÃ£es</span>, <span class="hlFld-ContribAuthor ">Camila O.  Alves</span>, <span class="hlFld-ContribAuthor ">Amanda R.  de Oliveira</span>. </span><span class="cited-content_cbyCitation_article-title">Haloperidolâinduced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Neuroscience</span><span> <strong>2021,</strong> <em>53 </em>
                                    (11)
                                     , 3743-3767. <a href="https://doi.org/10.1111/ejn.15222" title="DOI URL">https://doi.org/10.1111/ejn.15222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/ejn.15222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fejn.15222%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Neuroscience%26atitle%3DHaloperidol%2525E2%252580%252590induced%252Bcatalepsy%252Bas%252Ban%252Banimal%252Bmodel%252Bfor%252Bparkinsonism%25253A%252BA%252Bsystematic%252Breview%252Bof%252Bexperimental%252Bstudies%26aulast%3DWaku%26aufirst%3DIsabelle%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D11%26spage%3D3743%26epage%3D3767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mukuo  Wang</span>, <span class="hlFld-ContribAuthor ">Shujing  Hou</span>, <span class="hlFld-ContribAuthor ">Yu  Wei</span>, <span class="hlFld-ContribAuthor ">Dongmei  Li</span>, <span class="hlFld-ContribAuthor ">Jianping  Lin</span>, . </span><span class="cited-content_cbyCitation_article-title">Discovery of novel dual adenosine A1/A2A receptor antagonists using deep learning, pharmacophore modeling and molecular docking. </span><span class="cited-content_cbyCitation_journal-name">PLOS Computational Biology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (3)
                                     , e1008821. <a href="https://doi.org/10.1371/journal.pcbi.1008821" title="DOI URL">https://doi.org/10.1371/journal.pcbi.1008821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pcbi.1008821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pcbi.1008821%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Computational%2520Biology%26atitle%3DDiscovery%252Bof%252Bnovel%252Bdual%252Badenosine%252BA1%25252FA2A%252Breceptor%252Bantagonists%252Busing%252Bdeep%252Blearning%25252C%252Bpharmacophore%252Bmodeling%252Band%252Bmolecular%252Bdocking%26aulast%3DWang%26aufirst%3DMukuo%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D3%26spage%3De1008821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saleta  Vazquez-Rodriguez</span>, <span class="hlFld-ContribAuthor ">Santiago  Vilar</span>, <span class="hlFld-ContribAuthor ">Sonja  Kachler</span>, <span class="hlFld-ContribAuthor ">Karl-Norbert  Klotz</span>, <span class="hlFld-ContribAuthor ">Eugenio  Uriarte</span>, <span class="hlFld-ContribAuthor ">Fernanda  Borges</span>, <span class="hlFld-ContribAuthor ">Maria JoÃ£o  Matos</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine Receptor Ligands: CoumarinâChalcone Hybrids as Modulating Agents on the Activity of hARs. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (18)
                                     , 4306. <a href="https://doi.org/10.3390/molecules25184306" title="DOI URL">https://doi.org/10.3390/molecules25184306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25184306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25184306%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAdenosine%252BReceptor%252BLigands%25253A%252BCoumarin%2525E2%252580%252593Chalcone%252BHybrids%252Bas%252BModulating%252BAgents%252Bon%252Bthe%252BActivity%252Bof%252BhARs%26aulast%3DVazquez-Rodriguez%26aufirst%3DSaleta%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D18%26spage%3D4306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Omar H.A.  Al-Attraqchi</span>, <span class="hlFld-ContribAuthor ">Mahesh  Attimarad</span>, <span class="hlFld-ContribAuthor ">Katharigatta N.  Venugopala</span>, <span class="hlFld-ContribAuthor ">Anroop  Nair</span>, <span class="hlFld-ContribAuthor ">Noor H.A.  Al-Attraqchi</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor as a Potential Drug Target - Current Status and Future Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmaceutical Design</span><span> <strong>2019,</strong> <em>25 </em>
                                    (25)
                                     , 2716-2740. <a href="https://doi.org/10.2174/1381612825666190716113444" title="DOI URL">https://doi.org/10.2174/1381612825666190716113444</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1381612825666190716113444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1381612825666190716113444%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmaceutical%2520Design%26atitle%3DAdenosine%252BA2A%252BReceptor%252Bas%252Ba%252BPotential%252BDrug%252BTarget%252B-%252BCurrent%252BStatus%252Band%252BFuture%252BPerspectives%26aulast%3DAl-Attraqchi%26aufirst%3DOmar%2BH.A.%26date%3D2019%26volume%3D25%26issue%3D25%26spage%3D2716%26epage%3D2740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helena D.  Janse van Rensburg</span>, <span class="hlFld-ContribAuthor ">Lesetja J.  Legoabe</span>, <span class="hlFld-ContribAuthor ">Gisella  Terre'Blanche</span>, <span class="hlFld-ContribAuthor ">Mietha M.  Van der Walt</span>. </span><span class="cited-content_cbyCitation_article-title">Methoxy substituted 2-benzylidene-1-indanone derivatives as A
              1
              and/or A
              2A
              AR antagonists for the potential treatment of neurological conditions. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (2)
                                     , 300-309. <a href="https://doi.org/10.1039/C8MD00540K" title="DOI URL">https://doi.org/10.1039/C8MD00540K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00540K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00540K%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DMethoxy%252Bsubstituted%252B2-benzylidene-1-indanone%252Bderivatives%252Bas%252BA%252B1%252Band%25252For%252BA%252B2A%252BAR%252Bantagonists%252Bfor%252Bthe%252Bpotential%252Btreatment%252Bof%252Bneurological%252Bconditions%26aulast%3DJanse%2Bvan%2BRensburg%26aufirst%3DHelena%2BD.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D300%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leen  Kalash</span>, <span class="hlFld-ContribAuthor ">Cristina  Val</span>, <span class="hlFld-ContribAuthor ">Jhonny  Azuaje</span>, <span class="hlFld-ContribAuthor ">MarÃ­a I.  Loza</span>, <span class="hlFld-ContribAuthor ">Fredrik  Svensson</span>, <span class="hlFld-ContribAuthor ">Azedine  Zoufir</span>, <span class="hlFld-ContribAuthor ">Lewis  Mervin</span>, <span class="hlFld-ContribAuthor ">Graham  Ladds</span>, <span class="hlFld-ContribAuthor ">JosÃ©  Brea</span>, <span class="hlFld-ContribAuthor ">Robert  Glen</span>, <span class="hlFld-ContribAuthor ">Eddy  Sotelo</span>, <span class="hlFld-ContribAuthor ">Andreas  Bender</span>. </span><span class="cited-content_cbyCitation_article-title">Computer-aided design of multi-target ligands at A1R, A2AR and PDE10A, key proteins in neurodegenerative diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cheminformatics</span><span> <strong>2017,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13321-017-0249-4" title="DOI URL">https://doi.org/10.1186/s13321-017-0249-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13321-017-0249-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13321-017-0249-4%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cheminformatics%26atitle%3DComputer-aided%252Bdesign%252Bof%252Bmulti-target%252Bligands%252Bat%252BA1R%25252C%252BA2AR%252Band%252BPDE10A%25252C%252Bkey%252Bproteins%252Bin%252Bneurodegenerative%252Bdiseases%26aulast%3DKalash%26aufirst%3DLeen%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.D.  Janse van Rensburg</span>, <span class="hlFld-ContribAuthor ">G.  Terre'Blanche</span>, <span class="hlFld-ContribAuthor ">M.M.  van der Walt</span>, <span class="hlFld-ContribAuthor ">L.J.  Legoabe</span>. </span><span class="cited-content_cbyCitation_article-title">5-Substituted 2-benzylidene-1-tetralone analogues as A 1 and/or A 2A antagonists for the potential treatment of neurological conditions. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2017,</strong> <em>74 </em>, 251-259. <a href="https://doi.org/10.1016/j.bioorg.2017.08.013" title="DOI URL">https://doi.org/10.1016/j.bioorg.2017.08.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2017.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2017.08.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3D5-Substituted%252B2-benzylidene-1-tetralone%252Banalogues%252Bas%252BA%252B1%252Band%25252For%252BA%252B2A%252Bantagonists%252Bfor%252Bthe%252Bpotential%252Btreatment%252Bof%252Bneurological%252Bconditions%26aulast%3DJanse%2Bvan%2BRensburg%26aufirst%3DH.D.%26date%3D2017%26volume%3D74%26spage%3D251%26epage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Squarcialupi</span>, <span class="hlFld-ContribAuthor ">Marco  Betti</span>, <span class="hlFld-ContribAuthor ">Daniela  Catarzi</span>, <span class="hlFld-ContribAuthor ">Flavia  Varano</span>, <span class="hlFld-ContribAuthor ">Matteo  Falsini</span>, <span class="hlFld-ContribAuthor ">Annalisa  Ravani</span>, <span class="hlFld-ContribAuthor ">Silvia  Pasquini</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Vincenzi</span>, <span class="hlFld-ContribAuthor ">Veronica  Salmaso</span>, <span class="hlFld-ContribAuthor ">Mattia  Sturlese</span>, <span class="hlFld-ContribAuthor ">Katia  Varani</span>, <span class="hlFld-ContribAuthor ">Stefano  Moro</span>, <span class="hlFld-ContribAuthor ">Vittoria  Colotta</span>. </span><span class="cited-content_cbyCitation_article-title">The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-
              d
              ]pyrimidine core in affecting adenosine A
              1
              and A
              2A
              receptor affinity and selectivity profiles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2017,</strong> <em>32 </em>
                                    (1)
                                     , 248-263. <a href="https://doi.org/10.1080/14756366.2016.1247060" title="DOI URL">https://doi.org/10.1080/14756366.2016.1247060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2016.1247060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2016.1247060%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DThe%252Brole%252Bof%252B5-arylalkylamino-%252Band%252B5-piperazino-%252Bmoieties%252Bon%252Bthe%252B7-aminopyrazolo%25255B4%25252C3-%252Bd%252B%25255Dpyrimidine%252Bcore%252Bin%252Baffecting%252Badenosine%252BA%252B1%252Band%252BA%252B2A%252Breceptor%252Baffinity%252Band%252Bselectivity%252Bprofiles%26aulast%3DSquarcialupi%26aufirst%3DLucia%26date%3D2017%26date%3D2017%26volume%3D32%26issue%3D1%26spage%3D248%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ajinkya A.  Patravale</span>, <span class="hlFld-ContribAuthor ">Anil H.  Gore</span>, <span class="hlFld-ContribAuthor ">Govind B.  Kolekar</span>, <span class="hlFld-ContribAuthor ">Madhukar B.  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Prafulla B.  Choudhari</span>, <span class="hlFld-ContribAuthor ">Manish S.  Bhatia</span>, <span class="hlFld-ContribAuthor ">Shivadatta  Prabhu</span>, <span class="hlFld-ContribAuthor ">Mahendra D.  Jamdhade</span>, <span class="hlFld-ContribAuthor ">Milind S.  Patole</span>, <span class="hlFld-ContribAuthor ">Prashant V.  Anbhule</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, biological evaluation and molecular docking studies of some novel indenospiro derivatives as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Taiwan Institute of Chemical Engineers</span><span> <strong>2016,</strong> <em>68 </em>, 105-118. <a href="https://doi.org/10.1016/j.jtice.2016.09.034" title="DOI URL">https://doi.org/10.1016/j.jtice.2016.09.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtice.2016.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtice.2016.09.034%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Taiwan%2520Institute%2520of%2520Chemical%2520Engineers%26atitle%3DSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bsome%252Bnovel%252Bindenospiro%252Bderivatives%252Bas%252Banticancer%252Bagents%26aulast%3DPatravale%26aufirst%3DAjinkya%2BA.%26date%3D2016%26volume%3D68%26spage%3D105%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Squarcialupi</span>, <span class="hlFld-ContribAuthor ">Matteo  Falsini</span>, <span class="hlFld-ContribAuthor ">Daniela  Catarzi</span>, <span class="hlFld-ContribAuthor ">Flavia  Varano</span>, <span class="hlFld-ContribAuthor ">Marco  Betti</span>, <span class="hlFld-ContribAuthor ">Katia  Varani</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Vincenzi</span>, <span class="hlFld-ContribAuthor ">Diego  Dal Ben</span>, <span class="hlFld-ContribAuthor ">Catia  Lambertucci</span>, <span class="hlFld-ContribAuthor ">Rosaria  Volpini</span>, <span class="hlFld-ContribAuthor ">Vittoria  Colotta</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (12)
                                     , 2794-2808. <a href="https://doi.org/10.1016/j.bmc.2016.04.048" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.04.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.04.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.04.048%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DExploring%252Bthe%252B2-%252Band%252B5-positions%252Bof%252Bthe%252Bpyrazolo%25255B4%25252C3-d%25255Dpyrimidin-7-amino%252Bscaffold%252Bto%252Btarget%252Bhuman%252BA1%252Band%252BA2A%252Badenosine%252Breceptors%26aulast%3DSquarcialupi%26aufirst%3DLucia%26date%3D2016%26volume%3D24%26issue%3D12%26spage%3D2794%26epage%3D2808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarel J.  Robinson</span>, <span class="hlFld-ContribAuthor ">Jacobus P.  Petzer</span>, <span class="hlFld-ContribAuthor ">Amanda L.  Rousseau</span>, <span class="hlFld-ContribAuthor ">Gisella  TerreâBlanche</span>, <span class="hlFld-ContribAuthor ">AnÃ©l  Petzer</span>, <span class="hlFld-ContribAuthor ">Anna C.U.  Lourens</span>. </span><span class="cited-content_cbyCitation_article-title">Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (3)
                                     , 734-738. <a href="https://doi.org/10.1016/j.bmcl.2016.01.004" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.01.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.01.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCarbamate%252Bsubstituted%252B2-amino-4%25252C6-diphenylpyrimidines%252Bas%252Badenosine%252Breceptor%252Bantagonists%26aulast%3DRobinson%26aufirst%3DSarel%2BJ.%26date%3D2016%26volume%3D26%26issue%3D3%26spage%3D734%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akihiro  Tsuchioka</span>, <span class="hlFld-ContribAuthor ">Fumiki  Oana</span>, <span class="hlFld-ContribAuthor ">Takayuki  Suzuki</span>, <span class="hlFld-ContribAuthor ">Yuji  Yamauchi</span>, <span class="hlFld-ContribAuthor ">Tomoyuki  Ijiro</span>, <span class="hlFld-ContribAuthor ">Kouichi  Kaidoh</span>, <span class="hlFld-ContribAuthor ">Masahiro  Hiratochi</span>. </span><span class="cited-content_cbyCitation_article-title">Duration of drug action of dopamine D2 agonists in mice with 6-hydroxydopamine-induced lesions. </span><span class="cited-content_cbyCitation_journal-name">NeuroReport</span><span> <strong>2015,</strong> <em>26 </em>
                                    (18)
                                     , 1126-1132. <a href="https://doi.org/10.1097/WNR.0000000000000484" title="DOI URL">https://doi.org/10.1097/WNR.0000000000000484</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/WNR.0000000000000484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FWNR.0000000000000484%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroReport%26atitle%3DDuration%252Bof%252Bdrug%252Baction%252Bof%252Bdopamine%252BD2%252Bagonists%252Bin%252Bmice%252Bwith%252B6-hydroxydopamine-induced%252Blesions%26aulast%3DTsuchioka%26aufirst%3DAkihiro%26date%3D2015%26volume%3D26%26issue%3D18%26spage%3D1126%26epage%3D1132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Delia  Preti</span>, <span class="hlFld-ContribAuthor ">Pier Giovanni  Baraldi</span>, <span class="hlFld-ContribAuthor ">Allan R.  Moorman</span>, <span class="hlFld-ContribAuthor ">Pier Andrea  Borea</span>, <span class="hlFld-ContribAuthor ">Katia  Varani</span>. </span><span class="cited-content_cbyCitation_article-title">History and Perspectives of A
              2A
              Adenosine Receptor Antagonists as Potential Therapeutic Agents. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2015,</strong> <em>35 </em>
                                    (4)
                                     , 790-848. <a href="https://doi.org/10.1002/med.21344" title="DOI URL">https://doi.org/10.1002/med.21344</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21344%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DHistory%252Band%252BPerspectives%252Bof%252BA%252B2A%252BAdenosine%252BReceptor%252BAntagonists%252Bas%252BPotential%252BTherapeutic%252BAgents%26aulast%3DPreti%26aufirst%3DDelia%26date%3D2015%26date%3D2015%26volume%3D35%26issue%3D4%26spage%3D790%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gengyang  Yuan</span>, <span class="hlFld-ContribAuthor ">Nicholas G  Gedeon</span>, <span class="hlFld-ContribAuthor ">Tanner C  Jankins</span>, <span class="hlFld-ContribAuthor ">Graham B  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Novel approaches for targeting the adenosine A
              2A
              receptor. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2015,</strong> <em>10 </em>
                                    (1)
                                     , 63-80. <a href="https://doi.org/10.1517/17460441.2015.971006" title="DOI URL">https://doi.org/10.1517/17460441.2015.971006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/17460441.2015.971006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F17460441.2015.971006%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DNovel%252Bapproaches%252Bfor%252Btargeting%252Bthe%252Badenosine%252BA%252B2A%252Breceptor%26aulast%3DYuan%26aufirst%3DGengyang%26date%3D2015%26date%3D2014%26volume%3D10%26issue%3D1%26spage%3D63%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K. V.  Diveshkumar</span>, <span class="hlFld-ContribAuthor ">Saaz  Sakrikar</span>, <span class="hlFld-ContribAuthor ">S.  Harikrishna</span>, <span class="hlFld-ContribAuthor ">V.  Dhamodharan</span>, <span class="hlFld-ContribAuthor ">P. I.  Pradeepkumar</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Promoter G-Quadruplex DNAs by Indenopyrimidine-Based Ligands. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2014,</strong> <em>9 </em>
                                    (12)
                                     , 2754-2765. <a href="https://doi.org/10.1002/cmdc.201402394" title="DOI URL">https://doi.org/10.1002/cmdc.201402394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201402394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201402394%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DTargeting%252BPromoter%252BG-Quadruplex%252BDNAs%252Bby%252BIndenopyrimidine-Based%252BLigands%26aulast%3DDiveshkumar%26aufirst%3DK.%2BV.%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D12%26spage%3D2754%26epage%3D2765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annalisa  Pinna</span>, <span class="hlFld-ContribAuthor ">Micaela  Morelli</span>. </span><span class="cited-content_cbyCitation_article-title">A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Neurotoxicity Research</span><span> <strong>2014,</strong> <em>25 </em>
                                    (4)
                                     , 392-401. <a href="https://doi.org/10.1007/s12640-013-9446-8" title="DOI URL">https://doi.org/10.1007/s12640-013-9446-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12640-013-9446-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12640-013-9446-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurotoxicity%2520Research%26atitle%3DA%252BCritical%252BEvaluation%252Bof%252BBehavioral%252BRodent%252BModels%252Bof%252BMotor%252BImpairment%252BUsed%252Bfor%252BScreening%252Bof%252BAntiparkinsonian%252BActivity%25253A%252BThe%252BCase%252Bof%252BAdenosine%252BA2A%252BReceptor%252BAntagonists%26aulast%3DPinna%26aufirst%3DAnnalisa%26date%3D2014%26date%3D2013%26volume%3D25%26issue%3D4%26spage%3D392%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen P.  Andrews</span>, <span class="hlFld-ContribAuthor ">Giles A.  Brown</span>, <span class="hlFld-ContribAuthor ">John A.  Christopher</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based and Fragment-Based GPCR Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2014,</strong> <em>9 </em>
                                    (2)
                                     , 256-275. <a href="https://doi.org/10.1002/cmdc.201300382" title="DOI URL">https://doi.org/10.1002/cmdc.201300382</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300382%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DStructure-Based%252Band%252BFragment-Based%252BGPCR%252BDrug%252BDiscovery%26aulast%3DAndrews%26aufirst%3DStephen%2BP.%26date%3D2014%26date%3D2013%26volume%3D9%26issue%3D2%26spage%3D256%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian C.  Shook</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor Antagonists. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 1-42. <a href="https://doi.org/10.1007/7355_2014_67" title="DOI URL">https://doi.org/10.1007/7355_2014_67</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2014_67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2014_67%26sid%3Dliteratum%253Aachs%26atitle%3DAdenosine%252BA2A%252BReceptor%252BAntagonists%26aulast%3DShook%26aufirst%3DBrian%2BC.%26date%3D2014%26date%3D2014%26spage%3D1%26epage%3D42%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNovel%252BTherapeutic%252BApproaches%252Bto%252Bthe%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DHopkins%26aufirst%3DCorey%2BR.%26date%3D2016%26volume%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria JoÃ£o  Matos</span>, <span class="hlFld-ContribAuthor ">Veronika  Hogger</span>, <span class="hlFld-ContribAuthor ">Alexandra  Gaspar</span>, <span class="hlFld-ContribAuthor ">Sonja  Kachler</span>, <span class="hlFld-ContribAuthor ">Fernanda  Borges</span>, <span class="hlFld-ContribAuthor ">Eugenio  Uriarte</span>, <span class="hlFld-ContribAuthor ">Lourdes  Santana</span>, <span class="hlFld-ContribAuthor ">Karl-Norbert  Klotz</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and adenosine receptors binding affinities of a series of 3-arylcoumarins. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacy and Pharmacology</span><span> <strong>2013,</strong> <em>65 </em>
                                    (11)
                                     , 1590-1597. <a href="https://doi.org/10.1111/jphp.12135" title="DOI URL">https://doi.org/10.1111/jphp.12135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jphp.12135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjphp.12135%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacy%2520and%2520Pharmacology%26atitle%3DSynthesis%252Band%252Badenosine%252Breceptors%252Bbinding%252Baffinities%252Bof%252Ba%252Bseries%252Bof%252B3-arylcoumarins%26aulast%3DMatos%26aufirst%3DMaria%2BJo%25C3%25A3o%26date%3D2013%26date%3D2013%26volume%3D65%26issue%3D11%26spage%3D1590%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lanny S.  Liebeskind</span>, <span class="hlFld-ContribAuthor ">Ethel C.  Garnier-Amblard</span>. </span><span class="cited-content_cbyCitation_article-title">Toward Chemoselective Bioconjugative Desulfitative Catalysis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 295-303. <a href="https://doi.org/10.1002/9781118742952.ch23" title="DOI URL">https://doi.org/10.1002/9781118742952.ch23</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118742952.ch23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118742952.ch23%26sid%3Dliteratum%253Aachs%26atitle%3DToward%252BChemoselective%252BBioconjugative%252BDesulfitative%252BCatalysis%26aulast%3DLiebeskind%26aufirst%3DLanny%2BS.%26date%3D2013%26date%3D2013%26spage%3D295%26epage%3D303%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DAdvances%252Bin%252BOrganometallic%252BChemistry%252Band%252BCatalysis%26aulast%3DPombeiro%26aufirst%3DArmando%2BJ.%2BL.%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Zhou</span>, <span class="hlFld-ContribAuthor ">Robert C.  Hider</span>, <span class="hlFld-ContribAuthor ">Peter  Jenner</span>, <span class="hlFld-ContribAuthor ">Bruce  Campbell</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Hobbs</span>, <span class="hlFld-ContribAuthor ">Sarah  Rose</span>, <span class="hlFld-ContribAuthor ">Mark  Jairaj</span>, <span class="hlFld-ContribAuthor ">Kayhan A.  Tayarani-Binazir</span>, <span class="hlFld-ContribAuthor ">Alexander  Syme</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of peptide derivatives of l-dopa as anti-parkinsonian agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (19)
                                     , 5279-5282. <a href="https://doi.org/10.1016/j.bmcl.2013.08.007" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.08.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.08.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpeptide%252Bderivatives%252Bof%252Bl-dopa%252Bas%252Banti-parkinsonian%252Bagents%26aulast%3DZhou%26aufirst%3DTao%26date%3D2013%26volume%3D23%26issue%3D19%26spage%3D5279%26epage%3D5282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irene  Giorgi</span>, <span class="hlFld-ContribAuthor ">Paola  Nieri</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A
              1
              modulators: a patent update (2008 to present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2013,</strong> <em>23 </em>
                                    (9)
                                     , 1109-1121. <a href="https://doi.org/10.1517/13543776.2013.799142" title="DOI URL">https://doi.org/10.1517/13543776.2013.799142</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2013.799142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2013.799142%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAdenosine%252BA%252B1%252Bmodulators%25253A%252Ba%252Bpatent%252Bupdate%252B%2525282008%252Bto%252Bpresent%252529%26aulast%3DGiorgi%26aufirst%3DIrene%26date%3D2013%26date%3D2013%26volume%3D23%26issue%3D9%26spage%3D1109%26epage%3D1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian C.  Shook</span>, <span class="hlFld-ContribAuthor ">Devraj  Chakravarty</span>, <span class="hlFld-ContribAuthor ">J. Kent  Barbay</span>, <span class="hlFld-ContribAuthor ">Aihua  Wang</span>, <span class="hlFld-ContribAuthor ">Kristi  Leonard</span>, <span class="hlFld-ContribAuthor ">Vernon  Alford</span>, <span class="hlFld-ContribAuthor ">Mark T.  Powell</span>, <span class="hlFld-ContribAuthor ">Stefanie  Rassnick</span>, <span class="hlFld-ContribAuthor ">Robert H.  Scannevin</span>, <span class="hlFld-ContribAuthor ">Karen  Carroll</span>, <span class="hlFld-ContribAuthor ">Nathaniel  Wallace</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Crooke</span>, <span class="hlFld-ContribAuthor ">Mark  Ault</span>, <span class="hlFld-ContribAuthor ">Lisa  Lampron</span>, <span class="hlFld-ContribAuthor ">Lori  Westover</span>, <span class="hlFld-ContribAuthor ">Kenneth  Rhodes</span>, <span class="hlFld-ContribAuthor ">Paul F.  Jackson</span>. </span><span class="cited-content_cbyCitation_article-title">Substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (9)
                                     , 2688-2691. <a href="https://doi.org/10.1016/j.bmcl.2013.02.078" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.02.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.02.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.02.078%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSubstituted%252Bthieno%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Badenosine%252BA2A%252Breceptor%252Bantagonists%26aulast%3DShook%26aufirst%3DBrian%2BC.%26date%3D2013%26volume%3D23%26issue%3D9%26spage%3D2688%26epage%3D2691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saleta  Vazquez-Rodriguez</span>, <span class="hlFld-ContribAuthor ">Maria JoÃ£o  Matos</span>, <span class="hlFld-ContribAuthor ">Lourdes  Santana</span>, <span class="hlFld-ContribAuthor ">Eugenio  Uriarte</span>, <span class="hlFld-ContribAuthor ">Fernanda  Borges</span>, <span class="hlFld-ContribAuthor ">Sonja  Kachler</span>, <span class="hlFld-ContribAuthor ">Karl-Norbert  Klotz</span>. </span><span class="cited-content_cbyCitation_article-title">Chalcone-based derivatives as new scaffolds for
              h
              A3 adenosine receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacy and Pharmacology</span><span> <strong>2013,</strong> <em>65 </em>
                                    (5)
                                     , 697-703. <a href="https://doi.org/10.1111/jphp.12028" title="DOI URL">https://doi.org/10.1111/jphp.12028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jphp.12028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjphp.12028%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacy%2520and%2520Pharmacology%26atitle%3DChalcone-based%252Bderivatives%252Bas%252Bnew%252Bscaffolds%252Bfor%252Bh%252BA3%252Badenosine%252Breceptor%252Bantagonists%26aulast%3DVazquez-Rodriguez%26aufirst%3DSaleta%26date%3D2013%26date%3D2013%26volume%3D65%26issue%3D5%26spage%3D697%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafael  Franco</span>, <span class="hlFld-ContribAuthor ">Eva  MartÃ­nez-Pinilla</span>, <span class="hlFld-ContribAuthor ">Ana  Ricobaraza</span>, <span class="hlFld-ContribAuthor ">Peter J.  McCormick</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges in the Development of Heteromer-GPCR-Based Drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 143-162. <a href="https://doi.org/10.1016/B978-0-12-386931-9.00006-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-386931-9.00006-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-386931-9.00006-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-386931-9.00006-4%26sid%3Dliteratum%253Aachs%26atitle%3DChallenges%252Bin%252Bthe%252BDevelopment%252Bof%252BHeteromer-GPCR-Based%252BDrugs%26aulast%3DFranco%26aufirst%3DRafael%26date%3D2013%26spage%3D143%26epage%3D162%26pub%3DElsevier%26atitle%3DOligomerization%252Bin%252BHealth%252Band%252BDisease%26date%3D2013%26volume%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen P.  Andrews</span>, <span class="hlFld-ContribAuthor ">Benjamin  Tehan</span>. </span><span class="cited-content_cbyCitation_article-title">Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A
              2A
              receptor. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2013,</strong> <em>4 </em>
                                    (1)
                                     , 52-67. <a href="https://doi.org/10.1039/C2MD20164J" title="DOI URL">https://doi.org/10.1039/C2MD20164J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C2MD20164J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC2MD20164J%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DStabilised%252BG%252Bprotein-coupled%252Breceptors%252Bin%252Bstructure-based%252Bdrug%252Bdesign%25253A%252Ba%252Bcase%252Bstudy%252Bwith%252Badenosine%252BA%252B2A%252Breceptor%26aulast%3DAndrews%26aufirst%3DStephen%2BP.%26date%3D2013%26date%3D2013%26volume%3D4%26issue%3D1%26spage%3D52%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0001.jpeg" id="rightTab-GRAPHIC-d2141e682-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Metabolism of Compound <b>1</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reversal of neuroleptic-induced catalepsy in mice by compounds <b>13</b> and <b>14</b>. In this behavioral model, catalepsy was induced in male Balb/c mice by subcutaneous administration of haloperidol, a neuroleptic D<sub>2</sub> receptor antagonist. Compound <b>1</b> was used as the positive control for this model at 10 mg/kg, po. Compounds <b>13</b> (left panel) and <b>14</b> (right panel) were administered orally 30 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 1 h after dosing of <b>13</b> and <b>14</b>. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 8â12 mice per treatment group during a 60 s test session. Both compounds produced a dose-dependent reversal of haloperidol-induced catalepsy. The ED<sub>50</sub> of <b>13</b> for inhibiting haloperidol-induced catalepsy in mice was 0.4 mg/kg, po, and the minimum effective dose is shown to be 1 mg/kg, po. The ED<sub>50</sub> of <b>14</b> for inhibiting haloperidol-induced catalepsy in mice was <0.1 mg/kg, po, and the minimum effective dose is shown to be 0.1 mg/kg, po. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>4</b>â<b>13</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound <b>14</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Duration of action of <b>13</b> in the mouse model of neuroleptic-induced catalepsy. Catalepsy was induced by subcutaneous administration of haloperidol. Compound <b>13</b> was administered orally 30 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 30 min and 1, 2, and 4 h after administration of vehicle, <b>13</b>, or <b>1</b> (positive control) in male Balb/c mice. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 8 mice per treatment group during a 60 s test session. Haloperidol-induced catalepsy was evident at all measurement periods. Compound <b>13</b> was effective in reversing haloperidol-induced catalepsy 30 min and 1, 2, and 4 h after oral dosing. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Duration of action of <b>14</b> in the mouse model of neuroleptic-induced catalepsy. Catalepsy was induced by subcutaneous administration of haloperidol. Compound <b>14</b> was administered orally 30 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 30 min and 1, 2, and 4 h after administration of vehicle, <b>14</b>, or <b>1</b> (positive control) in male Balb/c mice. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 8 mice per treatment group during a 60 s test session. Haloperidol-induced catalepsy was evident at all measurement periods. Compound <b>14</b> was effective in reversing haloperidol-induced catalepsy 30 min and 1, 2, and 4 h after oral dosing. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Reversal of neuroleptic-induced catalepsy in rats by compounds <b>13</b> and <b>14</b>. In this behavioral model, catalepsy was induced in SpragueâDawley rats by subcutaneous administration of haloperidol, a neuroleptic D<sub>2</sub> receptor antagonist. Compound <b>1</b> was used as the positive control for this model at 10 mg/kg, po. Compounds <b>13</b> (left panel) and <b>14</b> (right panel) were administered orally 60 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 1 h after dosing of <b>13</b> and <b>14</b>. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 10 rats per treatment group during a 180 s test session. Both compounds produced a dose-dependent reversal of haloperidol-induced catalepsy. The ED<sub>50</sub> values of <b>13</b> and <b>14</b> for inhibiting haloperidol-induced catalepsy in rats were 0.6 and 0.3 mg/kg, po, respectively, and the minimum effective dose was shown to be 1 mg/kg, po, for both <b>13</b> and <b>14</b>. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Duration of action of <b>14</b> in the rat model of neuroleptic-induced catalepsy. Catalepsy was induced by subcutaneous administration of haloperidol. Compound <b>14</b> (1 mg/kg) was administered orally 60 min after haloperidol (1 mg/kg, sc). Behavioral testing was conducted 15 min and 1, 2, and 4 h after administration of vehicle, <b>14</b>, or <b>1</b> (positive control) in SpragueâDawley rats. Each value represents average (Â±SEM) time in cataleptic position of <i>n</i> = 10â12 rats per treatment group during a 180 s test session. Haloperidol-induced catalepsy was evident at all measurement periods. Compound <b>14</b> was effective in reversing haloperidol-induced catalepsy 1, 2, and 4 h after oral dosing of 1 mg/kg. Asterisks indicate significant differences as compared with the haloperidol + vehicle control treatment group (***<i>P</i> < 0.001, Dunnett's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0011.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Reversal of reserpine-induced akinesia by <b>13</b> (left) and <b>14</b> (right) in mice. In this behavioral model, akinesia was induced by subcutaneous administration reserpine, a monoamine-depleting drug in male CF-1 mice. Compounds <b>13</b>, <b>14</b>, <b>1</b> (10 mg/kg, positive control), or vehicle were administered orally 60 min before the behavioral test in the locomotor activity boxes. Each value shows the mean (Â±SEM) of the total distance traveled during the 30 min measurement period in the behavioral test session. Reserpine produced a marked decrease in locomotor activity as compared with vehicle + vehicle-treated controls. Compounds <b>13</b> and <b>14</b> reversed reserpine-induced akinesia with similar effectiveness to the control <b>1</b>, <i>N</i> = 14â16 mice per treatment group. Asterisks indicate significant differences as compared with the reserpine + vehicle control group (**<i>P</i> < 0.01, ***<i>P</i> < 0.001, Hochberg test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0012.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Reversal of reserpine-induced akinesia by <b>14</b> (left) and <b>13</b> (right) in rats. In this behavioral model, akinesia was induced by subcutaneous administration reserpine, a monoamine-depleting drug in male Wistar rats. Compounds <b>13</b>, <b>14</b>, <b>1</b> (10 mg/kg, positive control), or vehicle was administered orally 60 min before the behavioral test in the locomotor activity boxes. Each value shows the mean (Â±SEM) of the total distance traveled during a 60 min measurement period in the behavioral test session. Reserpine produced a marked decrease in locomotor activity as compared with vehicle + vehicle-treated controls. Compounds <b>13</b> and <b>14</b> reversed reserpine-induced akinesia with similar effectiveness to the control <b>1</b>, <i>N</i> = 16â18 rats per treatment group. Asterisks indicate significant differences as compared with the reserpine + vehicle control group (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001, Hochberg test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/medium/jm-2011-01640m_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0013.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>14</b> potentiates the effects of L-DOPA in the 6-OHDA-lesioned rat model of PD. Six weeks after administration of 6-OHDA, the behavioral test was started by dosing rats with L-DOPA [10 mg/kg, po coadministered with carbidopa (2.5 mg/k, sc)] alone or with each dose of <b>14</b> (0.1, 1.0, 3.0, 6.0, and 10 mg/kg, po). The effects of <b>14</b> alone at 10 mg/kg, po (indicated in both the left and the right panels as 10), were also studied in this model. For clarity, two separate groups of animals were dosed at 10 mg/kg, po. The rotational behavior was determined as each animal was tethered to a high-resolution optical sensor connected to an automated computerized system that quantifies circular motion. One rotation count was defined as one 360Â° turn. Each value represents the mean (Â±SEM) of total contralateral rotations of <i>n</i> = 16 rats per treatment group during the 2 h before and after L-DOPA administration. Asterisks in the left panel indicate significant differences as compared with vehicle control treatment group, and asterisks in the right panel indicate significant differences as compared with the L-DOPA + vehicle control treatment group (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001, Tukey's test of multiple comparisons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-3/jm201640m/production/images/large/jm-2011-01640m_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201640m&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 41 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lozano, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchison, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostrovsky, J. O.</span><span> </span><span class="NLM_article-title">New developments in understanding the etiology of Parkinson's disease and in its treatment</span> <span class="citation_source-journal">Curr. Opin. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">â</span> <span class="NLM_lpage">790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=783-790&author=A.+M.+Lozanoauthor=A.+E.+Langauthor=W.+D.+Hutchisonauthor=J.+O.+Dostrovsky&title=New+developments+in+understanding+the+etiology+of+Parkinson%27s+disease+and+in+its+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLozano%26aufirst%3DA.%2BM.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DHutchison%26aufirst%3DW.%2BD.%26aulast%3DDostrovsky%26aufirst%3DJ.%2BO.%26atitle%3DNew%2520developments%2520in%2520understanding%2520the%2520etiology%2520of%2520Parkinson%2527s%2520disease%2520and%2520in%2520its%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1998%26volume%3D8%26spage%3D783%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Fink, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivkees, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterfreund, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollack, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adler, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reppert, S. M.</span><span> </span><span class="NLM_article-title">Molecular cloning of the rat A<sub>2</sub> adenosine receptor: Selective co-expression with D<sub>2</sub> dopamine receptors in rat striatum</span> <span class="citation_source-journal">Mol. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">â</span> <span class="NLM_lpage">195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0169-328X%2892%2990173-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=1279342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVelt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1992&pages=186-195&author=J.+S.+Finkauthor=D.+R.+Weaverauthor=S.+A.+Rivkeesauthor=R.+A.+Peterfreundauthor=A.+E.+Pollackauthor=E.+M.+Adlerauthor=S.+M.+Reppert&title=Molecular+cloning+of+the+rat+A2+adenosine+receptor%3A+Selective+co-expression+with+D2+dopamine+receptors+in+rat+striatum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum</span></div><div class="casAuthors">Fink, J. Stephen; Weaver, David R.; Rivkees, Scott A.; Peterfreund, Robert A.; Pollack, Alexia E.; Adler, Elizabeth M.; Reppert, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-95</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    </div><div class="casAbstract">A cDNA fragment homologous to other G protein-coupled receptors was isolated from rat brain using the PCR method and demonstrated to be abundantly expressed in striatum.  Using this fragment as a probe, a 2.1 kb full-length cDNA was isolated from a rat striatal cDNA library.  This cDNA encodes a protein of 410 amino acids and is highly homologous to previously isolated adenosine receptor cDNA.  Expression of this cDNA in COS cells revealed high affinity (Kd = 38.6 nM) and saturable binding of the A2 adenosine receptor-selective ligand [3H]CGS 21680.  Agonist displacement profile of [3H]CGS 21680 binding was consistent with an adenosine receptor of the A2 subtype (NECA > (R)-PIA > CPA > (S)-PIA).  In situ hybridization demonstrated that rat A2 adenosine receptor mRNA was co-expressed in the same striatal neurons as D2 dopamine receptor mRNA, and never co-expressed with striatal D1 dopamine receptor mRNA.  Several lines of evidence have previously suggested that dopamine-induced changes in motor behavior can be modulated by adenosine analogs acting at the A2 subtype of adenosine receptor in the forebrain.  The co-expression of D2 dopamine and A2 adenosine receptors in a subset of striatal cells provides an anatomical basis for dopaminergic-adenosinergic interactions on motor behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Daq1pagx8bVg90H21EOLACvtfcHk0lhPc8dewmR3HA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVelt7o%253D&md5=c625968121ce9599d80d0d7cad3e1b56</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0169-328X%2892%2990173-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0169-328X%252892%252990173-9%26sid%3Dliteratum%253Aachs%26aulast%3DFink%26aufirst%3DJ.%2BS.%26aulast%3DWeaver%26aufirst%3DD.%2BR.%26aulast%3DRivkees%26aufirst%3DS.%2BA.%26aulast%3DPeterfreund%26aufirst%3DR.%2BA.%26aulast%3DPollack%26aufirst%3DA.%2BE.%26aulast%3DAdler%26aufirst%3DE.%2BM.%26aulast%3DReppert%26aufirst%3DS.%2BM.%26atitle%3DMolecular%2520cloning%2520of%2520the%2520rat%2520A2%2520adenosine%2520receptor%253A%2520Selective%2520co-expression%2520with%2520D2%2520dopamine%2520receptors%2520in%2520rat%2520striatum%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D1992%26volume%3D14%26spage%3D186%26epage%3D195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Schiffmann, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassart, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderhaeghen, J. J.</span><span> </span><span class="NLM_article-title">Distribution of adenosine A<sub>2</sub>receptor mRNA in the human brain</span> <span class="citation_source-journal">Neurosci. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">177</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=1991&pages=177-181&author=S.+N.+Schiffmannauthor=F.+Lipertauthor=G.+Vassartauthor=J.+J.+Vanderhaeghen&title=Distribution+of+adenosine+A2receptor+mRNA+in+the+human+brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26aulast%3DLipert%26aufirst%3DF.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DVanderhaeghen%26aufirst%3DJ.%2BJ.%26atitle%3DDistribution%2520of%2520adenosine%2520A2receptor%2520mRNA%2520in%2520the%2520human%2520brain%26jtitle%3DNeurosci.%2520Lett.%26date%3D1991%26volume%3D130%26spage%3D177%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Olanow, C. W.</span><span> </span><span class="NLM_article-title">MAO-B inhibitors in Parkinson's disease</span> <span class="citation_source-journal">Adv. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">â</span> <span class="NLM_lpage">671</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=8420207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK3sXktF2lurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=1993&pages=666-671&author=C.+W.+Olanow&title=MAO-B+inhibitors+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">MAO-B inhibitors in Parkinson's disease</span></div><div class="casAuthors">Olanow, C. Warren</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Neurology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">Parkinson's Disease</span>),
    <span class="NLM_cas:pages">666-71</span>CODEN:
                <span class="NLM_cas:coden">ADNRA3</span>;
        ISSN:<span class="NLM_cas:issn">0091-3952</span>.
    </div><div class="casAbstract">A review with 46 ref.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQFDRpN_SkdrVg90H21EOLACvtfcHk0lhPc8dewmR3HA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXktF2lurw%253D&md5=e90fcc306d9c58991fe71c94a48e5fba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26atitle%3DMAO-B%2520inhibitors%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DAdv.%2520Neurol.%26date%3D1993%26volume%3D60%26spage%3D666%26epage%3D671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gordin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, D. J.</span><span> </span><span class="NLM_article-title">Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease</span> <span class="citation_source-journal">J. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">254</span><span class="NLM_x">, </span> <span class="NLM_fpage">IV/37</span><span class="NLM_x">â</span> <span class="NLM_lpage">IV/48</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2007&pages=IV%2F37-IV%2F48&author=A.+Gordinauthor=D.+J.+Brooks&title=Clinical+pharmacology+and+therapeutic+use+of+COMT+inhibition+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGordin%26aufirst%3DA.%26aulast%3DBrooks%26aufirst%3DD.%2BJ.%26atitle%3DClinical%2520pharmacology%2520and%2520therapeutic%2520use%2520of%2520COMT%2520inhibition%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DJ.%2520Neurol.%26date%3D2007%26volume%3D254%26spage%3DIV%252F37%26epage%3DIV%252F48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Olanow, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span> </span><span class="NLM_article-title">COMT inhibitors in Parkinson's disease. Can they prevent and/or reverse levodopa-induced motor complications?</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">S72</span><span class="NLM_x">â</span> <span class="NLM_lpage">S81</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2004&pages=S72-S81&author=C.+W.+Olanowauthor=F.+Stocchi&title=COMT+inhibitors+in+Parkinson%27s+disease.+Can+they+prevent+and%2For+reverse+levodopa-induced+motor+complications%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DStocchi%26aufirst%3DF.%26atitle%3DCOMT%2520inhibitors%2520in%2520Parkinson%2527s%2520disease.%2520Can%2520they%2520prevent%2520and%252For%2520reverse%2520levodopa-induced%2520motor%2520complications%253F%26jtitle%3DNeurology%26date%3D2004%26volume%3D62%26spage%3DS72%26epage%3DS81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ramlackhansingh, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turkheimer, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavese, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, D. J.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor availability in dyskinetic and nondyskinetic patients with Parkinsonâs disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1811</span><span class="NLM_x">â</span> <span class="NLM_lpage">1816</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=1811-1816&author=A.+F.+Ramlackhansinghauthor=S.+K.+Boseauthor=I.+Ahmedauthor=F.+E.+Turkheimerauthor=N.+Paveseauthor=D.+J.+Brooks&title=Adenosine+A2A+receptor+availability+in+dyskinetic+and+nondyskinetic+patients+with+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRamlackhansingh%26aufirst%3DA.%2BF.%26aulast%3DBose%26aufirst%3DS.%2BK.%26aulast%3DAhmed%26aufirst%3DI.%26aulast%3DTurkheimer%26aufirst%3DF.%2BE.%26aulast%3DPavese%26aufirst%3DN.%26aulast%3DBrooks%26aufirst%3DD.%2BJ.%26atitle%3DAdenosine%2520A2A%2520receptor%2520availability%2520in%2520dyskinetic%2520and%2520nondyskinetic%2520patients%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurology%26date%3D2011%26volume%3D76%26spage%3D1811%26epage%3D1816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Antonini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clilia, R.</span><span> </span><span class="NLM_article-title">Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: Incidence, neurobiological basis, management and prevention</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">â</span> <span class="NLM_lpage">488</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.2165%2F00002018-200932060-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=19459715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVyls7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=475-488&author=A.+Antoniniauthor=R.+Clilia&title=Behavioural+adverse+effects+of+dopaminergic+treatments+in+Parkinson%27s+disease%3A+Incidence%2C+neurobiological+basis%2C+management+and+prevention"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention</span></div><div class="casAuthors">Antonini, Angelo; Cilia, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">475-488</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  Treatment of Parkinson's disease has traditionally focused on the management of motor disability while behavioral disturbances have received less attention.  Recently, impulse control disorders and aberrant repetitive behaviors have surged to clin. relevance as they occur during dopamine replacement treatment (mainly with dopamine agonists) and worsen patient and caregiver quality of life.  Patients are unable to adequately est. the neg. consequences of their actions and are prone to entertain compulsive reward-seeking activities.  This review aims to summarize current evidence on the epidemiol. of behavioral disturbances in Parkinson's disease, recent insights into their neurobiol. basis and to discuss strategies for management and prevention.  Studies from 1990 through to Dec. 2008 were retrieved via searches of the Cochrane Database of Systematic Reviews and PubMed.  The mechanisms underlying the development of behavioral disturbances in Parkinson's disease are debated but current evidence points to specific risk factors: male sex, young age at onset, underlying personality traits characterized by high impulsivity and novelty seeking, and personal or family history of addictive disorders.  Specifically, in predisposed individuals dopamine replacement therapy leads to overstimulation of dopamine receptors within the mesocorticolimbic pathways and in turn to the development of addictive behaviors, such as impulse control disorders and compulsive medication intake.  Since these disturbances affect individuals who have often unremarkable psychiatric history and no cognitive impairment, their identification and management is complex.  Compulsive medication intake (described as 'hedonistic homeostatic dysregulation' or 'dopamine dysregulation syndrome') is commonly assocd. with fluctuations in advanced disease, while impulse control disorders frequently occur in early Parkinson's disease and within normal-range medication dosages.  Management primarily requires redn. of dopaminergic therapy but psychosocial support is often required.  Use of selective serotonin reuptake inhibitors in the dose used for obsessive compulsive disorders may help, while benefit from atypical antipsychotics is limited in most cases.  Deep brain stimulation should be considered with caution in these subjects.  Prevention is based on the identification of at-risk individuals and active monitoring.  Given the social and potentially medical-legal consequences of these behaviors, we encourage treating physicians to discuss risks with patients before treatment is initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMVy-djioeu7Vg90H21EOLACvtfcHk0lgFXYemZw3_oA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVyls7o%253D&md5=91c7cb882454bfa47f2d0e4dbfae7c32</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.2165%2F00002018-200932060-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200932060-00004%26sid%3Dliteratum%253Aachs%26aulast%3DAntonini%26aufirst%3DA.%26aulast%3DClilia%26aufirst%3DR.%26atitle%3DBehavioural%2520adverse%2520effects%2520of%2520dopaminergic%2520treatments%2520in%2520Parkinson%2527s%2520disease%253A%2520Incidence%252C%2520neurobiological%2520basis%252C%2520management%2520and%2520prevention%26jtitle%3DDrug%2520Saf.%26date%3D2009%26volume%3D32%26spage%3D475%26epage%3D488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hansard, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheetham, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Dopamine, but not norepinephrine or serotonin reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">952</span><span class="NLM_x">â</span> <span class="NLM_lpage">958</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1124%2Fjpet.102.039743" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=12438514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD38Xptlamt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=952-958&author=M.+J.+Hansardauthor=L.+A.+Smithauthor=M.+J.+Jacksonauthor=S.+C.+Cheethamauthor=P.+Jenner&title=Dopamine%2C+but+not+norepinephrine+or+serotonin+reuptake+inhibition+reverses+motor+deficits+in+1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine-treated+primates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates</span></div><div class="casAuthors">Hansard, Matthew J.; Smith, Lance A.; Jackson, Michael J.; Cheetham, Sharon C.; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">952-958</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Monoamine reuptake inhibitors that do not discriminate between the transporters for dopamine (DA), norepinephrine (NE), or 5-hydroxytryptamine (5-HT, serotonin) can reverse locomotor deficits and motor disability in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.  DA reuptake inhibition is presumed to be primarily responsible, but the role played by inhibition of NE and 5-HT reuptake is unknown.  This work evaluated the efficacy of a range of monoamine reuptake inhibitors either alone or in combination in MPTP-treated common marmosets to det. the actions required for effective antiparkinsonian activity.  Monoamine reuptake inhibitors not discriminating between the DA, NE, and 5-HT transporters [1-[1-(3,4-dichlororphenyl)cyclobutyl]-2-(3-diaminethylaminopropylthio)ethanone monocitrate (BTS 74 398) and nomifensine] reversed locomotor deficits and motor disability in MPTP-treated marmosets but bupropion was without effect.  The selective DA reuptake inhibitor 1-(2-(bis-(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (GBR 12909) also reversed these motor deficits.  The relative efficacy of the compds. (BTS 74 398 > GBR 12909 > nomifensine Â» bupropion) paralleled their previously detd. potency in inhibiting DA uptake in vitro and in vivo.  In contrast, the selective NE reuptake inhibitor nisoxetine and the 5-HT reuptake inhibitor sertraline administered alone failed to improve motor function and tended to worsen the deficits.  Coadministration of nisoxetine attenuated the improvement in motor deficits produced by GBR 12909.  Coadministration of sertraline also abolished the reversal of motor deficits produced by GBR 12909.  Coadministration of both sertraline and nisoxetine similarly abolished the improvement of motor deficits produced by GBR 12909.  Mols. possessing potent DA reuptake inhibitory activity may be useful in the treatment of the motor symptoms of Parkinson's disease.  In contrast, there seems to be no role for NE or 5-HT reuptake inhibitors, and they may impair antiparkinsonian activity mediated through dopaminergic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprkAiG5hgKS7Vg90H21EOLACvtfcHk0lgFXYemZw3_oA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xptlamt7g%253D&md5=f5b88eadd0c931fe318d49b4701b8760</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039743&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039743%26sid%3Dliteratum%253Aachs%26aulast%3DHansard%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BA.%26aulast%3DJackson%26aufirst%3DM.%2BJ.%26aulast%3DCheetham%26aufirst%3DS.%2BC.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DDopamine%252C%2520but%2520not%2520norepinephrine%2520or%2520serotonin%2520reuptake%2520inhibition%2520reverses%2520motor%2520deficits%2520in%25201-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine-treated%2520primates%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D952%26epage%3D958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Antonini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolosa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizuno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poewe, W. H.</span><span> </span><span class="NLM_article-title">A reassessment of risks and benefits of dopamine agonists in Parkinson's disease</span> <span class="citation_source-journal">Lancet Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">â</span> <span class="NLM_lpage">937</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FS1474-4422%2809%2970225-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=19709931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Kitr7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=929-937&author=A.+Antoniniauthor=E.+Tolosaauthor=Y.+Mizunoauthor=M.+Yamamotoauthor=W.+H.+Poewe&title=A+reassessment+of+risks+and+benefits+of+dopamine+agonists+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">A reassessment of risks and benefits of dopamine agonists in Parkinson's disease</span></div><div class="casAuthors">Antonini, Angelo; Tolosa, Eduardo; Mizuno, Yoshikuni; Yamamoto, Mitsutoshi; Poewe, Werner H.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">929-937</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurologists have several choices of drugs that have been shown to be effective for the treatment of the symptoms of Parkinson's disease.  Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa.  However, before starting any treatment, the overall benefit-to-risk ratio to individual patients must be considered.  For the dopamine agonists, the available evidence on their symptomatic efficacy, effect on long-term levodopa-related motor complications, putative effect on progression of disease, and adverse event profile must be taken into account.  Recently, the occurrence of adverse events such as leg edema, daytime somnolence, impulse control disorders, and fibrosis have increasingly been recognized.  The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks vs. benefits for individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Rc8SOX7hMrVg90H21EOLACvtfcHk0ligC8zIc6CsRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Kitr7I&md5=3126e343054967641c318000aab5d2fe</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2809%2970225-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252809%252970225-X%26sid%3Dliteratum%253Aachs%26aulast%3DAntonini%26aufirst%3DA.%26aulast%3DTolosa%26aufirst%3DE.%26aulast%3DMizuno%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DPoewe%26aufirst%3DW.%2BH.%26atitle%3DA%2520reassessment%2520of%2520risks%2520and%2520benefits%2520of%2520dopamine%2520agonists%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DLancet%2520Neurol.%26date%3D2009%26volume%3D8%26spage%3D929%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yamamoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span> </span><span class="NLM_article-title">Dopamine agonists in Parkinsonâs disease</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">671</span><span class="NLM_x">â</span> <span class="NLM_lpage">677</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1586%2F14737175.8.4.671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=18416667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFSht70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=671-677&author=M.+Yamamotoauthor=A.+H.+V.+Schapira&title=Dopamine+agonists+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonists in Parkinson's disease</span></div><div class="casAuthors">Yamamoto, Mitsutoshi; Schapira, Anthony H. V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson's disease (PD) throughout its course.  As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications.  As an adjunct to levodopa, they improve motor control and limit the need for levodopa in those patients in whom this may be considered relevant.  The non-ergot dopamine agonists in particular have a good safety profile, although as with other agonists, sedation, and cognitive and behavioral problems may be limiting in some patients.  Pramipexole has shown benefit in improving depressive symptoms in PD.  Ropinirole and pramipexole have both demonstrated a redn. in the rate of loss of nigrostriatal innervation as detd. by imaging in PD patients, when compared with levodopa.  Thus, dopamine agonists contribute to several dimensions of the management of PD and have become an integral part of the disease treatment algorithm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxVM_IekUXprVg90H21EOLACvtfcHk0ligC8zIc6CsRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFSht70%253D&md5=9a145ab9c49de374322fb02fe543d4ad</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1586%2F14737175.8.4.671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.8.4.671%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DDopamine%2520agonists%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2008%26volume%3D8%26spage%3D671%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonists and Parkinson's disease</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">â</span> <span class="NLM_lpage">567</span></span><div class="citationLinks">[<a href="/doi/10.1021/cn2000537" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=555-567&author=B.+C.+Shookauthor=P.+F.+Jackson&title=Adenosine+A2A+receptor+antagonists+and+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A Receptor Antagonists and Parkinson's Disease</span></div><div class="casAuthors">Shook, Brian C.; Jackson, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">555-567</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This Review summarizes and updates the work on adenosine A2A receptor antagonists for Parkinson's disease from 2006 to the present.  There have been numerous publications, patent applications, and press releases within this time frame that highlight new medicinal chem. approaches to this attractive and promising target to treat Parkinson's disease.  The Review is broken down by scaffold type and will discuss the efforts to optimize particular scaffolds for activity, pharmacokinetics, and other drug discovery parameters.  The majority of approaches focus on prepg. selective A2A antagonists, but a few approaches to dual A2A/A1 antagonists will also be highlighted.  The in vivo profiles of compds. will be highlighted and discussed to compare activities across different chem. series.  A clin. report and update will be given on compds. that have entered clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9jbqVC-a6P7Vg90H21EOLACvtfcHk0ligC8zIc6CsRA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVSrsrc%253D&md5=81746259f96dd1a270f12c3cb2dbe1d3</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fcn2000537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn2000537%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520and%2520Parkinson%2527s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D555%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Neustadt, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamford, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertorelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredduzzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen-Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, K.</span><span> </span><span class="NLM_article-title">Potent and selective adenosine A<sub>2A</sub> antagonists 1,2,4-triazolo[1,5-c]pyrimidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">â</span> <span class="NLM_lpage">971</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=967-971&author=B.+R.+Neustadtauthor=H.+Liuauthor=J.+Haoauthor=W.+J.+Greenleeauthor=A.+W.+Stamfordauthor=C.+Fosterauthor=L.+Arikauthor=J.+Lachowiczauthor=H.+Zhangauthor=R.+Bertorelliauthor=S.+Fredduzziauthor=G.+Vartyauthor=M.+Cohen-Williamsauthor=K.+Ng&title=Potent+and+selective+adenosine+A2A+antagonists+1%2C2%2C4-triazolo%5B1%2C5-c%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DArik%26aufirst%3DL.%26aulast%3DLachowicz%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DVarty%26aufirst%3DG.%26aulast%3DCohen-Williams%26aufirst%3DM.%26aulast%3DNg%26aufirst%3DK.%26atitle%3DPotent%2520and%2520selective%2520adenosine%2520A2A%2520antagonists%25201%252C2%252C4-triazolo%255B1%252C5-c%255Dpyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D967%26epage%3D971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Slee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorjani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanier, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rueter, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lechner, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markison, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malany, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joswig, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Palomino, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gual, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diaz, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, J.</span><span> </span><span class="NLM_article-title">Identification of novel, water soluble, 2-amino-N-pyrimin-4-ylacetamides as A<sub>2A</sub> receptor antagonists with in vivo activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">400</span><span class="NLM_x">â</span> <span class="NLM_lpage">406</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070623o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=400-406&author=D.+H.+Sleeauthor=X.+Zhangauthor=M.+Moorjaniauthor=E.+Linauthor=M.+C.+Lanierauthor=Y.+Chenauthor=J.+K.+Rueterauthor=S.+M.+Lechnerauthor=S.+Markisonauthor=S.+Malanyauthor=T.+Joswigauthor=M.+Santosauthor=R.+S.+Grossauthor=J.+P.+Williamsauthor=J.+C.+Castro-Palominoauthor=M.+I.+Crespoauthor=M.+Pratauthor=S.+Gualauthor=J.+L.+Diazauthor=J.+Wenauthor=Z.+O%27Brienauthor=J.+Saunders&title=Identification+of+novel%2C+water+soluble%2C+2-amino-N-pyrimin-4-ylacetamides+as+A2A+receptor+antagonists+with+in+vivo+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=10.1021%2Fjm070623o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070623o%26sid%3Dliteratum%253Aachs%26aulast%3DSlee%26aufirst%3DD.%2BH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMoorjani%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DLanier%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DRueter%26aufirst%3DJ.%2BK.%26aulast%3DLechner%26aufirst%3DS.%2BM.%26aulast%3DMarkison%26aufirst%3DS.%26aulast%3DMalany%26aufirst%3DS.%26aulast%3DJoswig%26aufirst%3DT.%26aulast%3DSantos%26aufirst%3DM.%26aulast%3DGross%26aufirst%3DR.%2BS.%26aulast%3DWilliams%26aufirst%3DJ.%2BP.%26aulast%3DCastro-Palomino%26aufirst%3DJ.%2BC.%26aulast%3DCrespo%26aufirst%3DM.%2BI.%26aulast%3DPrat%26aufirst%3DM.%26aulast%3DGual%26aufirst%3DS.%26aulast%3DDiaz%26aufirst%3DJ.%2BL.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DO%2527Brien%26aufirst%3DZ.%26aulast%3DSaunders%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520novel%252C%2520water%2520soluble%252C%25202-amino-N-pyrimin-4-ylacetamides%2520as%2520A2A%2520receptor%2520antagonists%2520with%2520in%2520vivo%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D400%26epage%3D406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Shao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brescia, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rokosz, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuinness, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, I.</span><span> </span><span class="NLM_article-title">Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A<sub>2A</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1399</span><span class="NLM_x">â</span> <span class="NLM_lpage">1402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1399-1402&author=Y.+Shaoauthor=A.+G.+Coleauthor=M.+R.+Bresciaauthor=L.+Y.+Qinauthor=J.+Duoauthor=T.+M.+Staufferauthor=L.+L.+Rokoszauthor=B.+F.+McGuinnessauthor=I.+Henderson&title=Synthesis+and+SAR+studies+of+trisubstituted+purinones+as+potent+and+selective+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DY.%26aulast%3DCole%26aufirst%3DA.%2BG.%26aulast%3DBrescia%26aufirst%3DM.%2BR.%26aulast%3DQin%26aufirst%3DL.%2BY.%26aulast%3DDuo%26aufirst%3DJ.%26aulast%3DStauffer%26aufirst%3DT.%2BM.%26aulast%3DRokosz%26aufirst%3DL.%2BL.%26aulast%3DMcGuinness%26aufirst%3DB.%2BF.%26aulast%3DHenderson%26aufirst%3DI.%26atitle%3DSynthesis%2520and%2520SAR%2520studies%2520of%2520trisubstituted%2520purinones%2520as%2520potent%2520and%2520selective%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1399%26epage%3D1402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Vu, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumaravel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phadke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engber, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hetu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span> </span><span class="NLM_article-title">Piperazine derivatives of 1,2,4-triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A<sub>2A</sub> receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4291</span><span class="NLM_x">â</span> <span class="NLM_lpage">4299</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0498405" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4291-4299&author=C.+B.+Vuauthor=B.+Pengauthor=G.+Kumaravelauthor=G.+Smitsauthor=X.+Jinauthor=D.+Phadkeauthor=T.+Engberauthor=C.+Huangauthor=J.+Reillyauthor=S.+Tamauthor=D.+Grantauthor=G.+Hetuauthor=L.+Chenauthor=J.+Zhangauthor=R.+C.+Petter&title=Piperazine+derivatives+of+1%2C2%2C4-triazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazine+as+potent+and+selective+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=10.1021%2Fjm0498405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0498405%26sid%3Dliteratum%253Aachs%26aulast%3DVu%26aufirst%3DC.%2BB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DKumaravel%26aufirst%3DG.%26aulast%3DSmits%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DPhadke%26aufirst%3DD.%26aulast%3DEngber%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DGrant%26aufirst%3DD.%26aulast%3DHetu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26atitle%3DPiperazine%2520derivatives%2520of%25201%252C2%252C4-triazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazine%2520as%2520potent%2520and%2520selective%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4291%26epage%3D4299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Latini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedata, F.</span><span> </span><span class="NLM_article-title">Adenosine in the central nervous system: release mechanisms and extracellular concentrations</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">â</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1046%2Fj.1471-4159.2001.00607.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=11701750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotlSht7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2001&pages=463-484&author=S.+Latiniauthor=F.+Pedata&title=Adenosine+in+the+central+nervous+system%3A+release+mechanisms+and+extracellular+concentrations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine in the central nervous system: release mechanisms and extracellular concentrations</span></div><div class="casAuthors">Latini, Serena; Pedata, Felicita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">463-484</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine has several functions within the CNS that involve an inhibitory tone of neurotransmission and neuroprotective actions in pathol. conditions.  The understanding of adenosine prodn. and release in the brain is therefore of fundamental importance and has been extensively studied.  Conflicting results are often obtained regarding the cellular source of adenosine, the stimulus that induces release and the mechanism for release, in relation to different exptl. approaches used to study adenosine prodn. and release.  A neuronal origin of adenosine has been demonstrated through electrophysiol. approaches showing that neurons can release significant quantities of adenosine, sufficient to activate adenosine receptors and to modulate synaptic functions.  Specific actions of adenosine are mediated by different receptor subtypes (A1, A2A, A2B and A3), which are activated by various ranges of adenosine concns.  Another important issue is the measurement of adenosine concns. in the extracellular fluid under different conditions in order to know the degree of receptor stimulation and understand adenosine central actions.  For this purpose, several exptl. approaches have been used both in vivo and in vitro, which provide an estn. of basal adenosine levels in the range of 50-200 nM.  The purpose of this review is to describe pathways of adenosine prodn. and metab., and to summarize characteristics of adenosine release in the brain in response to different stimuli.  Finally, studies performed to evaluate adenosine concns. under physiol. and hypoxic/ischemic conditions will be described to evaluate the degree of adenosine receptor activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD81oBeM405rVg90H21EOLACvtfcHk0ljFQTXHRv8GzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotlSht7Y%253D&md5=c9636f206b3dbf0e3e2aa1c9ac9bb9fc</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2001.00607.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2001.00607.x%26sid%3Dliteratum%253Aachs%26aulast%3DLatini%26aufirst%3DS.%26aulast%3DPedata%26aufirst%3DF.%26atitle%3DAdenosine%2520in%2520the%2520central%2520nervous%2520system%253A%2520release%2520mechanisms%2520and%2520extracellular%2520concentrations%26jtitle%3DJ.%2520Neurochem.%26date%3D2001%26volume%3D79%26spage%3D463%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dunwiddie, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masino, S. A.</span><span> </span><span class="NLM_article-title">The role and regulation of adenosine in the central nervous system</span> <span class="citation_source-journal">Annu. Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">â</span> <span class="NLM_lpage">55</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1146%2Fannurev.neuro.24.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=11283304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3MXls1Siu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2001&pages=31-55&author=T.+V.+Dunwiddieauthor=S.+A.+Masino&title=The+role+and+regulation+of+adenosine+in+the+central+nervous+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">The role and regulation of adenosine in the central nervous system</span></div><div class="casAuthors">Dunwiddie, Thomas V.; Masino, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-55</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 166 refs.  Adenosine is a modulator that has a pervasive and generally inhibitory effect on neuronal activity.  Tonic activation of adenosine receptors by adenosine that is normally present in the extracellular space in brain tissue leads to inhibitory effects that appear to be mediated by both adenosine A1 and A2A receptors.  Relief from this tonic inhibition by receptor antagonists such as caffeine accounts for the excitatory actions of these agents.  Characterization of the effects of adenosine receptor agonists and antagonists has led to numerous hypotheses concerning the role of this nucleoside.  Previous work has established a role for adenosine in a diverse array of neural phenomena, which include regulation of sleep and the level of arousal, neuroprotection, regulation of seizure susceptibility, locomotor effects, analgesia, mediation of the effects of ethanol, and chronic drug use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0o-Qitx0a6LVg90H21EOLACvtfcHk0ljFQTXHRv8GzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXls1Siu7c%253D&md5=b9e0a3a4bc0c6cc23cc0ab9728d4b410</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.24.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.24.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DDunwiddie%26aufirst%3DT.%2BV.%26aulast%3DMasino%26aufirst%3DS.%2BA.%26atitle%3DThe%2520role%2520and%2520regulation%2520of%2520adenosine%2520in%2520the%2520central%2520nervous%2520system%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2001%26volume%3D24%26spage%3D31%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Stiles, G. L.</span><span> </span><span class="NLM_article-title">Adenosine receptors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">267</span><span class="NLM_x">, </span> <span class="NLM_fpage">6451</span><span class="NLM_x">â</span> <span class="NLM_lpage">6454</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=6451-6454&author=G.+L.+Stiles&title=Adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStiles%26aufirst%3DG.%2BL.%26atitle%3DAdenosine%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26spage%3D6451%26epage%3D6454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rosin, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robeva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodard, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guyenet, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, J.</span><span> </span><span class="NLM_article-title">Immunohistochemical localization of adenosine A<sub>2A</sub> receptors in rat central nervous system</span> <span class="citation_source-journal">J. Comp. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">401</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">â</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1002%2F%28SICI%291096-9861%2819981116%29401%3A2%3C163%3A%3AAID-CNE2%3E3.0.CO%3B2-D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=9822147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK1cXntlanu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1998&pages=163-186&author=D.+L.+Rosinauthor=A.+Robevaauthor=R.+L.+Woodardauthor=P.+G.+Guyenetauthor=J.+Linden&title=Immunohistochemical+localization+of+adenosine+A2A+receptors+in+rat+central+nervous+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system</span></div><div class="casAuthors">Rosin, Diane L.; Robeva, Anna; Woodard, Robin L.; Guyenet, Patrice G.; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Comparative Neurology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-186</span>CODEN:
                <span class="NLM_cas:coden">JCNEAM</span>;
        ISSN:<span class="NLM_cas:issn">0021-9967</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The A2A adenosine receptor (A2A-AR) transcript and radioligand binding sites have a distinct distribution in rat brain, restricted primarily to the striatum, nucleus accumbens, and olfactory tubercles.  The authors describe here the use of purified recombinant human A2A-ARs to generate a monoclonal antibody that has been used to better resolve the distribution of A2A-ARs in rat brain.  The antibody can detect 1 ng of purified recombinant receptor by Western blotting and is potent (EC50 = 0.62 Î¼g/mL) and highly selective for the A12A-AR subtype.  By Western blotting, the apparent mol. mass of recombinant and rat striatal receptors shifts upon deglycosylation from 43-48 to 42 kilodaltons.  Analyses of chimeric A1/A2A-ARs and synthesis of a blocking peptide pinpointed the epitope (SQPLPGER) of the antibody to the center of the third intracellular loop of the receptor.  Incubation of rat striatal membranes with antibody reduces receptor coupling to G-proteins.  In rat brain, dense A2A-AR-like immunoreactivity that is eliminated by the blocking peptide was found in the neuropil of the striatum, nucleus accumbens (rostral pole, core, and shell), cell bridges of the striatum, olfactory tubercles, and areas of extended amygdala with somewhat lighter labeling in the globus pallidus and nucleus of the solitary tract.  Light perikaryal labeling was found in other areas of the brain, including the cortex, hippocampus, thalamus, cerebellum, and portions of the hindbrain.  The obsd. distribution of A2A-AR immunoreactivity throughout the neuraxis is consistent with the receptors' role in modulating dopaminergic neurotransmission and central control of cardiovascular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNFUvkZHeam7Vg90H21EOLACvtfcHk0ljCUfYsUH4Hwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntlanu7Y%253D&md5=297b00a8d21c3430128983539209aa65</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-9861%2819981116%29401%3A2%3C163%3A%3AAID-CNE2%3E3.0.CO%3B2-D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-9861%252819981116%2529401%253A2%253C163%253A%253AAID-CNE2%253E3.0.CO%253B2-D%26sid%3Dliteratum%253Aachs%26aulast%3DRosin%26aufirst%3DD.%2BL.%26aulast%3DRobeva%26aufirst%3DA.%26aulast%3DWoodard%26aufirst%3DR.%2BL.%26aulast%3DGuyenet%26aufirst%3DP.%2BG.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DImmunohistochemical%2520localization%2520of%2520adenosine%2520A2A%2520receptors%2520in%2520rat%2520central%2520nervous%2520system%26jtitle%3DJ.%2520Comp.%2520Neurol.%26date%3D1998%26volume%3D401%26spage%3D163%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svenningsson, P.</span><span> </span><span class="NLM_article-title">Striatal adenosine A<sub>2A</sub> receptors-where are they? What do they do? Comments</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">46</span><span class="NLM_x">â</span> <span class="NLM_lpage">47</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1998&pages=46-47&author=B.+B.+Fredholmauthor=P.+Svenningsson&title=Striatal+adenosine+A2A+receptors-where+are+they%3F+What+do+they+do%3F+Comments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DSvenningsson%26aufirst%3DP.%26atitle%3DStriatal%2520adenosine%2520A2A%2520receptors-where%2520are%2520they%253F%2520What%2520do%2520they%2520do%253F%2520Comments%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1998%26volume%3D19%26spage%3D46%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ishiwata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mishina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span> </span><span class="NLM_article-title">First visualization of adenosine A<sub>2A</sub> receptors in the human brain by positron emission tomography with [<sup>11</sup>C]TMSX</span> <span class="citation_source-journal">Synapse</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">â</span> <span class="NLM_lpage">136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2005&pages=133-136&author=K.+Ishiwataauthor=M.+Mishinaauthor=Y.+Kimuraauthor=K.+Odaauthor=T.+Sasakiauthor=K.+Ishii&title=First+visualization+of+adenosine+A2A+receptors+in+the+human+brain+by+positron+emission+tomography+with+%5B11C%5DTMSX"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIshiwata%26aufirst%3DK.%26aulast%3DMishina%26aufirst%3DM.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DK.%26atitle%3DFirst%2520visualization%2520of%2520adenosine%2520A2A%2520receptors%2520in%2520the%2520human%2520brain%2520by%2520positron%2520emission%2520tomography%2520with%2520%255B11C%255DTMSX%26jtitle%3DSynapse%26date%3D2005%26volume%3D55%26spage%3D133%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Svenningsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedvall, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span> </span><span class="NLM_article-title">Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study</span> <span class="citation_source-journal">Synapse</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">â</span> <span class="NLM_lpage">335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=322-335&author=P.+Svenningssonauthor=H.+Hallauthor=G.+Sedvallauthor=B.+B.+Fredholm&title=Distribution+of+adenosine+receptors+in+the+postmortem+human+brain%3A+an+extended+autoradiographic+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DHall%26aufirst%3DH.%26aulast%3DSedvall%26aufirst%3DG.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DDistribution%2520of%2520adenosine%2520receptors%2520in%2520the%2520postmortem%2520human%2520brain%253A%2520an%2520extended%2520autoradiographic%2520study%26jtitle%3DSynapse%26date%3D1997%26volume%3D27%26spage%3D322%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Varani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincenzi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casetta, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazio, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLennan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granieri, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borea, P. A.</span><span> </span><span class="NLM_article-title">A<sub>2A</sub> adenosine receptor overexpression and functionality, as well as TNF-Î± levels, correlate with motor symptoms in Parkinson's disease</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">â</span> <span class="NLM_lpage">598</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=587-598&author=K.+Varaniauthor=F.+Vincenziauthor=A.+Tosiauthor=S.+Gessiauthor=I.+Casettaauthor=G.+Granieriauthor=P.+Fazioauthor=E.+Leungauthor=S.+MacLennanauthor=E.+Granieriauthor=P.+A.+Borea&title=A2A+adenosine+receptor+overexpression+and+functionality%2C+as+well+as+TNF-%CE%B1+levels%2C+correlate+with+motor+symptoms+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DVincenzi%26aufirst%3DF.%26aulast%3DTosi%26aufirst%3DA.%26aulast%3DGessi%26aufirst%3DS.%26aulast%3DCasetta%26aufirst%3DI.%26aulast%3DGranieri%26aufirst%3DG.%26aulast%3DFazio%26aufirst%3DP.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DMacLennan%26aufirst%3DS.%26aulast%3DGranieri%26aufirst%3DE.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DA2A%2520adenosine%2520receptor%2520overexpression%2520and%2520functionality%252C%2520as%2520well%2520as%2520TNF-%25CE%25B1%2520levels%252C%2520correlate%2520with%2520motor%2520symptoms%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DFASEB%2520J.%26date%3D2010%26volume%3D24%26spage%3D587%26epage%3D598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Pollack, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, J. S.</span><span> </span><span class="NLM_article-title">Adenosine antagonists potentiate D2 dopamine dependent activation of Fos in the striatopallidal pathway</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">â</span> <span class="NLM_lpage">728</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1995&pages=721-728&author=A.+E.+Pollackauthor=J.+S.+Fink&title=Adenosine+antagonists+potentiate+D2+dopamine+dependent+activation+of+Fos+in+the+striatopallidal+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPollack%26aufirst%3DA.%2BE.%26aulast%3DFink%26aufirst%3DJ.%2BS.%26atitle%3DAdenosine%2520antagonists%2520potentiate%2520D2%2520dopamine%2520dependent%2520activation%2520of%2520Fos%2520in%2520the%2520striatopallidal%2520pathway%26jtitle%3DNeuroscience%26date%3D1995%26volume%3D68%26spage%3D721%26epage%3D728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Duty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Animal models of Parkinson's disease: A source of novel treatments and clues to the cause of the disease</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">1357</span><span class="NLM_x">â</span> <span class="NLM_lpage">1391</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1111%2Fj.1476-5381.2011.01426.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=21486284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1357-1391&author=S.+Dutyauthor=P.+Jenner&title=Animal+models+of+Parkinson%27s+disease%3A+A+source+of+novel+treatments+and+clues+to+the+cause+of+the+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease</span></div><div class="casAuthors">Duty, Susan; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1391</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness.  Models based on specific pathogenic mechanisms may subsequently lead to the development of neuroprotective agents for PD that stop or slow disease progression.  The array of available rodent models is large and ranges from acute pharmacol. models, such as the reserpine- or haloperidol-treated rats that display one or more parkinsonian signs, to models exhibiting destruction of the dopaminergic nigro-striatal pathway, such as the classical 6-hydroxydopamine (6-OHDA) rat and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models.  All of these have provided test beds in which new mols. for treating the motor symptoms of PD can be assessed.  In addn., the emergence of abnormal involuntary movements (AIMs) with repeated treatment of 6-OHDA-lesioned rats with L-DOPA has allowed for examn. of the mechanisms responsible for treatment-related dyskinesia in PD, and the detection of mols. able to prevent or reverse their appearance.  Other toxin-based models of nigro-striatal tract degeneration include the systemic administration of the pesticides rotenone and paraquat, but while providing clues to disease pathogenesis, these are not so commonly used for drug development.  The MPTP-treated primate model of PD, which closely mimics the clin. features of PD and in which all currently used anti-parkinsonian medications have been shown to be effective, is undoubtedly the most clin.-relevant of all available models.  The MPTP-treated primate develops clear dyskinesia when repeatedly exposed to L-DOPA, and these parkinsonian animals have shown responses to novel dopaminergic agents that are highly predictive of their effect in man.  Whether non-dopaminergic drugs show the same degree of predictability of response is a matter of debate.  As our understanding of the pathogenesis of PD has improved, so new rodent models produced by agents mimicking these mechanisms, including proteasome inhibitors such as PSI, lactacystin and epoximycin or inflammogens like lipopolysaccharide (LPS) have been developed.  A further generation of models aimed at mimicking the genetic causes of PD has also sprung up.  While these newer models have provided further clues to the disease pathol., they have so far been less commonly used for drug development.  There is little doubt that the availability of exptl. animal models of PD has dramatically altered dopaminergic drug treatment of the illness and the prevention and reversal of drug-related side effects that emerge with disease progression and chronic medication.  However, so far, we have made little progress in moving into other pharmacol. areas for the treatment of PD, and we have not developed models that reflect the progressive nature of the illness and its complexity in terms of the extent of pathol. and biochem. change.  Only when this occurs are we likely to make progress in developing agents to stop or slow the disease progression.  The overarching question that draws all of these models together in the quest for better drug treatments for PD is how well do they recapitulate the human condition and how predictive are they of successful translation of drugs into the clinic.  This article aims to clarify the current position and highlight the strengths and weaknesses of available models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoptecPrVBnv7Vg90H21EOLACvtfcHk0lg8Cnz8NaUWBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM&md5=587852b53e518988f9ab89436aa23326</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01426.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01426.x%26sid%3Dliteratum%253Aachs%26aulast%3DDuty%26aufirst%3DS.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DAnimal%2520models%2520of%2520Parkinson%2527s%2520disease%253A%2520A%2520source%2520of%2520novel%2520treatments%2520and%2520clues%2520to%2520the%2520cause%2520of%2520the%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1357%26epage%3D1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beilstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonsalla, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzchild, M. A.</span><span> </span><span class="NLM_article-title">Neuroprotection by caffeine and A<sub>2A</sub> adenosine receptor inactivation in a model of Parkinson's disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">RC143/1</span><span class="NLM_x">â</span> <span class="NLM_lpage">RC143/6</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=RC143%2F1-RC143%2F6&author=J.+F.+Chenauthor=K.+Xuauthor=J.+P.+Petzerauthor=R.+Staalauthor=Y.+H.+Xuauthor=M.+Beilsteinauthor=P.+K.+Sonsallaauthor=K.+Castagnoliauthor=N.+Castagnoliauthor=M.+A.+Schwarzchild&title=Neuroprotection+by+caffeine+and+A2A+adenosine+receptor+inactivation+in+a+model+of+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DStaal%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DY.%2BH.%26aulast%3DBeilstein%26aufirst%3DM.%26aulast%3DSonsalla%26aufirst%3DP.%2BK.%26aulast%3DCastagnoli%26aufirst%3DK.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DSchwarzchild%26aufirst%3DM.%2BA.%26atitle%3DNeuroprotection%2520by%2520caffeine%2520and%2520A2A%2520adenosine%2520receptor%2520inactivation%2520in%2520a%2520model%2520of%2520Parkinson%2527s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2001%26volume%3D21%26spage%3DRC143%252F1%26epage%3DRC143%252F6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Grondin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedard, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahar, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregoire, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span> </span><span class="NLM_article-title">Antiparkinsonian effect of a new adenosine A<sub>2A</sub> receptor antagonist in MPTP-treated monkeys</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1673</span><span class="NLM_x">â</span> <span class="NLM_lpage">1677</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1999&pages=1673-1677&author=R.+Grondinauthor=P.+J.+Bedardauthor=A.+J.+Taharauthor=L.+Gregoireauthor=A.+Moriauthor=H.+Kase&title=Antiparkinsonian+effect+of+a+new+adenosine+A2A+receptor+antagonist+in+MPTP-treated+monkeys"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrondin%26aufirst%3DR.%26aulast%3DBedard%26aufirst%3DP.%2BJ.%26aulast%3DTahar%26aufirst%3DA.%2BJ.%26aulast%3DGregoire%26aufirst%3DL.%26aulast%3DMori%26aufirst%3DA.%26aulast%3DKase%26aufirst%3DH.%26atitle%3DAntiparkinsonian%2520effect%2520of%2520a%2520new%2520adenosine%2520A2A%2520receptor%2520antagonist%2520in%2520MPTP-treated%2520monkeys%26jtitle%3DNeurology%26date%3D1999%26volume%3D52%26spage%3D1673%26epage%3D1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ongini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monopoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Impagnatiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredduzzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzchild, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. F.</span><span> </span><span class="NLM_article-title">Dual actions of A<sub>2A</sub> adenosine receptor antagonists on motor dysfunction and neurodegenerative processes</span> <span class="citation_source-journal">Drug Dev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">386</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2001&pages=379-386&author=E.+Onginiauthor=A.+Monopoliauthor=F.+Impagnatielloauthor=S.+Fredduzziauthor=M.+Schwarzchildauthor=J.+F.+Chen&title=Dual+actions+of+A2A+adenosine+receptor+antagonists+on+motor+dysfunction+and+neurodegenerative+processes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOngini%26aufirst%3DE.%26aulast%3DMonopoli%26aufirst%3DA.%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DSchwarzchild%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26atitle%3DDual%2520actions%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520on%2520motor%2520dysfunction%2520and%2520neurodegenerative%2520processes%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2001%26volume%3D52%26spage%3D379%26epage%3D386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwana, Y.</span><span> </span><span class="NLM_article-title">Neuroprotection by adenosine A<sub>2A</sub> receptor blockade in experimental models of Parkinson's disease</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1046%2Fj.0022-3042.2001.00694.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=11902116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16d&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD38XptV2jsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2002&pages=262-270&author=K.+Ikedaauthor=M.+Kurokawaauthor=S.+Aoyamaauthor=Y.+Kuwana&title=Neuroprotection+by+adenosine+A2A+receptor+blockade+in+experimental+models+of+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16dR"><div class="casContent"><span class="casTitleNuber">16d</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease</span></div><div class="casAuthors">Ikeda, Ken; Kurokawa, Masako; Aoyama, Shiro; Kuwana, Yoshihisa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-270</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Adenosine A2A receptors are abundant in the caudate-putamen and involved in the motor control in several species.  In MPTP-treated monkeys, A2A receptor-blockade with an antagonist alleviates parkinsonian symptoms without provoking dyskinesia, suggesting this receptor may offer a new target for the antisymptomatic therapy of Parkinson's disease.  In the present study, a significant neuroprotective effect of A2A receptor antagonists is shown in exptl. models of Parkinson's disease.  Oral administration of A2A receptor antagonists protected against the loss of nigral dopaminergic neuronal cells induced by 6-hydroxydopamine in rats.  A2A antagonists also prevented the functional loss of dopaminergic nerve terminals in the striatum and the ensuing gliosis caused by MPTP in mice.  The neuroprotective property of A2A receptor antagonists may be exerted by altering the packaging of these neurotoxins into vesicles, thus reducing their effective intracellular concn.  We therefore conclude that the adenosine A2A receptor may provide a novel target for the long-term medication of Parkinson's disease, because blockade of this receptor exerts both acutely antisymptomatic and chronically neuroprotective activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb8toXJpqCzLVg90H21EOLACvtfcHk0liPepJUvX5eeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptV2jsQ%253D%253D&md5=68ddb10b0be184393df31567d2acc7ca</span></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=10.1046%2Fj.0022-3042.2001.00694.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0022-3042.2001.00694.x%26sid%3Dliteratum%253Aachs%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DKurokawa%26aufirst%3DM.%26aulast%3DAoyama%26aufirst%3DS.%26aulast%3DKuwana%26aufirst%3DY.%26atitle%3DNeuroprotection%2520by%2520adenosine%2520A2A%2520receptor%2520blockade%2520in%2520experimental%2520models%2520of%2520Parkinson%2527s%2520disease%26jtitle%3DJ.%2520Neurochem.%26date%3D2002%26volume%3D80%26spage%3D262%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, R. K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwana, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">â</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1002%2Fana.410430415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=9546333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK1cXisFyisbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1998&pages=507-513&author=T.+Kandaauthor=M.+J.+Jacksonauthor=L.+A.+Smithauthor=R.+K.+B.+Pearceauthor=J.+Nakamuraauthor=H.+Kaseauthor=Y.+Kuwanaauthor=P.+Jenner&title=Adenosine+A2A+antagonist%3A+a+novel+antiparkinsonian+agent+that+does+not+provoke+dyskinesia+in+parkinsonian+monkeys"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys</span></div><div class="casAuthors">Kanda, Tomoyuki; Jackson, Michael J.; Smith, Lance A.; Pearce, Ronald K. B.; Nakamura, Joji; Kase, Hiroshi; Kuwana, Yoshihisa; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">507-513</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Treatment of Parkinson's disease with L-DOPA therapy leads to long-term complications, including loss of drug efficacy and the onset of dyskinesia.  Adenosine A2A receptors in the striatum are selectively localized to GABAergic output neurons of the striato-pallidal pathway and may avoid such problems.  The novel adenosine A2A receptor antagonist KW-6002 was examd. for antiparkinsonian activity in MPTP-treated primates.  Oral administration of KW-6002 reversed motor disability in MPTP-treated common marmosets in a dose-dependent manner.  However, KW-6002 only modestly increased overall locomotor activity and did not cause abnormal movement, such as stereotypy.  The ability of KW-6002 to reverse motor disability was maintained on repeated daily administration for 21 days, and no tolerance was obsd.  KW-6002 induced little or no dyskinesia in MPTP-treated primates previously primed to exhibit dyskinesia by prior exposure to L-DOPA.  Thus, selective adenosine A2A receptor antagonists represent a new class of antiparkinsonian agents that do not produce hyperactivity or induce dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQ20y4EvPvLVg90H21EOLACvtfcHk0liPepJUvX5eeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFyisbw%253D&md5=36af21fdde02b63c588e3ca03785dafe</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1002%2Fana.410430415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.410430415%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BA.%26aulast%3DPearce%26aufirst%3DR.%2BK.%2BB.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DKuwana%26aufirst%3DY.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DAdenosine%2520A2A%2520antagonist%253A%2520a%2520novel%2520antiparkinsonian%2520agent%2520that%2520does%2520not%2520provoke%2520dyskinesia%2520in%2520parkinsonian%2520monkeys%26jtitle%3DAnn.%2520Neurol.%26date%3D1998%26volume%3D43%26spage%3D507%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Koga, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwana, Y.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">â</span> <span class="NLM_lpage">255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FS0014-2999%2800%2900745-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=11090641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1ygsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2000&pages=249-255&author=K.+Kogaauthor=M.+Kurokawaauthor=M.+Ochiauthor=J.+Nakamuraauthor=Y.+Kuwana&title=Adenosine+A2A+receptor+antagonists+KF17837+and+KW-6002+potentiate+rotation+induced+by+dopaminergic+drugs+in+hemi-Parkinsonian+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats</span></div><div class="casAuthors">Koga, K.; Kurokawa, M.; Ochi, M.; Nakamura, J.; Kuwana, Y.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-255</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The effects of novel adenosine A2A receptor antagonists KF17837 ((E)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione) and KW-6002 ((E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione), on rotational behavior induced by apomorphine or L-DOPA (l-3,4-dihydroxyphenylalanine) were investigated in rats with unilateral 6-hydroxydopamine lesions.  Both KF17837 and KW-6002 slightly induced rotational behavior per se.  However, KF17837 and KW-6002 significantly increased the total counts of turning induced by apomorphine at doses of 3 mg/kg, p.o. and 10 mg/kg, p.o., and at doses of 1 mg/kg, p.o. and higher, resp.  KF17837 and KW-6002 also potentiated the rotational behavior induced by L-DOPA at a dose of 3 mg/kg, p.o.  Furthermore, i.c.v. injection (10 Î¼g/20 Î¼l) of a selective adenosine A2 receptor agonist CGS 21680 {2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine} partially prevented the rotational behavior induced by apomorphine and this inhibition was reversed by KW-6002 (1 mg/kg, p.o.).  The increase in total counts of apomorphine-induced turning by the adenosine A2A receptor antagonists seems to be mainly attributable to prolongation of turning duration rather than enhancement of intensity.  These results suggest that these adenosine A2A receptor antagonists may be useful to ameliorate shortening in the duration of dopaminergic drug response in patients with advanced Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZbOArDCv31rVg90H21EOLACvtfcHk0liPepJUvX5eeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1ygsb0%253D&md5=1763bbd6e38fbfc8bf3f9ab1b3f12374</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2800%2900745-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252800%252900745-7%26sid%3Dliteratum%253Aachs%26aulast%3DKoga%26aufirst%3DK.%26aulast%3DKurokawa%26aufirst%3DM.%26aulast%3DOchi%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKuwana%26aufirst%3DY.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonists%2520KF17837%2520and%2520KW-6002%2520potentiate%2520rotation%2520induced%2520by%2520dopaminergic%2520drugs%2520in%2520hemi-Parkinsonian%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D408%26spage%3D249%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Neustadt, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenlee, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamford, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulshian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ongini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monopoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertorelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, K. I.</span><span> </span><span class="NLM_article-title">Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1376</span><span class="NLM_x">â</span> <span class="NLM_lpage">1380</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1376-1380&author=B.+R.+Neustadtauthor=J.+Haoauthor=N.+Lindoauthor=W.+J.+Greenleeauthor=A.+W.+Stamfordauthor=D.+Tulshianauthor=E.+Onginiauthor=J.+Hunterauthor=A.+Monopoliauthor=R.+Bertorelliauthor=C.+Fosterauthor=L.+Arikauthor=J.+Lachowiczauthor=K.+Ngauthor=K.+I.+Feng&title=Potent%2C+selective%2C+and+orally+active+adenosine+A2A+receptor+antagonists%3A+arylpiperazine+derivatives+of+pyrazolo%5B4%2C3-e%5D-1%2C2%2C4-triazolo%5B1%2C5-c%5Dpyrimidines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DHao%26aufirst%3DJ.%26aulast%3DLindo%26aufirst%3DN.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DTulshian%26aufirst%3DD.%26aulast%3DOngini%26aufirst%3DE.%26aulast%3DHunter%26aufirst%3DJ.%26aulast%3DMonopoli%26aufirst%3DA.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DArik%26aufirst%3DL.%26aulast%3DLachowicz%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DK.%2BI.%26atitle%3DPotent%252C%2520selective%252C%2520and%2520orally%2520active%2520adenosine%2520A2A%2520receptor%2520antagonists%253A%2520arylpiperazine%2520derivatives%2520of%2520pyrazolo%255B4%252C3-e%255D-1%252C2%252C4-triazolo%255B1%252C5-c%255Dpyrimidines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D1376%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hodgson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertorelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varty, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachowicz, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forlani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredduzzi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen-Williams, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Impagnatiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolussi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parra, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foster, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neustadt, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamford, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reggiani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J. C.</span><span> </span><span class="NLM_article-title">Characterization of the potent and highly selective 2A receptor antagonists preladenant and SCH 412348 [7-[2-[4â2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">â</span> <span class="NLM_lpage">303</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1124%2Fjpet.108.149617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=19332567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=294-303&author=R.+A.+Hodgsonauthor=R.+Bertorelliauthor=G.+B.+Vartyauthor=J.+E.+Lachowiczauthor=A.+Forlaniauthor=S.+Fredduzziauthor=M.+E.+Cohen-Williamsauthor=G.+A.+Higginsauthor=F.+Impagnatielloauthor=E.+Nicolussiauthor=L.+E.+Parraauthor=C.+Fosterauthor=Y.+Zhaiauthor=B.+R.+Neustadtauthor=A.+W.+Stamfordauthor=E.+M.+Parkerauthor=A.+Reggianiauthor=J.+C.+Hunter&title=Characterization+of+the+potent+and+highly+selective+2A+receptor+antagonists+preladenant+and+SCH+412348+%5B7-%5B2-%5B4%E2%80%932%2C4-difluorophenyl%5D-1-piperazinyl%5Dethyl%5D-2-%282-furanyl%29-7H-pyrazolo%5B4%2C3-e%5D%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-c%5Dpyrimidin-5-amine%5D+in+rodent+models+of+movement+disorders+and+depression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression</span></div><div class="casAuthors">Hodgson, Robert A.; Bertorelli, Rosalia; Varty, Geoffrey B.; Lachowicz, Jean E.; Forlani, Angelo; Fredduzzi, Silva; Cohen-Williams, Mary E.; Higgins, Guy A.; Impagnatiello, Francesco; Nicolussi, Elisa; Parra, Leonard E.; Foster, Carolyn; Zhai, Ying; Neustadt, Bernie R.; Stamford, Andrew W.; Parker, Eric M.; Reggiani, Angelo; Hunter, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">294-303</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The adenosine A2A receptor has been implicated in the underlying biol. of various neurol. and psychiatric disorders, including Parkinson's disease (PD) and depression.  Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] are potent competitive antagonists of the human A2A receptor (Ki = 1.1 and 0.6 nM, resp.) and have > 1000-fold selectivity over all other adenosine receptors, making these compds. the most selective A2A receptor antagonists reported to date.  Both compds. attenuate hypolocomotion induced by the A2A receptor agonist CGS-21680 [2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine], suggesting that they inhibit A2A receptor activity in vivo.  Their high degree of selectivity and robust in vivo activity make preladenant and SCH 412348 useful tools to investigate the role of the A2A receptor system in animal models of PD and depression.  Oral administration of preladenant and SCH 412348 (0.1-1 mg/kg) to rats potentiated 3,4-dihydroxy-L-phenylalanine (L-Dopa)-induced contralateral rotations after 6-hydroxydopamine lesions in the medial forebrain bundle and potently attenuated the cataleptic effects of haloperidol.  Preladenant (1 mg/kg) inhibited L-Dopa-induced behavioral sensitization after repeated daily administration, which suggests a reduced risk of the development of dyskinesias.  Finally, preladenant and SCH 412348 exhibited antidepressant-like profiles in models of behavioral despair, namely the mouse tail suspension test and the mouse and rat forced swim test.  These studies demonstrate that preladenant and SCH 412348 are potent and selective A2A receptor antagonists and provide further evidence of the potential therapeutic benefits of A2A receptor inhibition in PD (with reduced risk of dyskinesias) and depression (one of the primary nonmotor symptoms of PD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNkJMOfNlLc7Vg90H21EOLACvtfcHk0ljgAWEnR8V66A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeluro%253D&md5=b8ce809c2d57a994d201ecca4daa39a3</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.149617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.149617%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DBertorelli%26aufirst%3DR.%26aulast%3DVarty%26aufirst%3DG.%2BB.%26aulast%3DLachowicz%26aufirst%3DJ.%2BE.%26aulast%3DForlani%26aufirst%3DA.%26aulast%3DFredduzzi%26aufirst%3DS.%26aulast%3DCohen-Williams%26aufirst%3DM.%2BE.%26aulast%3DHiggins%26aufirst%3DG.%2BA.%26aulast%3DImpagnatiello%26aufirst%3DF.%26aulast%3DNicolussi%26aufirst%3DE.%26aulast%3DParra%26aufirst%3DL.%2BE.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DZhai%26aufirst%3DY.%26aulast%3DNeustadt%26aufirst%3DB.%2BR.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DReggiani%26aufirst%3DA.%26aulast%3DHunter%26aufirst%3DJ.%2BC.%26atitle%3DCharacterization%2520of%2520the%2520potent%2520and%2520highly%2520selective%25202A%2520receptor%2520antagonists%2520preladenant%2520and%2520SCH%2520412348%2520%255B7-%255B2-%255B4%25E2%2580%25932%252C4-difluorophenyl%255D-1-piperazinyl%255Dethyl%255D-2-%25282-furanyl%2529-7H-pyrazolo%255B4%252C3-e%255D%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-c%255Dpyrimidin-5-amine%255D%2520in%2520rodent%2520models%2520of%2520movement%2520disorders%2520and%2520depression%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D294%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearce, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwana, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span> </span><span class="NLM_article-title">Combined use of the adenosine A<sub>2A</sub> antagonist KW-6002 with L-DOPA or with selective D<sub>1</sub> or D<sub>2</sub> dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys</span> <span class="citation_source-journal">Exp. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">162</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">â</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1006%2Fexnr.2000.7350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=10739638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3cXitVWqsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2000&pages=321-327&author=T.+Kandaauthor=M.+J.+Jacksonauthor=L.+A.+Smithauthor=R.+K.+Pearceauthor=J.+Nakamuraauthor=H.+Kaseauthor=Y.+Kuwanaauthor=P.+Jenner&title=Combined+use+of+the+adenosine+A2A+antagonist+KW-6002+with+L-DOPA+or+with+selective+D1+or+D2+dopamine+agonists+increases+antiparkinsonian+activity+but+not+dyskinesia+in+MPTP-treated+monkeys"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys</span></div><div class="casAuthors">Kanda, Tomoyuki; Jackson, Michael J.; Smith, Lance A.; Pearce, Ronald K. B.; Nakamura, Joji; Kase, Hiroshi; Kuwana, Yoshihisa; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">321-327</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The novel selective adenosine A2A receptor antagonist KW-6002 improves motor disability in MPTP-treated parkinsonian marmosets without provoking dyskinesia.  In this study we have investigated whether KW-6002 in combination with l-DOPA or selective D1 or D2 dopamine receptor agonists enhances antiparkinsonian activity in MPTP-treated common marmosets.  Combination of KW-6002 with the selective dopamine D2 receptor agonist quinpirole or the D1 receptor agonist SKF80723 produced an additive improvement in motor disability.  Coadministration of KW-6002 with a low dose of l-DOPA also produced an additive improvement in motor disability, and increased locomotor activity.  The ability of KW-6002 to enhance antiparkinsonian activity was more marked with l-DOPA and quinpirole than with the D1 agonist.  However, despite producing an enhanced antiparkinsonian response KW-6002 did not exacerbate l-DOPA-induced dyskinesia in MPTP-treated common marmosets previously primed to exhibit dyskinesia by prior exposure to l-DOPA.  Selective adenosine A2A receptor antagonists, such as KW-6002, may be one means of reducing the dosage of l-DOPA used in treating Parkinson's disease and are potentially a novel approach to treating the illness both as monotherapy and in combination with dopaminergic drugs.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsA7cu-aJS8rVg90H21EOLACvtfcHk0ljgAWEnR8V66A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXitVWqsLY%253D&md5=28db343f66ae2a8179d7113246f39ae7</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1006%2Fexnr.2000.7350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexnr.2000.7350%26sid%3Dliteratum%253Aachs%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DJackson%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BA.%26aulast%3DPearce%26aufirst%3DR.%2BK.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DKuwana%26aufirst%3DY.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DCombined%2520use%2520of%2520the%2520adenosine%2520A2A%2520antagonist%2520KW-6002%2520with%2520L-DOPA%2520or%2520with%2520selective%2520D1%2520or%2520D2%2520dopamine%2520agonists%2520increases%2520antiparkinsonian%2520activity%2520but%2520not%2520dyskinesia%2520in%2520MPTP-treated%2520monkeys%26jtitle%3DExp.%2520Neurol.%26date%3D2000%26volume%3D162%26spage%3D321%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hauser, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubble, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truong, D. D.</span><span> </span><span class="NLM_article-title">Randomized trial of adenosine A<sub>2A</sub> receptor antagonist istradefylline in advanced PD</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">â</span> <span class="NLM_lpage">303</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2003&pages=297-303&author=R.+A.+Hauserauthor=J.+P.+Hubbleauthor=D.+D.+Truong&title=Randomized+trial+of+adenosine+A2A+receptor+antagonist+istradefylline+in+advanced+PD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DR.%2BA.%26aulast%3DHubble%26aufirst%3DJ.%2BP.%26aulast%3DTruong%26aufirst%3DD.%2BD.%26atitle%3DRandomized%2520trial%2520of%2520adenosine%2520A2A%2520receptor%2520antagonist%2520istradefylline%2520in%2520advanced%2520PD%26jtitle%3DNeurology%26date%3D2003%26volume%3D61%26spage%3D297%26epage%3D303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bara-Jimenez, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherzai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favit, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibbiani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mouradian, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, T. N.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> receptor antagonist treatment of Parkinsonâs disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">296</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2003&pages=293-296&author=W.+Bara-Jimenezauthor=A.+Sherzaiauthor=T.+Dimitrovaauthor=A.+Favitauthor=F.+Bibbianiauthor=M.+Gillespieauthor=M.+J.+Morrisauthor=M.+M.+Mouradianauthor=T.+N.+Chase&title=Adenosine+A2A+receptor+antagonist+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBara-Jimenez%26aufirst%3DW.%26aulast%3DSherzai%26aufirst%3DA.%26aulast%3DDimitrova%26aufirst%3DT.%26aulast%3DFavit%26aufirst%3DA.%26aulast%3DBibbiani%26aufirst%3DF.%26aulast%3DGillespie%26aufirst%3DM.%26aulast%3DMorris%26aufirst%3DM.%2BJ.%26aulast%3DMouradian%26aufirst%3DM.%2BM.%26aulast%3DChase%26aufirst%3DT.%2BN.%26atitle%3DAdenosine%2520A2A%2520receptor%2520antagonist%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurology%26date%3D2003%26volume%3D61%26spage%3D293%26epage%3D296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">For the current status of preladenant, go to <a href="http://clinicaltrials.gov" class="extLink">clinicaltrials.gov</a> and use the following identifiers: NCT01155479, NCT01227265, NCT01155466, NCT01294800, NCT01215227, and NCT01323855.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukumitsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiwata, K.</span><span> </span><span class="NLM_article-title">Quantitative analysis of adenosine A<sub>1</sub>receptors in human brain using positron emission tomography and [1-methyl-<sup>11</sup>C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine</span> <span class="citation_source-journal">Nuclear Med. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">â</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2Fj.nucmedbio.2004.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=15607479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVyqsbzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2004&pages=975-981&author=Y.+Kimuraauthor=K.+Ishiiauthor=N.+Fukumitsuauthor=K.+Odaauthor=T.+Sasakiauthor=K.+Kawamuraauthor=K.+Ishiwata&title=Quantitative+analysis+of+adenosine+A1receptors+in+human+brain+using+positron+emission+tomography+and+%5B1-methyl-11C%5D8-dicyclopropylmethyl-1-methyl-3-propylxanthine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1 -methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine</span></div><div class="casAuthors">Kimura, Yuichi; Ishii, Kenji; Fukumitsu, Nobuyoshi; Oda, Keiichi; Sasaki, Toru; Kawamura, Kazunori; Ishiwata, Kiichi</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">975-981</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Fully quant. anal. of the adenosine A1 receptor (A1R) in the brain with 11C-MPDX and positron emission tomog. is reported.  The kinetics is described using a two-tissue three-compartment model, and estd. binding potentials correspond well with the ests. made by Logan plot.  The image of the binding potential of the MPDX is physiol. reasonable.  We conclude that MPDX is applicable to the visualization of the A1Rs in the brain with Logan plot.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj_Ng1prMQZbVg90H21EOLACvtfcHk0ljpMiLEwyQUcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVyqsbzL&md5=b0bd06a1abeef2f6850e12a4f6afb6dd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2004.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2004.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DFukumitsu%26aufirst%3DN.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DT.%26aulast%3DKawamura%26aufirst%3DK.%26aulast%3DIshiwata%26aufirst%3DK.%26atitle%3DQuantitative%2520analysis%2520of%2520adenosine%2520A1receptors%2520in%2520human%2520brain%2520using%2520positron%2520emission%2520tomography%2520and%2520%255B1-methyl-11C%255D8-dicyclopropylmethyl-1-methyl-3-propylxanthine%26jtitle%3DNuclear%2520Med.%2520Biol.%26date%3D2004%26volume%3D31%26spage%3D975%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ballarin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiriz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrosio, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahy, N.</span><span> </span><span class="NLM_article-title">Effect of locally infused 2-cholroadenosine, an A<sub>1</sub> receptor agonist, on spontaneous and evoked dopamine release in rat neostriatum</span> <span class="citation_source-journal">Neurosci. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">185</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">â</span> <span class="NLM_lpage">32</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1995&pages=29-32&author=M.+Ballarinauthor=J.+Reirizauthor=S.+Ambrosioauthor=N.+Mahy&title=Effect+of+locally+infused+2-cholroadenosine%2C+an+A1+receptor+agonist%2C+on+spontaneous+and+evoked+dopamine+release+in+rat+neostriatum"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBallarin%26aufirst%3DM.%26aulast%3DReiriz%26aufirst%3DJ.%26aulast%3DAmbrosio%26aufirst%3DS.%26aulast%3DMahy%26aufirst%3DN.%26atitle%3DEffect%2520of%2520locally%2520infused%25202-cholroadenosine%252C%2520an%2520A1%2520receptor%2520agonist%252C%2520on%2520spontaneous%2520and%2520evoked%2520dopamine%2520release%2520in%2520rat%2520neostriatum%26jtitle%3DNeurosci.%2520Lett.%26date%3D1995%26volume%3D185%26spage%3D29%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Moore, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, D.</span><span> </span><span class="NLM_article-title">Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">14397</span><span class="NLM_x">â</span> <span class="NLM_lpage">14402</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=14397-14402&author=K.+A.+Mooreauthor=R.+A.+Nicollauthor=D.+Schmitz&title=Adenosine+gates+synaptic+plasticity+at+hippocampal+mossy+fiber+synapses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DK.%2BA.%26aulast%3DNicoll%26aufirst%3DR.%2BA.%26aulast%3DSchmitz%26aufirst%3DD.%26atitle%3DAdenosine%2520gates%2520synaptic%2520plasticity%2520at%2520hippocampal%2520mossy%2520fiber%2520synapses%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%26date%3D2003%26volume%3D100%26spage%3D14397%26epage%3D14402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rebola, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinheiro, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malva, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, R. A.</span><span> </span><span class="NLM_article-title">Subcellular localization of adenosine A<sub>1</sub> receptors in nerve terminal and synapses of the rat hippocampus</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">987</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">â</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FS0006-8993%2803%2903247-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=14499945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1aqsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=987&publication_year=2003&pages=49-58&author=N.+Rebolaauthor=P.+C.+Pinheiroauthor=C.+R.+Oliveiraauthor=J.+O.+Malvaauthor=R.+A.+Cunha&title=Subcellular+localization+of+adenosine+A1+receptors+in+nerve+terminal+and+synapses+of+the+rat+hippocampus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular localization of adenosine A1 receptors in nerve terminals and synapses of the rat hippocampus</span></div><div class="casAuthors">Rebola, Nelson; Pinheiro, Paulo C.; Oliveira, Catarina R.; Malva, Joao O.; Cunha, Rodrigo A.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">987</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-58</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Adenosine is a neuromodulator in the CNS that mainly acts through pre- and postsynaptic A1 receptors to inhibit the release of excitatory neurotransmitters and NMDA receptor function.  This might result from a highly localized distribution of A1 receptors in the active zone and postsynaptic d. of CNS synapses that we now investigated in the rat hippocampus.  The binding d. of the selective A1 receptor antagonist, [3H]1,3-dipropyl-8-cyclopentylxanthine ([3H]DPCPX), was enriched in membranes from Percoll-purified nerve terminals (Bmax=1839Â±52 fmol/mg protein) compared to total membranes from the hippocampus (Bmax=984Â±31 fmol/mg protein), the same occurring with A1 receptor immunoreactivity.  [3H]DPCPX binding occurred mainly to the plasma membrane rather than to intracellular sites, since the binding of the membrane permeable A1 receptor ligand [3H]DPCPX to intact hippocampal nerve terminals (Bmax=1901Â±192 fmol/mg protein) was markedly reduced (Bmax=321Â±30 fmol/mg protein) by the membrane impermeable adenosine receptor antagonist, 8-sulfophenyltheophilline (25 Î¼M).  Further subcellular fractionation of hippocampal nerve terminals revealed that A1 receptor immunoreactivity was strategically located in the active zone of presynaptic nerve terminals, as expected to understand the efficiency of A1 receptors to depress neurotransmitter release.  A1 Receptors were also present in nerve terminals outside the active zone in accordance with the existence of a presynaptic A1 receptor reserve.  Finally, A1 receptor immunoreactivity was evident in the postsynaptic d. together with NMDA receptor subunits 1, 2A and 2B and with N-and P/Q-type calcium channel immunoreactivity, emphasizing the importance of A1 receptors in the control of dendritic integration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXNS9YJIv75rVg90H21EOLACvtfcHk0lgrds-wQF2EOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1aqsr8%253D&md5=3400357993c99c6aa97d2def8af5b8ca</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2FS0006-8993%2803%2903247-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-8993%252803%252903247-5%26sid%3Dliteratum%253Aachs%26aulast%3DRebola%26aufirst%3DN.%26aulast%3DPinheiro%26aufirst%3DP.%2BC.%26aulast%3DOliveira%26aufirst%3DC.%2BR.%26aulast%3DMalva%26aufirst%3DJ.%2BO.%26aulast%3DCunha%26aufirst%3DR.%2BA.%26atitle%3DSubcellular%2520localization%2520of%2520adenosine%2520A1%2520receptors%2520in%2520nerve%2520terminal%2520and%2520synapses%2520of%2520the%2520rat%2520hippocampus%26jtitle%3DBrain%2520Res.%26date%3D2003%26volume%3D987%26spage%3D49%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Maemoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miho, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takuma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noriko, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katsuya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takayuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoharu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoru, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atsushi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nobuya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitaro, M.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of FR194921, a new potent, selective, orally active antagonist for central adenosine A<sub>1</sub> receptors</span> <span class="citation_source-journal">J. Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">42</span><span class="NLM_x">â</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1254%2Fjphs.FP0040359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=15351792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFyjs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2004&pages=42-52&author=T.+Maemotoauthor=T.+Mihoauthor=M.+Takumaauthor=U.+Norikoauthor=M.+Hideakiauthor=H.+Katsuyaauthor=Y.+Takayukiauthor=S.+Kiyoharuauthor=K.+Satoruauthor=A.+Atsushiauthor=I.+Akinoriauthor=M.+Nobuyaauthor=M.+Seitaro&title=Pharmacological+characterization+of+FR194921%2C+a+new+potent%2C+selective%2C+orally+active+antagonist+for+central+adenosine+A1+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors</span></div><div class="casAuthors">Maemoto, Takuya; Tada, Miho; Mihara, Takuma; Ueyama, Noriko; Matsuoka, Hideaki; Harada, Katsuya; Yamaji, Takayuki; Shirakawa, Kiyoharu; Kuroda, Satoru; Akahane, Atsushi; Iwashita, Akinori; Matsuoka, Nobuya; Mutoh, Seitaro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-52</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">Adenosine A1 receptors in the brain are believed to play an important role in brain functioning.  We have discovered a novel adenosine A1 receptor antagonist, FR194921 (2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-3(2H)-pyridazinone), and characterized the pharmacol. activity in the present study.  FR194921 showed potent and selective affinity for the adenosine A1 receptor without affinity for A2A and A3 receptors and did not show any species differences in binding affinity profile among human, rat, and mouse.  Pharmacokinetic study in rats revealed that FR194921 was orally active and highly brain penetrable.  Oral administration of FR194921 dose-dependently ameliorated the hypolocomotion induced by the A1 receptor agonist N6-cyclopentyladenosine in rats, indicating this compd. exerts A1-antagonistic action in vivo.  In the passive avoidance test, scopolamine (1 mg/kg)-induced memory deficits were significantly ameliorated by FR194921 (0.32, 1 mg/kg).  In two animal models of anxiety, the social interaction test and elevated plus maze, FR194921 showed specific anxiolytic activity without significantly influencing general behavior.  In contrast, FR194921 did not show antidepressant activity even at a dose of 32 mg/kg in the rat forced swimming test.  These results indicate that the novel, potent, and selective adenosine A1 receptor antagonist FR194921 exerts both cognitive-enhancing and anxiolytic activity, suggesting the therapeutic potential of this compd. for dementia and anxiety disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpor8cuLg5xVrVg90H21EOLACvtfcHk0lgrds-wQF2EOg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFyjs78%253D&md5=1828b4e7afe4c25a61aa0fa094f64c38</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1254%2Fjphs.FP0040359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.FP0040359%26sid%3Dliteratum%253Aachs%26aulast%3DMaemoto%26aufirst%3DT.%26aulast%3DMiho%26aufirst%3DT.%26aulast%3DTakuma%26aufirst%3DM.%26aulast%3DNoriko%26aufirst%3DU.%26aulast%3DHideaki%26aufirst%3DM.%26aulast%3DKatsuya%26aufirst%3DH.%26aulast%3DTakayuki%26aufirst%3DY.%26aulast%3DKiyoharu%26aufirst%3DS.%26aulast%3DSatoru%26aufirst%3DK.%26aulast%3DAtsushi%26aufirst%3DA.%26aulast%3DAkinori%26aufirst%3DI.%26aulast%3DNobuya%26aufirst%3DM.%26aulast%3DSeitaro%26aufirst%3DM.%26atitle%3DPharmacological%2520characterization%2520of%2520FR194921%252C%2520a%2520new%2520potent%252C%2520selective%252C%2520orally%2520active%2520antagonist%2520for%2520central%2520adenosine%2520A1%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D96%26spage%3D42%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Yonishi, S.; Aoki, S.; Matsushima, Y.; Akahane, A.</span><span> </span><span class="NLM_article-title">Preparation of pyrazines as adenosine A<sub>1</sub> and A<sub>2A</sub> receptor antagonists and their pharmaceutical compositions</span>. PCT Int. Appl. WO 2005040151,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=S.+Yonishi&author=S.+Aoki&author=Y.+Matsushima&author=A.+Akahane&title=Preparation+of+pyrazines+as+adenosine+A1+and+A2A+receptor+antagonists+and+their+pharmaceutical+compositions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYonishi%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520pyrazines%2520as%2520adenosine%2520A1%2520and%2520A2A%2520receptor%2520antagonists%2520and%2520their%2520pharmaceutical%2520compositions%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span> </span><span class="NLM_article-title">A novel adenosine A<sub>1</sub> and A<sub>2A</sub> receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">194</span><span class="NLM_x">, </span> <span class="NLM_fpage">152</span><span class="NLM_x">â</span> <span class="NLM_lpage">161</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2008&pages=152-161&author=T.+Miharaauthor=A.+Iwashitaauthor=N.+Matsuoka&title=A+novel+adenosine+A1+and+A2A+receptor+antagonist+ASP5854+ameliorates+motor+impairment+in+MPTP-treated+marmosets%3A+Comparison+with+existing+anti-Parkinson%27s+disease+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMihara%26aufirst%3DT.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3DA%2520novel%2520adenosine%2520A1%2520and%2520A2A%2520receptor%2520antagonist%2520ASP5854%2520ameliorates%2520motor%2520impairment%2520in%2520MPTP-treated%2520marmosets%253A%2520Comparison%2520with%2520existing%2520anti-Parkinson%2527s%2520disease%2520drugs%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2008%26volume%3D194%26spage%3D152%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuya, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span> </span><span class="NLM_article-title">Brain adenosine A2A receptor occupancy by a novel A<sub>1</sub>/A<sub>2A</sub> receptor antagonist, ASP5854, in rhesus monkeys: Relationship to anticataleptic effect</span> <span class="citation_source-journal">J. Nucl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1183</span><span class="NLM_x">â</span> <span class="NLM_lpage">1188</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=1183-1188&author=T.+Miharaauthor=A.+Nodaauthor=H.+Araiauthor=K.+Miharaauthor=A.+Iwashitaauthor=Y.+Murakamiauthor=T.+Matsuyaauthor=S.+Miyoshiauthor=S.+Nishimuraauthor=N.+Matsuoka&title=Brain+adenosine+A2A+receptor+occupancy+by+a+novel+A1%2FA2A+receptor+antagonist%2C+ASP5854%2C+in+rhesus+monkeys%3A+Relationship+to+anticataleptic+effect"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMihara%26aufirst%3DT.%26aulast%3DNoda%26aufirst%3DA.%26aulast%3DArai%26aufirst%3DH.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMurakami%26aufirst%3DY.%26aulast%3DMatsuya%26aufirst%3DT.%26aulast%3DMiyoshi%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DS.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3DBrain%2520adenosine%2520A2A%2520receptor%2520occupancy%2520by%2520a%2520novel%2520A1%252FA2A%2520receptor%2520antagonist%252C%2520ASP5854%252C%2520in%2520rhesus%2520monkeys%253A%2520Relationship%2520to%2520anticataleptic%2520effect%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2008%26volume%3D49%26spage%3D1183%26epage%3D1188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Mihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yarimizu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akahane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span> </span><span class="NLM_article-title">Pharmacological characterization of a novel, potent adenosine A<sub>1</sub> and A<sub>2A</sub> receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinsonâs disease and cognition</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">â</span> <span class="NLM_lpage">719</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1124%2Fjpet.107.121962" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=17684118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ynsb%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=708-719&author=T.+Miharaauthor=K.+Miharaauthor=J.+Yarimizuauthor=Y.+Mitaniauthor=R.+Matsudaauthor=H.+Yamamotoauthor=S.+Aokiauthor=A.+Akahaneauthor=A.+Iwashitaauthor=N.+Matsuoka&title=Pharmacological+characterization+of+a+novel%2C+potent+adenosine+A1+and+A2A+receptor+dual+antagonist%2C+5-%5B5-amino-3-%284-fluorophenyl%29pyrazin-2-yl%5D-1-isopropylpyridine-2%281H%29-one+%28ASP5854%29%2C+in+models+of+Parkinson%E2%80%99s+disease+and+cognition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition</span></div><div class="casAuthors">Mihara, Takuma; Mihara, Kayoko; Yarimizu, Junko; Mitani, Yasuyuki; Matsuda, Ritsuko; Yamamoto, Hiroko; Aoki, Satoshi; Akahane, Atsushi; Iwashita, Akinori; Matsuoka, Nobuya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">708-719</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Central adenosine A2A receptor is a promising target for drugs to treat Parkinson's disease (PD), and the central blockade of adenosine A1 receptor improves cognitive function.  In the present study, we investigated the effect of a novel adenosine A1 and A2A dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one(ASP5854),in animal models of PD and cognition.  The binding affinities of ASP5854 for human A1 and A2A receptors were 9.03 and 1.76 nM, resp., with higher specificity and no species differences.  ASP5854 also showed antagonistic action on A1 and A2A agonist-induced increases of intracellular Ca2+ concn.  ASP5854 ameliorated A2A agonist 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680)- and haloperidol-induced catalepsy in mice, with the min. EDs of 0.32 and 0.1 mg/kg, resp., and it also improved haloperidol-induced catalepsy in rats at doses higher than 0.1 mg/kg.  In unilateral 6-hydroxydopamine-lesioned rats, ASP5854 significantly potentiated 7-dihydroxyphenylalanine (L-DOPA)-induced rotational behavior at doses higher than 0.032 mg/kg.  ASP5854 also significantly restored the striatal dopamine content reduced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment in mice at doses higher than 0.1 mg/kg.  Furthermore, in the rat passive avoidance test, ASP5854 significantly reversed the scopolamine-induced memory deficits, whereas the specific adenosine A2A antagonist 8-((E)-2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (KW-6002; istradefylline) did not.  Scopolamine- or 5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate) (MK-801)-induced impairment of spontaneous alternation in the mouse Y-maze test was ameliorated by ASP5854, whereas KW-6002 did not exert improvement at therapeutically relevant dosages.  These results demonstrate that the novel, selective, and orally active dual adenosine A1 and A2A receptors antagonist ASP5854 improves motor impairments, is neuroprotective via A2A antagonism, and also enhances cognitive function through A1 antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKhOITDQ8dxrVg90H21EOLACvtfcHk0lglOabWWTfvIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ynsb%252FF&md5=2d9770179a47a228d825a49feab70ef2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.121962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.121962%26sid%3Dliteratum%253Aachs%26aulast%3DMihara%26aufirst%3DT.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DYarimizu%26aufirst%3DJ.%26aulast%3DMitani%26aufirst%3DY.%26aulast%3DMatsuda%26aufirst%3DR.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DS.%26aulast%3DAkahane%26aufirst%3DA.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMatsuoka%26aufirst%3DN.%26atitle%3DPharmacological%2520characterization%2520of%2520a%2520novel%252C%2520potent%2520adenosine%2520A1%2520and%2520A2A%2520receptor%2520dual%2520antagonist%252C%25205-%255B5-amino-3-%25284-fluorophenyl%2529pyrazin-2-yl%255D-1-isopropylpyridine-2%25281H%2529-one%2520%2528ASP5854%2529%252C%2520in%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520cognition%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D708%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupert, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heintzelman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullington, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchamp, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demarest, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span> </span><span class="NLM_article-title">In Vivo Characterization of a Dual Adenosine A<sub>2A</sub>/A<sub>1</sub> Receptor Antagonist in Animal Models of Parkinson's Disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8104</span><span class="NLM_x">â</span> <span class="NLM_lpage">8115</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100971t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8104-8115&author=B.+C.+Shookauthor=S.+Rassnickauthor=M.+C.+Osborneauthor=S.+Davisauthor=L.+Westoverauthor=J.+Bouletauthor=D.+Hallauthor=K.+C.+Rupertauthor=G.+R.+Heintzelmanauthor=K.+Hansenauthor=D.+Chakravartyauthor=J.+L.+Bullingtonauthor=R.+Russellauthor=S.+Branumauthor=K.+M.+Wellsauthor=S.+Damonauthor=S.+Youellsauthor=X.+Liauthor=D.+A.+Beauchampauthor=D.+Palmerauthor=M.+Reyesauthor=K.+Demarestauthor=Y.-T.+Tangauthor=K.+Rhodesauthor=P.+F.+Jackson&title=In+Vivo+Characterization+of+a+Dual+Adenosine+A2A%2FA1+Receptor+Antagonist+in+Animal+Models+of+Parkinson%27s+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Fjm100971t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100971t%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DOsborne%26aufirst%3DM.%2BC.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DWestover%26aufirst%3DL.%26aulast%3DBoulet%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DRupert%26aufirst%3DK.%2BC.%26aulast%3DHeintzelman%26aufirst%3DG.%2BR.%26aulast%3DHansen%26aufirst%3DK.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DBullington%26aufirst%3DJ.%2BL.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DBranum%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DK.%2BM.%26aulast%3DDamon%26aufirst%3DS.%26aulast%3DYouells%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DBeauchamp%26aufirst%3DD.%2BA.%26aulast%3DPalmer%26aufirst%3DD.%26aulast%3DReyes%26aufirst%3DM.%26aulast%3DDemarest%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DY.-T.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DIn%2520Vivo%2520Characterization%2520of%2520a%2520Dual%2520Adenosine%2520A2A%252FA1%2520Receptor%2520Antagonist%2520in%2520Animal%2520Models%2520of%2520Parkinson%2527s%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8104%26epage%3D8115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupert, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heintzelman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullington, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magliaro, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osbourne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demarest, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span> </span><span class="NLM_article-title">Methylene amine substituted arylindenopyrimidines as potent adenosine A<sub>2A</sub>/A<sub>1</sub> antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2864</span><span class="NLM_x">â</span> <span class="NLM_lpage">2867</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2864-2867&author=B.+C.+Shookauthor=S.+Rassnickauthor=D.+Hallauthor=K.+C.+Rupertauthor=G.+R.+Heintzelmanauthor=K.+Hansenauthor=D.+Chakravartyauthor=J.+L.+Bullingtonauthor=R.+Scannevinauthor=B.+Magliaroauthor=L.+Westoverauthor=K.+Carrollauthor=L.+Lampronauthor=R.+Russellauthor=S.+Branumauthor=K.+Wellsauthor=S.+Damonauthor=S.+Youellsauthor=X.+Liauthor=M.+Osbourneauthor=K.+Demarestauthor=Y.+Tangauthor=K.+Rhodesauthor=P.+F.+Jackson&title=Methylene+amine+substituted+arylindenopyrimidines+as+potent+adenosine+A2A%2FA1+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DRupert%26aufirst%3DK.%2BC.%26aulast%3DHeintzelman%26aufirst%3DG.%2BR.%26aulast%3DHansen%26aufirst%3DK.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DBullington%26aufirst%3DJ.%2BL.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DMagliaro%26aufirst%3DB.%26aulast%3DWestover%26aufirst%3DL.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DLampron%26aufirst%3DL.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DBranum%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DK.%26aulast%3DDamon%26aufirst%3DS.%26aulast%3DYouells%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DOsbourne%26aufirst%3DM.%26aulast%3DDemarest%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DMethylene%2520amine%2520substituted%2520arylindenopyrimidines%2520as%2520potent%2520adenosine%2520A2A%252FA1%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2864%26epage%3D2867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ault, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crooke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbay, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alford, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupert, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heintzelman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullington, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampron, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westover, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchamp, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span> </span><span class="NLM_article-title">Optimization of arylindenopyrimidines as potent adenosine A<sub>2A</sub>/A<sub>1</sub> antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2868</span><span class="NLM_x">â</span> <span class="NLM_lpage">2871</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2868-2871&author=B.+C.+Shookauthor=S.+Rassnickauthor=D.+Chakravartyauthor=N.+Wallaceauthor=M.+Aultauthor=J.+Crookeauthor=J.+K.+Barbayauthor=A.+Wangauthor=K.+Leonardauthor=M.+T.+Powellauthor=V.+Alfordauthor=D.+Hallauthor=K.+C.+Rupertauthor=G.+R.+Heintzelmanauthor=K.+Hansenauthor=J.+L.+Bullingtonauthor=R.+Scannevinauthor=K.+Carrollauthor=L.+Lampronauthor=L.+Westoverauthor=R.+Russellauthor=S.+Branumauthor=K.+Wellsauthor=S.+Damonauthor=S.+Youellsauthor=D.+Beauchampauthor=X.+Liauthor=K.+Rhodesauthor=P.+F.+Jackson&title=Optimization+of+arylindenopyrimidines+as+potent+adenosine+A2A%2FA1+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DWallace%26aufirst%3DN.%26aulast%3DAult%26aufirst%3DM.%26aulast%3DCrooke%26aufirst%3DJ.%26aulast%3DBarbay%26aufirst%3DJ.%2BK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLeonard%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DM.%2BT.%26aulast%3DAlford%26aufirst%3DV.%26aulast%3DHall%26aufirst%3DD.%26aulast%3DRupert%26aufirst%3DK.%2BC.%26aulast%3DHeintzelman%26aufirst%3DG.%2BR.%26aulast%3DHansen%26aufirst%3DK.%26aulast%3DBullington%26aufirst%3DJ.%2BL.%26aulast%3DScannevin%26aufirst%3DR.%26aulast%3DCarroll%26aufirst%3DK.%26aulast%3DLampron%26aufirst%3DL.%26aulast%3DWestover%26aufirst%3DL.%26aulast%3DRussell%26aufirst%3DR.%26aulast%3DBranum%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DK.%26aulast%3DDamon%26aufirst%3DS.%26aulast%3DYouells%26aufirst%3DS.%26aulast%3DBeauchamp%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26atitle%3DOptimization%2520of%2520arylindenopyrimidines%2520as%2520potent%2520adenosine%2520A2A%252FA1%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2868%26epage%3D2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Zarrindast, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modabber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabetkasai, M.</span><span> </span><span class="NLM_article-title">Influence on different adenosine receptor subtypes on catalepsy in mice</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1993&pages=257-261&author=M.+R.+Zarrindastauthor=M.+Modabberauthor=M.+Sabetkasai&title=Influence+on+different+adenosine+receptor+subtypes+on+catalepsy+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZarrindast%26aufirst%3DM.%2BR.%26aulast%3DModabber%26aufirst%3DM.%26aulast%3DSabetkasai%26aufirst%3DM.%26atitle%3DInfluence%2520on%2520different%2520adenosine%2520receptor%2520subtypes%2520on%2520catalepsy%2520in%2520mice%26jtitle%3DPsychopharmacology%26date%3D1993%26volume%3D113%26spage%3D257%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Mandhane, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopde, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span> </span><span class="NLM_article-title">Adenosine A<sub>2</sub> receptors modulate haloperidol-induced catalepsy in rats</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x"> (</span><span class="NLM_issue">2/3</span><span class="NLM_x">) </span> <span class="NLM_fpage">135</span><span class="NLM_x">â</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FS0014-2999%2897%2983039-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=9218695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK2sXjsVKgt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=1997&pages=135-141&issue=2%2F3&author=S.+N.+Mandhaneauthor=C.+T.+Chopdeauthor=A.+K.+Ghosh&title=Adenosine+A2+receptors+modulate+haloperidol-induced+catalepsy+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats</span></div><div class="casAuthors">Mandhane, Sanjay N.; Chopde, Chandrabhan T.; Ghosh, Anuradha K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">135-141</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The effect of adenosine A1 and A2 receptor agonists and antagonists was investigated on haloperidol-induced catalepsy in rats.  Pretreatment (i.p.) with the non-selective adenosine receptor antagonist, theophylline, or the selective adenosine A2 receptor antagonist, 3,7-dimethyl-1-propargylxanthine (DMPX), significantly reversed haloperidol-induced catalepsy, whereas the selective adenosine A1 receptor antagonists, 8-phenyltheophylline and 8-cyclopentyl-1,3-dipropylxanthine produced no effect.  Similar administration of the adenosine A2 receptor agonists, 5'-(N-cyclopropyl)carboxamidoadenosine and 5'-N-ethylcarboxamidoadenosine (NECA), and the mixed agonists with predominantly A1 site of action, N6-(2-phenylisopropyl)adenosine or 2-chloroadenosine, potentiated haloperidol-induced catalepsy.  Higher doses of the adenosine agonists produced catalepsy when given alone.  However, N6-cyclopentyladenosine, a highly selective adenosine A1 receptor agonist, was ineffective in these respects.  The per se cataleptic effect of adenosine agonists was blocked by DMPX and the centrally acting anticholinergic agent, scopolamine.  Scopolamine also attenuated the potentiation of haloperidol-induced catalepsy by adenosine agonists.  Further, i.c.v. administration of NECA and DMPX produced a similar effect as that produced after their systemic administration.  These findings demonstrate the differential influence of adenosine A1 and A2 receptors on haloperidol-induced catalepsy and support the hypothesis that the functional interaction between adenosine and dopamine mechanisms might occur through adenosine A2 receptors at the level of cholinergic neurons.  The results suggest that adenosine A2, but not A1, receptor antagonists may be of potential use in the treatment of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_yuXIH62xu7Vg90H21EOLACvtfcHk0ljSvMnAXKtjQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsVKgt70%253D&md5=369d9508f13df6a3a9e3ce41bf83fa13</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2983039-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252983039-7%26sid%3Dliteratum%253Aachs%26aulast%3DMandhane%26aufirst%3DS.%2BN.%26aulast%3DChopde%26aufirst%3DC.%2BT.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26atitle%3DAdenosine%2520A2%2520receptors%2520modulate%2520haloperidol-induced%2520catalepsy%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D328%26issue%3D2%252F3%26spage%3D135%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Cooper, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marrel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsden, C. D.</span><span> </span><span class="NLM_article-title">L-Dopa esters as potential prodrugs: Behavioral activity in experimental models of Parkinson's disease</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">â</span> <span class="NLM_lpage">635</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1111%2Fj.2042-7158.1987.tb03441.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=2888854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaL2sXmtFWnt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1987&pages=627-635&author=D.+R.+Cooperauthor=C.+Marrelauthor=H.+van+de+Waterbeemdauthor=B.+Testaauthor=P.+Jennerauthor=C.+D.+Marsden&title=L-Dopa+esters+as+potential+prodrugs%3A+Behavioral+activity+in+experimental+models+of+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">L-Dopa esters as potential prodrugs:  behavioral activity in experimental models of Parkinson's disease</span></div><div class="casAuthors">Cooper, D. R.; Marrel, C.; Van de Waterbeemd, H.; Testa, B.; Jenner, P.; Marsden, C. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-35</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    </div><div class="casAbstract">The behavioral activity of 13 ester prodrugs of L-dopa (I; R = Me, Et, Pr, CH2CH(OH)Me, CHMeCH2OMe, cyclohexyl, tetrahydropyranylmethyl, CH2Ph, substituted benzyl, phenylethyl, phenoxyethyl, substituted phenylethyl) was evaluated on 2 exptl. animal models of Parkinson's disease; reverse of reserpine-induced akinesia in mice and induction of circling behavior in rats with 6-hydroxydopamine lesion of the medial forebrain bundle.  In general, I did not have markedly greater activity or a more sustained effect than L-dopa itself and thus would be unlikely to offer major therapeutic advantages on intermittent oral dosage.  However, their various physiochem. properties may make them more suitable i.v. or s.c. infusions.  Structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx_hPJDd522bVg90H21EOLACvtfcHk0ljSvMnAXKtjQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmtFWnt7k%253D&md5=06e8a60094d1a7d55c4017a2ff462cd3</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1987.tb03441.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1987.tb03441.x%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DD.%2BR.%26aulast%3DMarrel%26aufirst%3DC.%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DTesta%26aufirst%3DB.%26aulast%3DJenner%26aufirst%3DP.%26aulast%3DMarsden%26aufirst%3DC.%2BD.%26atitle%3DL-Dopa%2520esters%2520as%2520potential%2520prodrugs%253A%2520Behavioral%2520activity%2520in%2520experimental%2520models%2520of%2520Parkinson%2527s%2520disease%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D1987%26volume%3D39%26spage%3D627%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ungerstedt, U.</span><span> </span><span class="NLM_article-title">6-Hydroxydopamine-induced generation of central monoamine neurons</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">107</span><span class="NLM_x">â</span> <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0014-2999%2868%2990164-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=5718510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaF1MXns1eisw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1968&pages=107-110&author=U.+Ungerstedt&title=6-Hydroxydopamine-induced+generation+of+central+monoamine+neurons"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">6-Hydroxydopamine-induced degeneration of central monoamine neurons</span></div><div class="casAuthors">Ungerstedt, Urban</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-10</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">6-Hydroxydopamine (I) (2 or 8 Î¼g.) injected into the nucleus caudatus putamen, the zona compacta of the substantia nigra, and the area dorsolateral to the nucleus interpedunclaris of rats caused degeneration of dopamine and noradrenaline cell bodies, axons, and terminals in the vicinity of the injection site.  The degeneration of the nigroneostriatal dopamine neuron system occurring after I injections into the substantia nigra produced marked motor disturbances.  Intracerebral administration of I may be used as a tool for anatomical and functional studies on central monoamine neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI9wsRougpvrVg90H21EOLACvtfcHk0liibBeYBb9g7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXns1eisw%253D%253D&md5=57298843164b07af35ca21b4624826c4</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2868%2990164-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252868%252990164-7%26sid%3Dliteratum%253Aachs%26aulast%3DUngerstedt%26aufirst%3DU.%26atitle%3D6-Hydroxydopamine-induced%2520generation%2520of%2520central%2520monoamine%2520neurons%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1968%26volume%3D5%26spage%3D107%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ungerstedt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuthnott, G. W.</span><span> </span><span class="NLM_article-title">Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1970</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">â</span> <span class="NLM_lpage">493</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0006-8993%2870%2990187-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=5494536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A280%3ADyaE3M%252Fotl2msA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1970&pages=485-493&author=U.+Ungerstedtauthor=G.+W.+Arbuthnott&title=Quantitative+recording+of+rotational+behavior+in+rats+after+6-hydroxy-dopamine+lesions+of+the+nigrostriatal+dopamine+system"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system</span></div><div class="casAuthors">Ungerstedt U; Arbuthnott G W</div><div class="citationInfo"><span class="NLM_cas:title">Brain research</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-93</span>
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxWjpxbmSViUg6wdEZmT2rfW6udTcc2eZi3Z7JMU0fUrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE3M%252Fotl2msA%253D%253D&md5=e31a2eee4f4fff68329c0ab8a8a62788</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2870%2990187-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252870%252990187-3%26sid%3Dliteratum%253Aachs%26aulast%3DUngerstedt%26aufirst%3DU.%26aulast%3DArbuthnott%26aufirst%3DG.%2BW.%26atitle%3DQuantitative%2520recording%2520of%2520rotational%2520behavior%2520in%2520rats%2520after%25206-hydroxy-dopamine%2520lesions%2520of%2520the%2520nigrostriatal%2520dopamine%2520system%26jtitle%3DBrain%2520Res.%26date%3D1970%26volume%3D24%26spage%3D485%26epage%3D493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Luthman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredriksson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundstroem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonsson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, T.</span><span> </span><span class="NLM_article-title">Selective lesion of central dopamine or moradenaline neuron systems in the neonatal rat: Motor behavior and monoamine alteration at adult stage</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">â</span> <span class="NLM_lpage">277</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1989&pages=267-277&author=J.+Luthmanauthor=A.+Fredrikssonauthor=E.+Sundstroemauthor=G.+Jonssonauthor=T.+Archer&title=Selective+lesion+of+central+dopamine+or+moradenaline+neuron+systems+in+the+neonatal+rat%3A+Motor+behavior+and+monoamine+alteration+at+adult+stage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuthman%26aufirst%3DJ.%26aulast%3DFredriksson%26aufirst%3DA.%26aulast%3DSundstroem%26aufirst%3DE.%26aulast%3DJonsson%26aufirst%3DG.%26aulast%3DArcher%26aufirst%3DT.%26atitle%3DSelective%2520lesion%2520of%2520central%2520dopamine%2520or%2520moradenaline%2520neuron%2520systems%2520in%2520the%2520neonatal%2520rat%253A%2520Motor%2520behavior%2520and%2520monoamine%2520alteration%2520at%2520adult%2520stage%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D1989%26volume%3D33%26spage%3D267%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bankiewicz, K. S.</span><span> </span><span class="NLM_article-title">MPTP-induced parkinsonism in nonhuman primates</span> <span class="citation_source-journal">Methods Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">â</span> <span class="NLM_lpage">182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2FB978-0-12-185263-4.50018-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaK38XisFejt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1991&pages=168-182&author=K.+S.+Bankiewicz&title=MPTP-induced+parkinsonism+in+nonhuman+primates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">MPTP-induced parkinsonism in nonhuman primates</span></div><div class="casAuthors">Bankiewicz, Krzysztof S.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Neurosciences</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">Lesions Transplant.</span>),
    <span class="NLM_cas:pages">168-82</span>CODEN:
                <span class="NLM_cas:coden">MENEE5</span>;
        ISSN:<span class="NLM_cas:issn">1043-9471</span>.
    </div><div class="casAbstract">A review with 45 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx3yh0hBeYerVg90H21EOLACvtfcHk0li6ASc4lmsbrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisFejt7s%253D&md5=d3848e6d09f0015f716ca9cdca6933ea</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-185263-4.50018-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-185263-4.50018-2%26sid%3Dliteratum%253Aachs%26aulast%3DBankiewicz%26aufirst%3DK.%2BS.%26atitle%3DMPTP-induced%2520parkinsonism%2520in%2520nonhuman%2520primates%26jtitle%3DMethods%2520Neurosci.%26date%3D1991%26volume%3D7%26spage%3D168%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jakowec, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzinger, G. M.</span><span> </span><span class="NLM_article-title">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced lesion model of Parkinson's disease, with emphasis on mice and nonhuman primates</span> <span class="citation_source-journal">Comp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">â</span> <span class="NLM_lpage">513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=15575363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVejsrrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2004&pages=497-513&author=M.+W.+Jakowecauthor=G.+M.+Petzinger&title=1-methyl-4-phenyl-1%2C2%2C3%2C6-tetrahydropyridine-induced+lesion+model+of+Parkinson%27s+disease%2C+with+emphasis+on+mice+and+nonhuman+primates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates</span></div><div class="casAuthors">Jakowec, Michael W.; Petzinger, Giselle M.</div><div class="citationInfo"><span class="NLM_cas:title">Comparative Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">497-513</span>CODEN:
                <span class="NLM_cas:coden">COMEFT</span>;
        ISSN:<span class="NLM_cas:issn">1532-0820</span>.
    
            (<span class="NLM_cas:orgname">American Association for Laboratory Animal Science</span>)
        </div><div class="casAbstract">A review.  Animal models play a crit. role in our understanding of the cause of human diseases and provide an opportunity to evaluate new therapeutic treatments.  The usefulness of an animal model is dependent, in part, on how closely it resembles neurochem., neuropathol., and behavioral features of the human condition.  Other considerations that may enhance the value of a model include expense, availability, reproducibility, animal morbidity and mortality, and investigator experience.  Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by slow movements, tremor, and walking impairment due to loss of midbrain nigrostriatal neurons and depletion of striatal dopamine.  In the PD research field, a no. of neurotoxic, pharmacol., and transgenic animal models are available for research studies.  We will focus on the advantages and disadvantages of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mouse and nonhuman primate models of PD.  Our goal is to guide researchers in the appropriateness of the MPTP models in their studies by balancing understanding of the models, objectives of the study, and health and safety of the animals.  In addn., the tech. use and safe handling of MPTP are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1AbpYksctuLVg90H21EOLACvtfcHk0li6ASc4lmsbrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVejsrrE&md5=268362f3d9a889531b0d888f0c86a96f</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJakowec%26aufirst%3DM.%2BW.%26aulast%3DPetzinger%26aufirst%3DG.%2BM.%26atitle%3D1-methyl-4-phenyl-1%252C2%252C3%252C6-tetrahydropyridine-induced%2520lesion%2520model%2520of%2520Parkinson%2527s%2520disease%252C%2520with%2520emphasis%2520on%2520mice%2520and%2520nonhuman%2520primates%26jtitle%3DComp.%2520Med.%26date%3D2004%26volume%3D54%26spage%3D497%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Campos-Romo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ojeda-Flores, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno-Briseno, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez-Ruiz, J.</span><span> </span><span class="NLM_article-title">Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the hallway task</span> <span class="citation_source-journal">J. Neurosci. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">177</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">â</span> <span class="NLM_lpage">368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2Fj.jneumeth.2008.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=19022292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFeisQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2009&pages=361-368&author=A.+Campos-Romoauthor=R.+Ojeda-Floresauthor=P.+Moreno-Brisenoauthor=J.+Fernandez-Ruiz&title=Quantitative+evaluation+of+MPTP-treated+nonhuman+parkinsonian+primates+in+the+hallway+task"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33cR"><div class="casContent"><span class="casTitleNuber">33c</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task</span></div><div class="casAuthors">Campos-Romo, Aurelio; Ojeda-Flores, Rafael; Moreno-Briseno, Pablo; Fernandez-Ruiz, Juan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Methods</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-368</span>CODEN:
                <span class="NLM_cas:coden">JNMEDT</span>;
        ISSN:<span class="NLM_cas:issn">0165-0270</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Parkinson's disease (PD) is a progressive neurodegenerative disorder.  An exptl. model of this disease is produced in nonhuman primates by the administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).  In this work, we put forward a new quant. evaluation method that uses video recordings to measure the displacement, gate, gross and fine motor performance of freely moving subjects.  Four Vervet monkeys (Cercopithecus aethiops) were trained in a behavioral observation hallway while being recorded with digital video cameras from four different angles.  After MPTP intoxication the animals were tested without any drug and after 30 and 90 min of Levodopa/Carbidopa administration.  Using a personal computer the following behaviors were measured and evaluated from the video recordings: displacement time across the hallway, reaching time towards rewards, ingestion time, no. of attempts to obtain rewards, no. of rewards obtained, and level of the highest shelf reached for rewards.  Our results show that there was an overall behavioral deterioration after MPTP administration and an overall improvement after Levodopa/Carbidopa treatment.  This demonstrates that the HALLWAY task is a sensitive and objective method that allows detailed behavioral evaluation of freely moving monkeys in the MPTP Parkinson's disease model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruYimo678roLVg90H21EOLACvtfcHk0li6ASc4lmsbrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFeisQ%253D%253D&md5=e824a38d96e1e6d37bac316822174a89</span></div><a href="/servlet/linkout?suffix=cit33c&amp;dbid=16384&amp;doi=10.1016%2Fj.jneumeth.2008.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneumeth.2008.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DCampos-Romo%26aufirst%3DA.%26aulast%3DOjeda-Flores%26aufirst%3DR.%26aulast%3DMoreno-Briseno%26aufirst%3DP.%26aulast%3DFernandez-Ruiz%26aufirst%3DJ.%26atitle%3DQuantitative%2520evaluation%2520of%2520MPTP-treated%2520nonhuman%2520parkinsonian%2520primates%2520in%2520the%2520hallway%2520task%26jtitle%3DJ.%2520Neurosci.%2520Methods%26date%3D2009%26volume%3D177%26spage%3D361%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Lim, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sensenhauser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preston, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shook, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhodes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopaul, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. C.</span><span> </span><span class="NLM_article-title">Overcoming the genotoxicity of a pyrrolidine substituted arylindenopyrimidine as a potent adenosine A<sub>2A</sub>/A<sub>1</sub> antagonist by minimizing bioactivation to an iminium ion reactive intermediate</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1012</span><span class="NLM_x">â</span> <span class="NLM_lpage">1030</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx1004437" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1012-1030&author=H.-K.+Limauthor=J.+Chenauthor=C.+Sensenhauserauthor=K.+Cookauthor=R.+Prestonauthor=T.+Thomasauthor=B.+Shookauthor=P.+F.+Jacksonauthor=S.+Rassnickauthor=K.+Rhodesauthor=V.+Gopaulauthor=R.+Salterauthor=J.+Silvaauthor=D.+C.+Evans&title=Overcoming+the+genotoxicity+of+a+pyrrolidine+substituted+arylindenopyrimidine+as+a+potent+adenosine+A2A%2FA1+antagonist+by+minimizing+bioactivation+to+an+iminium+ion+reactive+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Ftx1004437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx1004437%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DH.-K.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSensenhauser%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DK.%26aulast%3DPreston%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DShook%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DP.%2BF.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DRhodes%26aufirst%3DK.%26aulast%3DGopaul%26aufirst%3DV.%26aulast%3DSalter%26aufirst%3DR.%26aulast%3DSilva%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DD.%2BC.%26atitle%3DOvercoming%2520the%2520genotoxicity%2520of%2520a%2520pyrrolidine%2520substituted%2520arylindenopyrimidine%2520as%2520a%2520potent%2520adenosine%2520A2A%252FA1%2520antagonist%2520by%2520minimizing%2520bioactivation%2520to%2520an%2520iminium%2520ion%2520reactive%2520intermediate%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1012%26epage%3D1030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Hyttel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larsen, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnt, J.</span><span> </span><span class="NLM_article-title">Receptor-binding profiles of neuroleptics</span> <span class="citation_source-journal">Psychopharmacol. Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">â</span> <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1007%2F978-3-642-70140-5_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=2860665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaL2MXlvVyrurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1985&pages=9-18&author=J.+Hyttelauthor=J.+J.+Larsenauthor=A.+V.+Christensenauthor=J.+Arnt&title=Receptor-binding+profiles+of+neuroleptics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor-binding profiles of neuroleptics</span></div><div class="casAuthors">Hyttel, J.; Larsen, J. J.; Christensen, A. V.; Arnt, J.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology, Supplementum</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">Dyskinesia</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">PSSUE5</span>;
        ISSN:<span class="NLM_cas:issn">0179-8456</span>.
    </div><div class="casAbstract">A review with 33 refs. of the dopaminergic receptor binding blockade by neuroleptics in relation to antipsychotic activity and side-effects of neuroleptics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBA2EApKaKZ7Vg90H21EOLACvtfcHk0liazTZ4DMB5Wg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvVyrurk%253D&md5=fb425b1ed020812fdd72f602a9e398e4</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-70140-5_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-70140-5_2%26sid%3Dliteratum%253Aachs%26aulast%3DHyttel%26aufirst%3DJ.%26aulast%3DLarsen%26aufirst%3DJ.%2BJ.%26aulast%3DChristensen%26aufirst%3DA.%2BV.%26aulast%3DArnt%26aufirst%3DJ.%26atitle%3DReceptor-binding%2520profiles%2520of%2520neuroleptics%26jtitle%3DPsychopharmacol.%2520Suppl.%26date%3D1985%26volume%3D2%26spage%3D9%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Kraus, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sy, J. O.</span><span> </span><span class="NLM_article-title">A synthetic approach to rocaglamide via reductive cyclization of Î´-keto nitriles</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">83</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00262a022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1989&pages=77-83&author=G.+A.+Krausauthor=J.+O.+Sy&title=A+synthetic+approach+to+rocaglamide+via+reductive+cyclization+of+%CE%B4-keto+nitriles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjo00262a022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00262a022%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DG.%2BA.%26aulast%3DSy%26aufirst%3DJ.%2BO.%26atitle%3DA%2520synthetic%2520approach%2520to%2520rocaglamide%2520via%2520reductive%2520cyclization%2520of%2520%25CE%25B4-keto%2520nitriles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1989%26volume%3D54%26spage%3D77%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Heintzelman, G. R.; Bullington, J. L.; Rupert, K. C.</span><span> </span><span class="NLM_article-title">Preparation of arylindenopyridines and arylindenopyrimidines and their use as adenosine A<sub>2A</sub> receptor antagonists</span>. PCT Int. Appl. WO 2005042500,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=G.+R.+Heintzelman&author=J.+L.+Bullington&author=K.+C.+Rupert&title=Preparation+of+arylindenopyridines+and+arylindenopyrimidines+and+their+use+as+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeintzelman%26aufirst%3DG.%2BR.%26atitle%3DPreparation%2520of%2520arylindenopyridines%2520and%2520arylindenopyrimidines%2520and%2520their%2520use%2520as%2520adenosine%2520A2A%2520receptor%2520antagonists%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebeskind, L. S.</span><span> </span><span class="NLM_article-title">Copper-mediated, palladium-catalyzed coupling of thiol ester with aliphatic organoboron reagents</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3554</span><span class="NLM_x">â</span> <span class="NLM_lpage">3557</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo049964p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3554-3557&author=Y.+Yuauthor=L.+S.+Liebeskind&title=Copper-mediated%2C+palladium-catalyzed+coupling+of+thiol+ester+with+aliphatic+organoboron+reagents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38a&amp;dbid=16384&amp;doi=10.1021%2Fjo049964p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo049964p%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DY.%26aulast%3DLiebeskind%26aufirst%3DL.%2BS.%26atitle%3DCopper-mediated%252C%2520palladium-catalyzed%2520coupling%2520of%2520thiol%2520ester%2520with%2520aliphatic%2520organoboron%2520reagents%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3554%26epage%3D3557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kusturin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liebeskind, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sample, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweitzer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srogl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, W. L.</span><span> </span><span class="NLM_article-title">Switchable catalysis: Modular synthesis of functionalized pyrimidones via selective sulfide and halide cross-coupling chemistry</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">4349</span><span class="NLM_x">â</span> <span class="NLM_lpage">4352</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol035649y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=4349-4352&author=C.+Kusturinauthor=L.+S.+Liebeskindauthor=H.+Rahmanauthor=K.+Sampleauthor=B.+Schweitzerauthor=J.+Sroglauthor=W.+L.+Neumann&title=Switchable+catalysis%3A+Modular+synthesis+of+functionalized+pyrimidones+via+selective+sulfide+and+halide+cross-coupling+chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38b&amp;dbid=16384&amp;doi=10.1021%2Fol035649y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol035649y%26sid%3Dliteratum%253Aachs%26aulast%3DKusturin%26aufirst%3DC.%26aulast%3DLiebeskind%26aufirst%3DL.%2BS.%26aulast%3DRahman%26aufirst%3DH.%26aulast%3DSample%26aufirst%3DK.%26aulast%3DSchweitzer%26aufirst%3DB.%26aulast%3DSrogl%26aufirst%3DJ.%26aulast%3DNeumann%26aufirst%3DW.%2BL.%26atitle%3DSwitchable%2520catalysis%253A%2520Modular%2520synthesis%2520of%2520functionalized%2520pyrimidones%2520via%2520selective%2520sulfide%2520and%2520halide%2520cross-coupling%2520chemistry%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D4349%26epage%3D4352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit38c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Liebeskind, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srogl, J.</span><span> </span><span class="NLM_article-title">Heteroaromatic thioether-boronic acid cross-coupling under neutral reaction conditions</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">979</span><span class="NLM_x">â</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol0200091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38c&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1Gktb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=979-981&author=L.+S.+Liebeskindauthor=J.+Srogl&title=Heteroaromatic+thioether-boronic+acid+cross-coupling+under+neutral+reaction+conditions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38cR"><div class="casContent"><span class="casTitleNuber">38c</span><div class="casTitle"><span class="NLM_cas:atitle">Heteroaromatic Thioether-Boronic Acid Cross-Coupling under Neutral Reaction Conditions</span></div><div class="casAuthors">Liebeskind, Lanny S.; Srogl, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">979-981</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ï-Deficient heteroarom. thioethers undergo efficient palladium-catalyzed cross-coupling with boronic acids, mediated by copper(I) thiophene-2-carboxylate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowmqoxHMYfLbVg90H21EOLACvtfcHk0lgUiathvKbFEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1Gktb0%253D&md5=ce42d2952572e0b36f0f60e6037a18f6</span></div><a href="/servlet/linkout?suffix=cit38c&amp;dbid=16384&amp;doi=10.1021%2Fol0200091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0200091%26sid%3Dliteratum%253Aachs%26aulast%3DLiebeskind%26aufirst%3DL.%2BS.%26aulast%3DSrogl%26aufirst%3DJ.%26atitle%3DHeteroaromatic%2520thioether-boronic%2520acid%2520cross-coupling%2520under%2520neutral%2520reaction%2520conditions%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26spage%3D979%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Marsden, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolphin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duvoisin, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarsy, D.</span><span> </span><span class="NLM_article-title">Role of noradrenaline in levodopa reversal of reserpine akinesia</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">521</span><span class="NLM_x">â</span> <span class="NLM_lpage">525</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0006-8993%2874%2990643-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaE2MXlsVA%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1974&pages=521-525&author=C.+D.+Marsdenauthor=A.+Dolphinauthor=R.+C.+Duvoisinauthor=P.+Jennerauthor=D.+Tarsy&title=Role+of+noradrenaline+in+levodopa+reversal+of+reserpine+akinesia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Role of noradrenaline in levodopa reversal of reserpine akinesia</span></div><div class="casAuthors">Marsden, C. D.; Dolphin, A.; Duvoisin, R. C.; Jenner, P.; Tarsy, D.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-5</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">Pretreatment of reserpinized rats with 25 mg FLA-63/kg, a dopamine Î²-hydroxylase inhibitor, or with 20 mg phenoxybenzamine/kg, a noradrenaline (I) [51-41-2] receptor blocker, decreased the levodopa [59-92-7] (500 mg/kg) reversal of akinesia induced by reserpine [50-55-5].  Some spontaneous activity did occur after levodopa administration in animals pretreated with FLA-63 or phenoxybenzamine but this activity was unlike that of reserpinized animals treated with levodopa alone.  Other compds. which blocked both central dopamine [51-61-6] and I receptors in the brain also decreased the levodopa effect, whereas pimozide, which primarily blocks only dopamine receptors, had no effect on the response to levodopa.  Thus, levodopa reversal of reserpine akinesia may require the formation of  I as well as dopamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQMLyHwjYI7rVg90H21EOLACvtfcHk0lgUiathvKbFEg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXlsVA%253D&md5=68b938889d6e3945f83bbcaa2539642c</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2874%2990643-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252874%252990643-X%26sid%3Dliteratum%253Aachs%26aulast%3DMarsden%26aufirst%3DC.%2BD.%26aulast%3DDolphin%26aufirst%3DA.%26aulast%3DDuvoisin%26aufirst%3DR.%2BC.%26aulast%3DJenner%26aufirst%3DP.%26aulast%3DTarsy%26aufirst%3DD.%26atitle%3DRole%2520of%2520noradrenaline%2520in%2520levodopa%2520reversal%2520of%2520reserpine%2520akinesia%26jtitle%3DBrain%2520Res.%26date%3D1974%26volume%3D17%26spage%3D521%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Starr, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, B. S.</span><span> </span><span class="NLM_article-title">Comparison of the effects NMDA and AMPA antagonist on the locomotor activity induced by selective D<sub>1</sub> and D<sub>2</sub> dopamine agonists in reserpine-treated mice</span> <span class="citation_source-journal">Psychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">495</span><span class="NLM_x">â</span> <span class="NLM_lpage">504</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1994&pages=495-504&author=M.+S.+Starrauthor=B.+S.+Starr&title=Comparison+of+the+effects+NMDA+and+AMPA+antagonist+on+the+locomotor+activity+induced+by+selective+D1+and+D2+dopamine+agonists+in+reserpine-treated+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStarr%26aufirst%3DM.%2BS.%26aulast%3DStarr%26aufirst%3DB.%2BS.%26atitle%3DComparison%2520of%2520the%2520effects%2520NMDA%2520and%2520AMPA%2520antagonist%2520on%2520the%2520locomotor%2520activity%2520induced%2520by%2520selective%2520D1%2520and%2520D2%2520dopamine%2520agonists%2520in%2520reserpine-treated%2520mice%26jtitle%3DPsychopharmacology%26date%3D1994%26volume%3D114%26spage%3D495%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Robinson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, J. B.</span><span> </span><span class="NLM_article-title">The rotational behavior model: Asymmetry in the effects of unilateral 6-OHDA lesions of the substantia nigra in rats</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">â</span> <span class="NLM_lpage">131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm201640m&amp;key=10.1016%2F0006-8993%2883%2991129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm201640m&amp;key=6405975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm201640m&amp;key=1%3ACAS%3A528%3ADyaL3sXitV2rtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1983&pages=127-131&author=T.+E.+Robinsonauthor=J.+B.+Becker&title=The+rotational+behavior+model%3A+Asymmetry+in+the+effects+of+unilateral+6-OHDA+lesions+of+the+substantia+nigra+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The rotational behavior model:  asymmetry in the effects of unilateral 6-OHDA lesions of the substantia nigra in rats</span></div><div class="casAuthors">Robinson, Terry E.; Becker, Jill B.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-31</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">The d-amphetamine  [51-64-9]-induced rotational behavior of rats with dopamine  [51-61-6] depletion in the dominant striatum was in the opposite direction of that obsd. in rats with damage to the nondominant striatum.  Thus, when using the 6-hydroxydopamine (6-OHDA) lesion rotation model, the intrinsic asymmetry in the nigrostriatal dopaminergic system should be taken into consideration with respect to the side of lesion placement, since different results may be obtained depending on the side of the lesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG7YxiJKMBTbVg90H21EOLACvtfcHk0ljdDl6mdxWz3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXitV2rtbg%253D&md5=b90687387f1f528f0b5ed09e84084344</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2883%2991129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252883%252991129-0%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DT.%2BE.%26aulast%3DBecker%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520rotational%2520behavior%2520model%253A%2520Asymmetry%2520in%2520the%2520effects%2520of%2520unilateral%25206-OHDA%2520lesions%2520of%2520the%2520substantia%2520nigra%2520in%2520rats%26jtitle%3DBrain%2520Res.%26date%3D1983%26volume%3D264%26spage%3D127%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Damier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agid, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graybiel, A. M.</span><span> </span><span class="NLM_article-title">The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease</span> <span class="citation_source-journal">Brain</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1437</span><span class="NLM_x">â</span> <span class="NLM_lpage">1448</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1999&pages=1437-1448&author=P.+Damierauthor=E.+C.+Hirschauthor=Y.+Agidauthor=A.+M.+Graybiel&title=The+substantia+nigra+of+the+human+brain.+II.+Patterns+of+loss+of+dopamine-containing+neurons+in+Parkinson%27s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDamier%26aufirst%3DP.%26aulast%3DHirsch%26aufirst%3DE.%2BC.%26aulast%3DAgid%26aufirst%3DY.%26aulast%3DGraybiel%26aufirst%3DA.%2BM.%26atitle%3DThe%2520substantia%2520nigra%2520of%2520the%2520human%2520brain.%2520II.%2520Patterns%2520of%2520loss%2520of%2520dopamine-containing%2520neurons%2520in%2520Parkinson%2527s%2520disease%26jtitle%3DBrain%26date%3D1999%26volume%3D122%26spage%3D1437%26epage%3D1448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm201640m&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-3%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm201640m" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm201640m" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c76102be043c7c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
